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Depression and its recurrent nature
Major Depressive Disorder (MDD) is a common but serious psychiatric 
disorder. In the United States, its lifetime prevalence is estimated at 13 
- 16% (Hasin, Goodwin, Stinson, & Grant, 2005; Kessler et al., 2003). In 
the Netherlands, about one in five adults experience episodes of MDD at 
least once in their life (Bijl, Ravelli, & Van Zessen, 1998). According to the 
Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5; 
American Psychiatric Association, 2013), a depressive episode is diagnosed 
when patients report at least 5 out of 9 symptoms for two weeks or longer, 
including at least one core symptom. Core symptoms are low mood and 
loss of interest in (normally) pleasant activities. Additional symptoms 
include changes in appetite or weight, sleep disturbances, psychomotor 
agitation or retardation, fatigue or energy loss, feelings of worthlessness 
or inappropriate guilt, cognitive problems such as a lack of concentration 
or indecisiveness, and suicidal ideations or intentions. Throughout the 
current thesis, the previous version of the DSM (fourth edition text revised; 
American Psychiatric Association, 2000) was used because the fifth edition 
was published after the start of the study in 2009. However, there are no 
differences in the above mentioned criteria between the two editions. In 
addition to the presence of depressive symptoms for two weeks or longer, an 
episode of MDD typically has significant impact on a patient’s functioning, 
for example due to social disengagement or absence from work. Hence, 
depression leads to suffering not only on a personal level, but has impact 
on the societal level as well. Unfortunately, depression often has a recurrent 
nature (Richards, 2011) and the risk of relapse increases with every episode 
(Solomon et al., 2000). 
 Relapse is defined as ‘a return of symptoms satisfying the full syndrome 
criteria for an episode that occurs during the period of remission, but before 
recovery’, where remission is a period in which the individual no longer 
meets syndrome criteria for the disorder and has no more than minimal 
symptoms, and recovery is being in remission for 6 months or longer; 
recurrence is ‘the appearance of a new episode of MDD, occurring during 
recovery’ (c.f. Frank et al., 1991). As there is insufficient consistency between 
studies in the way they have operationalized these constructs, I will refer 
to relapse/recurrence throughout this thesis. For about half of the people 
who experience their first episode of depression, MDD will develop into a 
recurrent or chronic disorder (Eaton et al., 2008). After three depressive 
episodes, the risk of relapse/recurrence is very high, with estimates around 
85% (Mueller et al., 1999) in the absence of prophylactic treatment. In 
addition, many patients have persistent residual symptoms of depression 
in between episodes, which is a risk factor for new episodes of depression 
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and leads to social and occupational impairment (Judd et al., 1998; Vieta, 
Sanchez-Moreno, Lahuerta, Zaragoza, & Group, 2008). Moreover, MDD is 
often associated with other mental and physical problems. Due to these 
adverse characteristics of MDD, it is among the leading causes of disability 
worldwide, now and probably even more so in the future (Mathers & Loncar, 
2006), which signifies the need for preventive treatments.
How can we prevent relapse/recurrence of depression?
Currently, the most commonly used treatment to prevent new episodes of 
depression is maintenance antidepressant medication (mADM). This has 
been shown to be more effective than placebo (Borges et al., 2014; Geddes 
et al., 2003; Kaymaz, van Os, Loonen, & Nolen, 2008), especially in the first 
six months. However, it remains unclear how long mADM should be taken to 
prevent relapse and recurrence, and many patients are unwilling to continue 
mADM for a longer period, leading to high rates of non-adherence (Bockting 
et al., 2008; ten Doesschate, Bockting, & Schene, 2009). In addition, one 
of the disadvantages of mADM is that it does not address the underlying 
mechanisms that make patients vulnerable to relapse/recurrence. 
Besides, many patients prefer psychological treatment (Gelhorn, Sexton, 
& Classi, 2011; van Schaik et al., 2004), for example because of pregnancy 
(Dimidjian & Goodman, 2014). Moreover, medication is only effective as 
long as it is taken, and discontinuation is often followed by re-emergence 
of the symptoms (Lejoyeux & Ades, 1997; Rosenbaum, Fava, Hoog, Ascroft, 
& Krebs, 1998). In contrast, psychological interventions appear to have 
more enduring prophylactic effects: a recent meta-analysis showed that 
psychological interventions are superior to antidepressants in reducing the 
risk of relapse/recurrence, with a risk ratio of 0.83 (Biesheuvel-Leliefeld et 
al., 2015). The meta-analysis included different types of therapies, including 
cognitive (behavioural) therapy, interpersonal therapy, problem solving 
therapy, psychodynamic therapy and mindfulness-based cognitive therapy 
(MBCT). The current thesis focuses on this latter.
What is mindfulness-based cognitive therapy and how can it help to 
prevent depressive relapse?
MBCT is a relatively new approach to prevent depressive relapse/recurrence 
developed by Segal, Williams and Teasdale (2002). It is a group-based 
intervention based on Jon Kabat-Zinn’s mindfulness-based stress reduction 
(MBSR) program (Kabat-Zinn, 1990), combined with elements from cognitive 
behavioural therapy (CBT; Beck, Rush, Shaw, & Emery, 1979). MBCT is 
delivered in groups of 8 – 12 participants and consists of 8 weekly sessions of 
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2 - 2.5 hours and if possible, one day of silent practice in the second half of the 
program (Segal, Williams, & Teasdale, 2012). Participants are encouraged to 
practice at home for about 45 minutes a day to increase their level of mindful 
awareness. Mindfulness is often defined as “paying attention in a particular 
way: on purpose, in the present moment, and nonjudgmentally” (Kabat-
Zinn, 1994, p.4). For example in the ‘body scan’, the first exercise in the MBCT 
program, participants are invited to bring their attention to different parts 
of the body and to the physical sensations that can be noticed from moment 
to moment. If the mind wanders off, for example to thinking about the past 
or future, the instruction is to kindly bring the attention back to the bodily 
sensations without judging them, or judging yourself for being distracted. 
Other practices include sitting meditation, mindful movement and the three-
minute breathing space. In sitting meditation, the instruction is to start with 
noticing the movement of the breath, then expanding awareness by bringing 
it to the body as a whole, followed by sounds, thoughts and feelings, and 
finally to the entire breadth of experience as it comes and goes (“choiceless 
awareness”). During mindful movement (based on hatha yoga) participants 
learn to be aware of their (moving) body, form moment to moment, rather 
than to strive for a particular outcome. The three-minute breathing space 
is a short but vital exercise that participants can use throughout the day. 
It is considered a key practice for translating formal practice into mindful 
living by stopping and pausing every now and then, allowing mindfulness 
to ‘infiltrate’ one’s activities. The aim of these exercises is to shift from the 
“doing-mode”, which is goal-oriented and includes planning, evaluating, 
striving for a particular outcome, etcetera, to the “being-mode” which is 
characterized by moment-to-moment awareness, allowing things to be as 
they are in that moment. In the doing-mode, the mind is typically engaged in 
thinking about the past and the future, for example trying to solve a problem. 
Although this can be helpful in many practical situations, it appears to be less 
suitable for negative emotional states.
 In MBCT, patients learn to recognize and disengage from the automatic 
thinking patterns that lead to depression. The underlying theoretical model 
is called the “differential activation hypothesis” proposed by John Teasdale 
(1988). This framework assumes that vulnerability to depression increases 
with each depressive episode, because previous patterns of negative thinking 
become more readily accessible whenever low mood returns, for example in 
response to a stressful event. In this way, the relation between low mood 
and negative thinking or behaving becomes stronger with each successive 
depressive episode. For example, a person who has experienced MDD in the 
past may wake up in the morning experiencing a slightly lowered mood, 
followed by anxious feelings and thoughts such as “I will become depressed 
again”, in turn leading to a further lowering of mood, etcetera. This tendency 
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to react to small changes in mood with strong negative thinking patterns is 
called cognitive reactivity. Another example of cognitive reactivity is when 
patients are more inclined to avoid difficulties or conflicts when feeling down. 
Recognizing this downward spiral creates the opportunity to see things as 
they are: a moment of low mood followed by an anxious reaction to it, not 
necessarily the beginning of a new depressive episode. Patients also learn to 
recognize other possible signs of a relapse in depression, such as irritability, 
changes in appetite, fatigue or social avoidance, in an early stage so they can 
take appropriate action if necessary. Thus, mindfulness training increases 
awareness of the early signs of vulnerability and promotes an attitude of 
self-kindness, rather than self-criticism, in the face of difficult experiences.
 Since its development, research on the effectiveness of MBCT has grown 
progressively. In the most recent meta-analysis on MBCT to prevent relapse/
recurrence in MDD, individual patient data were collected from most RCTs 
to date (Kuyken et al., 2016). Results showed that patients who had received 
MBCT showed a reduced risk of relapse/recurrence within 60 weeks of 
study, compared with those who did not receive MBCT. In addition, MBCT 
was slightly more effective than other active treatments, which was mADM 
in most studies. This suggests that MBCT can be a viable alternative to 
mADM. The same meta-analysis (Kuyken et al., 2016) showed that patients 
with different baseline characteristics appear to benefit to the same extent, 
i.e. that MBCT’s effectiveness is not related to factors such as age, gender, 
educational level or relationship status, but that patients with higher 
levels of depression seem to benefit more from MBCT. Previous findings 
have suggested that MBCT is more effective for patients with a history of 
childhood trauma (Williams et al., 2014). Taken together, these findings may 
indicate that MBCT is particularly useful for the most vulnerable patients. In 
addition, MBCT seems to be as beneficial in reducing depressive symptoms 
for patients with a current episode of MDD as for those with MDD in remission 
(van Aalderen et al., 2012).
 With regard to possible mechanisms of change, the current knowledge 
base is still in its infancy. A systematic review by van der Velden et al. (2015) 
suggested that changes in mindfulness skills, rumination, worry, (self)
compassion and meta-awareness could be linked to improvements in MBCT 
treatment outcomes, such as depressive symptoms or relapse/recurrence 
risk. Mindfulness skills are typically assessed using the Five Facet Mindfulness 
Questionnaire (FFMQ; Baer, Smith, Hopkins, Krietemeyer, & Toney, 2006), 
consisting of 5 subscales: observing, describing, acting with awareness, non-
judging and non-reactivity. Rumination refers to repeatedly thinking about 
one’s depressive mood and the possible causes (“why do I always feel this 
way?”) and implications (“I won’t be able to work” or “this is bad for my 
health”) and is very common in patients with MDD. Research has shown that 
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rumination is an important vulnerability factor for the onset, maintenance 
and recurrence of depression (Kirkegaard Thomsen, 2006). Worry is also 
a common type of perseverative negative thinking in patients with MDD. 
The two papers that examined worry as a possible mechanism of change in 
MBCT (Batink, Peeters, Geschwind, van Os, & Wichers, 2013; van Aalderen 
et al., 2012) have used the Penn State Worry questionnaire (PSWQ; Meyer, 
Miller, Metzger, & Borkovec, 1990), which includes items such as “once I start 
worrying, I cannot stop”. Self-compassion can be described as a combination of 
(a) self-kindness - being kind and understanding toward oneself in instances 
of pain or failure, (b) common humanity - perceiving one’s experiences as 
part of the larger human experience, and (c) mindfulness - holding painful 
thoughts and feelings in balanced awareness (c.f. Neff, 2003). Meta-awareness, 
meta-cognitive awareness or decentering are similar constructs, referring 
to a cognitive set in which negative thoughts and feelings are experienced 
as mental events, rather than as the self (Teasdale et al., 2002). In addition 
to these ‘direct’ mechanisms of change, it has been suggested that MBCT 
decreases the ‘toxic’ relationship between cognitive reactivity and depressive 
symptoms, and that this is (partly) due to increased levels of self-compassion 
(Kuyken et al., 2010). That study compared MBCT (including discontinuation 
of mADM) with mADM, and although the MBCT group showed a higher level 
of cognitive reactivity post treatment, it did not predict depression severity 
at 15-month follow-up, as was the case in the control (mADM) group. In 
addition, both mindfulness skills and self-compassion mediated the effect of 
MBCT on depression severity at follow-up (Kuyken et al., 2010). 
 Another line of research is concerned with structural and functional 
changes in the brain as a result of mindfulness meditation. In a systematic 
review and meta-analysis, Fox and colleagues (2014) showed that there are 
some consistent differences between advanced meditation practitioners 
and meditation-naïve controls in several brain regions hypothesized to 
be involved in meditation practice. These are regions related to meta-
awareness and introspection, body awareness, memory consolidation and 
reconsolidation, self- and emotion regulation, and intra- and interhemispheric 
communication. The effect sizes of these differences are, on average, in the 
moderate range (Fox et al., 2014). However, the cross-sectional nature of 
most studies makes it difficult to infer causal relations between meditation 
practice and structural changes in the brain. In other words, pre-existing 
differences may account for these effects as well. In terms of functional 
changes in the brain, another systematic review and meta-analysis by Fox 
and colleagues (2016) showed that a few brain regions were consistently 
involved (activated and de-activated) across different types of meditation 
practice: the insular cortex, the premotor cortex and supplementary motor 
area, the dorsal anterior cingulate cortex, and the frontopolar cortex. 
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However, the divergence between studies (in terms of brain regions) was 
much larger than their convergence, suggesting that different meditation 
practices recruit different brain regions. In sum, it appears that mindfulness 
meditation is associated with structural and functional changes in the 
brain, but longitudinal studies are needed to draw conclusions about causal 
relationships.
Where to go next?
So, despite the promising results of a rapidly accumulating evidence base for 
mindfulness-based interventions (MBIs), there is still a lot of work to be done. 
For example, up till now, we do not know whether the combination of MBCT 
and mADM might be better for preventing relapse/recurrence than either of 
these treatments on its own. We also know little about the possible influence 
of the teacher on the outcomes of MBCT, as most RCTs so far have used highly 
experienced mindfulness teachers. Thus, these and other questions are still 
on the research agenda. In a very informative paper, Dimidjian and Segal 
(2015) used the National Institutes of Health (NIH) stage model (Onken, 
Carroll, Shoham, Cuthbert, & Riddle, 2014) to map the current knowledge 
base for MBIs. These stages proceed from stage 0 (basic, fundamental 
research) to stage V (implementation and dissemination), describing the 
complete journey of intervention development (see figure 1.1). By mapping 
the available studies across these stages, it became clear that stages I and II 
are highly overrepresented. In other words: many studies have investigated 
MBIs for an increasing variety of populations, but often with small sample 
sizes and without proceeding to the later stages of effectiveness and 
implementation research. Dimidjian and Segal therefore provided a set of 
recommendations to fill the gaps in this stage model, with the ultimate goal 
of increasing the public health impact of mindfulness research and practice. 
Two of these recommendations are particularly relevant for the current 
thesis, namely recommendation 3: “Engage the thorny question of clinician 
training” and recommendation 6: “Efficacy is necessary but not sufficient 
for effectiveness”. Given the unique expectations for mindfulness teachers, 
which include a solid personal practice of mindfulness in addition to their 
professional training, examining the possible impact of clinician training 
seems particularly relevant for the field of MBIs. This is very much related 
to the question of effectiveness: efficacy trials typically include the most 
experienced teachers, whereas effectiveness trials are usually more reflective 
of the ‘real world setting’ in which the levels of experience or competency are 
more diverse. In addition, effectiveness trials typically include a more varied 
patient population as well. Whereas an efficacy trial may include primarily 
those participants who are highly motivated and familiar with a university-
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based research setting, participants in effectiveness trials could come from 
different regions and backgrounds, and may have more varying levels of 
motivation. An effectiveness trial is also suitable to examine whether the 
intervention (MBCT) is a useful alternative to established therapies (such as 
mADM), either as stand-alone or as adjunctive treatment.
Stage I:
Intervention
Generation/
Refinement
45%
Stage 0:
Basic Research
25%
Stage V:
Implementation &
Dissemination
< 1%
Stage II:
Efficacy in
Research Clinic
(WLC/TAU)
20%
Stage II:
Efficacy in
Research Clinic
(active control)
9%
Stage III:
Efficacy in
Community Clinic
< 1%
Stage IV:
Effectiveness
1%
100%
80%
60%
40%
20%
0%
Figure 1.1. Evidence Base for Mindfulness-Based Interventions (i.e., Mindfulness-Based Stress Reduction 
and Mindfulness-Based Cognitive Therapy) Mapped According to the Adapted National Institutes of 
Health Stage Model. Adapted from “Prospects for a clinical science of mindfulness-based intervention,” 
by S. Dimidjian and Z.V. Segal, 2015, American Psychologist, 70, p. 604. Copyright 2015 by the American 
Psychological Association.
Note. Recommended pathways between stages are represented with solid arrows; pathways that 
should be undertaken with caution are represented with dotted arrows. Color saturation represents the 
proportion of the total number of published studies of mindfulness-based interventions mapped at a 
given stage, with the specific percentage indicated at each stage.
Aims of this thesis
The primary aim of the current thesis is to investigate the effectiveness of 
MBCT, mADM or their combination to prevent relapse/recurrence in patients 
with recurrent depression. As previous studies have looked at either MBCT 
or mADM, but not the combination of these interventions, our aim was to fill 
this gap. Originally, the intention was to conduct a three-armed randomized 
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controlled trial (RCT) of MBCT alone, mADM alone or the combination (MBCT 
added to mADM), but only a few patients were willing to be randomized 
over these three groups. Because of their treatment preferences, we 
decided to conduct two parallel RCTs which constitute the backbone of this 
thesis. In trial A, patients with a preference for MBCT either discontinued 
or continued their medication after participation in MBCT. Our aim was 
to investigate whether MBCT alone (including discontinuation) would be 
non-inferior to the combination in terms of risk of relapse/recurrence. In 
trial B, patients preferring to hold on to their mADM either did or did not 
receive MBCT in addition. Here, we wanted to know whether adding MBCT 
to mADM would be superior in preventing relapse/recurrence compared 
with mADM alone. As patients’ preferences had strongly influenced our trial 
design and recruitment, we decided to look more deeply into the possible 
influence of these preferences on treatment outcomes. In addition, we took 
the opportunity to study the relation between the teacher’s competency 
and the outcomes of MBCT since the intervention was delivered in twelve 
different sites with even more teachers participating. 
Thesis outline
Chapter 2 describes the design and protocol of both RCTs, together 
referred to as the “MOMENT” study. It provides detailed information about 
the methodological aspects of the study, including the design, participant 
selection, sample size calculation, research procedures, measures, and 
statistical analyses.
 In chapter 3, the results of trial A are presented. Patients who entered 
the study (N = 249) had a relative preference for MBCT. They were randomly 
allocated to the MBCT+Discontinuation group or the combination group, and 
followed up for 15 months from baseline. Relapse/recurrence of MDD was the 
primary outcome, measured every three months using a structured clinical 
interview. In terms of the primary outcome, this trial was designed as a non-
inferiority trial, meaning that we hypothesized that MBCT+Discontinuation 
would lead to a higher risk of relapse/recurrence than the combination, 
but that the difference would not be unacceptably large (more than 25% 
difference in relapse rates). Other outcomes were severity of (residual) 
depressive symptoms, number, duration and severity of relapse/recurrence, 
and quality of life.
 Chapter 4 describes the results of the second, smaller RCT (trial B) 
involving 68 patients who had a relative preference for holding on to their 
medication. They were randomly allocated to mADM with MBCT, or to mADM 
alone. The methodology and outcomes were identical to trial A, except 
that this was a superiority trial, i.e. we hypothesized that the combination 
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of mADM and MBCT would lead to a significantly lower risk of relapse/
recurrence than the combination. 
 The possible influence of patients’ preferences on the outcomes of MBCT 
added to mADM are presented in chapter 5. In this study we first compared 
the patient characteristics of those who preferred MBCT (and participated in 
trial A) with those who preferred mADM (and participated in trial B). Then 
we combined the datasets from all patients who were randomly allocated 
to the combination group, in both RCTs (N = 154). They fulfilled the same 
in- and exclusion criteria, received the same intervention and went through 
the same research procedures. The only a priori difference was that they 
preferred either MBCT or mADM (and possible other characteristics). 
We compared these preference groups in terms of adherence (to MBCT 
and mADM) and clinical outcomes (relapse/recurrence risk, severity of 
depressive symptoms, or quality of life), and hypothesized that patients with 
a preference for MBCT would show better adherence and outcomes.
 In chapter 6, I describe how teacher competency was measured in the RCTs 
and whether this was related to the outcomes of patients who participated 
in MBCT. For this study, we used the videotapes that were recorded during 
the MBCT sessions (15 teachers) and asked a group of expert teachers (n 
= 16) to rate the competence of the teaching using a validated instrument. 
Competence ratings were then used to predict adherence (number of MBCT 
sessions attended), possible mechanisms of change (rumination, cognitive 
reactivity, mindfulness, and self-compassion) and key outcomes (depressive 
symptoms and depressive relapse/recurrence). We hypothesized that there 
would be differences between teachers with regard to levels of competence, 
and that higher levels of teacher competence would be associated with better 
adherence, decreases in rumination and cognitive reactivity, increases in 
mindfulness and self-compassion, lower levels of depression post treatment 
and a lower risk of relapse/recurrence in the year after MBCT.
 A summary of the findings of all mentioned studies can be found in 
chapter 7, followed by a general discussion of the results in relation to 
current knowledge and advances in the field of mindfulness research and 
practice. Strengths and limitations of the current thesis are discussed. 
Subsequently, indications for future research and practice are presented.
20
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ABSTRACT
Background
Depression is a common psychiatric disorder characterized by a high rate of 
relapse and recurrence. The most commonly used strategy to prevent relapse/
recurrence is maintenance treatment with antidepressant medication 
(mADM). Recently, it has been shown that Mindfulness-Based Cognitive 
Therapy (MBCT) is at least as effective as mADM in reducing the relapse/
recurrence risk. However, it is not yet known whether combination treatment 
of MBCT and mADM is more effective than either of these treatments alone. 
Given the fact that most patients have a preference for either mADM or for 
MBCT, the aim of the present study is to answer the following questions. 
First, what is the effectiveness of MBCT in addition to mADM? Second, how 
large is the risk of relapse/recurrence in patients withdrawing from mADM 
after participating in MBCT, compared to those who continue to use mADM 
after MBCT?
Methods/design
Two parallel-group, multi-center randomized controlled trials are conducted. 
Adult patients with a history of depression (3 or more episodes), currently 
either in full or partial remission and currently treated with mADM (6 months 
or longer) are recruited. In the first trial, we compare mADM on its own 
with mADM plus MBCT. In the second trial, we compare MBCT on its own, 
including tapering of mADM, with mADM plus MBCT. Follow-up assessments 
are administered at 3-month intervals for 15 months. Primary outcome is 
relapse/recurrence. Secondary outcomes are time to, duration and severity 
of relapse/recurrence, quality of life, personality, several process variables, 
and incremental cost-effectiveness ratio.
Discussion
Taking into account patient preferences, this study will provide information 
about a) the clinical and cost-effectiveness of mADM only compared with 
mADM plus MBCT, in patients with a preference for mADM, and b) the clinical 
and cost-effectiveness of withdrawing from mADM after MBCT, compared 
with mADM plus MBCT, in patients with a preference for MBCT.
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INTRODUCTION
Major depressive disorder (MDD) is one of the most prevalent psychiatric 
disorders characterized by high relapse and/or recurrence rates. Relapse 
is defined as ‘a return of symptoms satisfying the full syndrome criteria 
for an episode that occurs during the period of remission, but before 
recovery’, where remission is a period in which the individual no longer 
meets syndrome criteria for the disorder and has no more than minimal 
symptoms, and recovery is being in remission for 6 months or longer; 
recurrence is ’ the appearance of a new episode of MDD occurring during 
recovery’ (c.f. Frank et al., 1991). In a large prospective study, a recurrence 
rate of 85% was observed in outpatients with MDD during a follow-up 
period of 15 years (Mueller et al., 1999). Furthermore, the recurrence 
risk has been shown to increase with 16% after each successive episode 
(Solomon et al., 2000). Given the high psychological as well as social and 
economic burden associated with MDD, relapse/recurrence prevention is 
extremely important. The most commonly used strategy to prevent relapse/
recurrence is maintenance treatment with antidepressant medication 
(mADM). International guidelines recommend that patients with recurrent 
MDD should continue mADM for at least two years after remission (National 
Institute for Clinical Excellence, 2004). A meta-analysis showed that mADM 
reduces relapse/recurrence rates significantly compared to placebo (18% 
versus 41%) based on 31 randomized controlled trials with follow-up 
periods ranging from 6 to 36 months (Geddes et al., 2003). However, despite 
the established effectiveness of mADM as a preventive strategy, it has several 
disadvantages. First, many patients are unwilling to continue mADM for a 
longer period (Bockting et al., 2008) and adherence is typically low (ten 
Doesschate, Bockting, & Schene, 2009). Second, many patients experience 
disturbing side effects (Kelly, Posternak, & Alpert, 2008). Moreover, many 
patients prefer psychological over pharmacological treatment (van Schaik 
et al., 2004). Psychotherapeutic approaches also seem to have long-term 
beneficial effects, whereas effects of mADM cease after discontinuation 
(Dobson et al., 2008). 
 To address the need for psychological interventions targeting relapse 
prevention, Segal, Williams and Teasdale developed Mindfulness-Based 
Cognitive Therapy (MBCT; Segal, Williams, & Teasdale, 2002). The aim of 
MBCT is not to change or eliminate depressive symptoms, but rather to 
relate to them in a different way, i.e. with a more accepting, mild attitude. 
The rationale behind the MBCT program is based on an empirically 
supported, theoretical framework suggesting that patients with recurrent 
depression become more vulnerable to developing depression as cognitive 
reactivity increases (for a review see Scher, Ingram, & Segal (2005)). 
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Cognitive reactivity refers to negative modes of thinking and behaving that 
are reactivated in periods of stress or low mood. It is suggested that these 
(automatic) negative reactions in turn, lead to a further lowering of mood, 
eventually turning into a depressive relapse/recurrence (Segal, Gemar, 
& Williams, 1999). Cognitive reactivity is strongly related to rumination, 
which refers to recurrently thinking about one’s depressive symptoms 
and their possible causes and implications. Rumination is thought to be 
an important cognitive vulnerability factor for both onset and relapse/
recurrence in depression (Nolen-Hoeksema, 2000; Robinson & Alloy, 2003). 
MBCT is targeted at recognizing these cognitive and behavioral reactions 
to low mood or other stressful situations, and to observe these reactions 
with acceptance and kindness and from a wider, decentered perspective. 
Indeed, there is evidence that MBCT diminishes the ‘toxic’ relationship 
between post-treatment cognitive reactivity and depressive relapse (Kuyken 
et al., 2010) and that decreased rumination mediates the effects of MBCT 
(van Aalderen et al., 2012). Unlike cognitive reactivity and rumination, 
self-compassion seems to be a beneficial factor that is protective against 
depression. Self-compassion can be described as a combination of (a) self-
kindness - being kind and understanding toward oneself in instances of pain 
or failure, (b) common humanity - perceiving one’s experiences as part of 
the larger human experience, and (c) mindfulness - holding painful thoughts 
and feelings in balanced awareness (c.f. Neff, 2003). Evidence suggests that 
both self-compassion and mindfulness skills mediate the effect of MBCT on 
relapse/recurrence (Kuyken et al., 2010).
 Three randomized controlled trials (RCTs) have shown that MBCT in 
addition to treatment as usual (TAU) significantly reduced the relapse/
recurrence risk compared with TAU alone, over a period of 14 months 
(Godfrin & van Heeringen, 2010; Ma & Teasdale, 2004; Teasdale et al., 
2000). In the first two trials (Ma & Teasdale, 2004; Teasdale et al., 2000), 
beneficial effects of MBCT were seen in patients with three or more past 
episodes, whereas no difference in relapse/recurrence percentages between 
MBCT and TAU was observed in patients with two past episodes (but see 
Geschwind (2011) for positive effects of MBCT in patients with one or two 
past episodes). Another trial has shown that MBCT’s prophylactic effect 
is at least equal to mADM for patients with three or more past episodes 
(Kuyken et al., 2008). This latter finding may specifically apply to patients 
whose remission is unstable (Segal et al., 2010). There is also evidence that 
MBCT might reduce subthreshold depressive symptoms, an important risk 
factor for relapse/recurrence, in patients remitted from MDD (Geschwind, 
2011) and patients with current MDD (van Aalderen et al., 2012). A recent 
meta-analysis (Piet & Hougaard, 2011) showed that the overall risk ratio 
for relapse/recurrence after MBCT is 0.66 (a relative risk reduction of 34%) 
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compared with TAU or placebo indicating that MBCT is indeed an effective 
prophylactic intervention for patients with recurrent MDD in remission. 
However, the prophylactic effectiveness of the combination of MBCT plus 
mADM has not yet been compared with either mADM or MBCT on their own. 
More specifically, MBCT has not been studied as an additional treatment in 
patients continuing mADM, rather than TAU, to prevent relapse/recurrence. 
Also, up to now we do not know if continuing mADM after MBCT has 
additional benefits over withdrawing from mADM after MBCT. As more 
and more MBCT courses are available, answering these specific questions 
becomes increasingly important for patients and clinicians in order to find 
the optimal strategy to prevent relapse/recurrence. The current study is 
designed to answer these questions.
Aims
The purpose of the ‘MOMENT’ study is twofold using two separate but 
connected RCTs to answer the following questions: 1) “In patients who are 
in remission of depression, who are being prescribed mADM and who are 
reluctant to discontinue medical treatment, is MBCT when given as an add-
on therapy superior to the continuation of medical treatment alone?” (mADM 
versus mADM + MBCT) and 2) “In patients who are in remission of depression 
who are being prescribed mADM and who are willing to try MBCT and not 
unwilling to discontinue medical treatment, is MBCT with a tapering off 
regimen of the medical treatment not inferior to MBCT in combination with 
continued medical treatment?” (MBCT versus mADM + MBCT). Our primary 
outcome is relapse and/or recurrence. Thus, the results of this study will 
inform patients with MDD and mental health professionals about the relapse 
and recurrence risks associated with the different treatment options given 
a certain treatment preference, and will support decision making processes 
regarding these options. In addition to these primary aims, we intend to 
examine; 3) the effect of mADM versus mADM + MBCT on the time to, number, 
duration and severity of relapse/recurrence, quality of life, and personality; 
4) the effect of MBCT versus mADM + MBCT on the time to number, duration 
and severity of relapse/recurrence, quality of life, and personality; 5) several 
process variables such as MBCT adherence, rumination, cognitive reactivity, 
mindfulness skills, and self-compassion as possible mechanisms underlying 
the clinical effectiveness of MBCT; 6) the cost-effectiveness of mADM versus 
mADM + MBCT and 7) the cost-effectiveness of MBCT versus mADM + MBCT.
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METHODS
Design
Originally the study was designed as a single trial, randomizing patients who 
are in remission of depression over [a] continuation of medical treatment, 
[b] switching to MBCT, or [c] MBCT as an add-on to medical treatment. This 
protocol was approved by our ethical review board (CMO Arnhem-Nijmegen) 
and registered under number 2008/242. However, inclusion of patients was 
hampered by the fact that many patients turned out to have a strong treatment 
preference: some patients were eager to start with MBCT and other patients 
were reluctant to discontinue medical treatment. Continuing the trial as a 
trial with preference arms would have resulted in a substantial proportion 
of patients who would not have been randomly allocated to treatment, 
introducing a potential serious bias. We therefore decided to conduct two 
separate RCTs, one with patients who are reluctant to discontinue medical 
treatment, and one with patients who are particularly eager to try MBCT 
and at least not unwilling to discontinue medical treatment. In the former, 
patients are randomly allocated to either continuation of medical treatment, 
or continuation of medical treatment with MBCT as an add-on therapy (a 
parallel-group, randomized controlled superiority trial). In the latter, patients 
are allocated to either MBCT while continuing medical treatment, or to MBCT 
in combination with a tapering-off regimen of the medical treatment (a 
parallel-group, randomized controlled non-inferiority trial). In this way, we 
take optimal account of the patient preferences and the study population will 
be as representative as possible of patients seen in routine clinical practice. 
The change in protocol has been approved by the Medical Ethics Committee 
Arnhem-Nijmegen (20-02-2011). Here, we report the design of the two trials. 
See figure 2.1 for a flow chart of the recruitment and study procedure.
Sample size
Trial 1: mADM versus mADM + MBCT
For trial 1 we need to recruit 96 participants (n = 48 per group) in order to 
demonstrate a difference of 25% in relapse/recurrence rates between mADM 
and mADM + MBCT, with a power of 80% (alpha 0.05, one-sided). This calculation 
is based on earlier studies reporting relapse/recurrence percentages of 60% 
in the mADM group (Kuyken et al., 2008) and approximately 38% in the MBCT 
plus TAU group (Piet & Hougaard, 2011). Because our trial investigates MBCT 
plus mADM rather than MBCT plus TAU, we expect an even lower relapse/
recurrence percentage (about 35%) in the combination group. Our expected 
difference is therefore 60% (mADM) minus 35% (mADM + MBCT) resulting 
in 25%.
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Recruitment via mental health professionals’ referrals, general practitioners’ 
referrals, media attention, posters and advertisements.
Interested individuals screened by telephone to assess eligibility after verbal 
consent is obtained.
Does patient (probably) meet in- and exclusion criteria? No Exclude
Yes
Study procedure explained in detial and information is sent by mail. 
After ≥ week, the patient is contacted again.
Patient still interested in participation?
Patient is invited for the research interview, in which the in- and 
exclusion criteria are assessed in detail. Informed consent is taken.
Eligible and informed consent obtained?
Randomization (stratification variables: research centre; full vs. partial remission 
(IDS-C ≤ 11 versus > 11); number of depressions in the past (3-4 versus ≥ 5); CBT 
experience (yes/no); gender). Baseline questionnaires taken (T0).
Preference for MBCT Preference for continuing mADM
MBCT mADM + 
MBCT
mADM + 
MBCT
mADM
Assessment during MBCT
Medication consultations
Follow-up assessment at T1 (3 months post-randomization), T2 
(6 months), T3 (9 months), T4 (12 months) and T5 (15 months).
No Exclude
Yes
No Exclude
Yes
Figure 2.1. Flow chart of the recruitment and study procedure. 
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Trial 2: MBCT versus mADM + MBCT
The sample size of trial 2 is based on the principle of non-inferiority. 
According to the Draft Guidance for Industry Non-Inferiority Clinical Trials 
of the US Food and Drug Administration (FDA, 2010) non-inferiority should 
be demonstrated by comparing the new, experimental treatment with 
an established efficacious treatment. In the case of relapse prevention in 
depression, this established treatment is mADM. However, since a head to 
head comparison of MBCT with mADM is complicated due to our design, we 
compare MBCT with the combination therapy (mADM + MBCT). We reasoned 
that the difference in relapse/recurrence between MBCT and mADM + MBCT 
should not be larger than the difference between the established treatment 
(mADM) and mADM + MBCT, which is expected to be approximately 
25%. Therefore, we chose a non-inferiority margin of 25%. Based on this 
assumption, the sample size needed in this non-inferiority trial is 280 in 
total (n = 140 per group) with a power of 80% (alpha 0.05, one-sided).
Participants
The study protocol has been approved by the Medical Ethics Committee 
Arnhem-Nijmegen (nr. 2008/242) for all participating sites. Local Ethics 
Committees approved local feasibility. Patients are included in the study 
only after written informed consent has been obtained. Participation is 
completely voluntary and patients can withdraw from the study and/or 
treatment at any time without having to give a reason for withdrawal and 
without consequences for their treatment options. Suspected serious adverse 
events are recorded and reported to the Medical Ethics Committee Arnhem-
Nijmegen. Patients are recruited from nine centers across the Netherlands: 
Department of Psychiatry, Radboud University Nijmegen Medical Center; 
Department of Psychiatry, Academic Medical Center, Amsterdam; GGZ 
inGeest, partner VU University Medical Center, Amsterdam; Pro Persona 
Ede, Tiel and Arnhem; Parnassia Bavo Psychiatric Institute, The Hague; PsyQ 
Psycho Medical Programmes, The Hague; Leiden University Medical Center 
Leiden and GGZ Rivierduinen, Leiden and Lisse; GGZ Centraal, Amersfoort; 
and GGZ Noord-Holland-Noord, Alkmaar. Recruitment was done via referrals 
from mental health professionals and by media advertisements.
Inclusion criteria
Inclusion criteria for the MOMENT study are: a) MDD with a history of at least 
three depressive episodes according to the Diagnostic and Statistical Manual 
of Mental Disorders - 4th edition (DSM-IV; American Psychiatric Association, 
2000) using the Structured Clinical Interview for DSM disorders I (SCID-I; 
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First, Gibbon, Spitzer, & Williams, 1996); b) treated with a stable dose of 
mADM over the last 6 months or longer; c) currently either in full or partial 
remission. Full remission is defined in our study as not currently meeting 
the criteria for a depressive episode assessed by the SCID and having a score 
of ≤ 11 on the Inventory of Depressive Symptomatology – Clinician rating 
(IDS-C30; Akkerhuis, 1997). Partial remission is defined as not currently 
meeting the criteria for a depressive episode and having an IDS-C score > 11. 
The cut-off point of ≤ 11 > on the IDS-C corresponds to a Hamilton Rating 
Scale for Depression score of 8 which is often used as a cut-off score for 
remission (University of Pittsburgh Epidemiology Data Center); d) native 
Dutch speaking.
Exclusion criteria
We exclude people in case of: a) bipolar disorder any primary psychotic 
disorder (current and previous), clinically relevant neurological or other 
somatic illness and/or current alcohol or drug dependency, assessed with the 
Mini International Neuropsychiatric Interview (MINI; Sheehan et al., 1998); 
b) high dosage of benzodiazepines (> 2 mg Lorazepam equivalents daily); 
c) recent electroconvulsive therapy (< 3 months ago); d) previous MBCT/
MBSR course and/or extensive meditation experience (e.g. retreats); e) 
current psychotherapy with a frequency of more than once per three weeks 
and f) visual hearing or cognitive impairments that impair the completion of 
self-report questionnaires and interviews.
Interventions
mADM
All study participants are on a stable dose of mADM for at least 6 months 
prior to enrollment (inclusion criterion). In the mADM group participants 
continue their use of mADM during the study period of 15 months. After 
randomisation, participants are seen by a study psychiatrist for a review 
of their mADM. For optimisation of mADM, psychiatrists taking part in the 
study use a protocol based on national (Moleman, 2009) and international 
(Fawcett, Epstein, Fiester, Elkin, & Autry, 1987) guidelines, made applicable 
for the MOMENT study by two experts in pharmacological treatment of MDD 
(WN and MB). Switching or augmenting medication is allowed between 
T0 and T1, and recommendations to manage side effects are provided. 
Compliance with mADM is measured prospectively during the whole study 
period using a daily calendar. Participants in the mADM condition are invited 
to take part in the MBCT training after the study period if they are interested.
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mADM + MBCT
In the combination group participants are seen by a psychiatrist for a review 
of their mADM as described above, and are asked to continue their mADM 
during the study period. In addition, these patients are invited to take part 
in the MBCT training, a manualized group skills-training program (Segal 
et al., 2002). MBCT is based on the protocol of Mindfulness-Based Stress 
Reduction (MBSR) which was developed by Jon Kabat-Zinn (1991) combined 
with elements of Cognitive Behavioral Therapy (CBT; Beck, Rush, Shaw, & 
Emery, 1979), turning it into a relapse prevention programme for patients 
with recurrent depression. The training consists of eight weekly sessions 
in a group (8 – 15 participants) with a duration of 2.5 hours, plus one day 
of silent practice between the 6th and 7th session. The silent day, although 
originally not in the MBCT program, was incorporated following the MBSR 
protocol (Kabat-Zinn, 1991) to give participants the opportunity to deepen 
their mindfulness practice. Formal meditation exercises that are part of 
the program are the body scan, sitting meditation, walking meditation and 
mindful movement. The program also encourages participants to cultivate 
awareness of everyday activities, such as eating or taking a shower. Cognitive 
techniques that are part of the program are education, monitoring and 
scheduling of activities, identification of negative automatic thoughts and 
devising a relapse prevention plan. Participants are expected to practice 
meditation at home for about an hour a day. In addition, participants in the 
MBCT conditions are invited to take part in three booster sessions every 
three months during the study period (around 3, 6 and 9 months after MBCT) 
to enhance their mindfulness practice through peer and teacher support and 
rehearsal of the key components of MBCT. 
 MBCT courses are provided at 12 different locations in the Netherlands 
and are led by one or two MBCT teachers per site. MBCT teachers were 
trained in the study protocol for MBCT during a 3-day training retreat in the 
beginning of the project, as well as at three subsequent training days every 
6 months. Teaching sessions of each (pair of) teacher(s) are videotaped to 
check treatment integrity. Two tapes per teacher are randomly selected 
and rated by highly experienced MBCT/MBSR trainers. Competence and 
adherence are evaluated with the Mindfulness-Based Interventions – 
Teaching Assessment Criteria (Crane et al., 2012).
MBCT (with tapering of mADM)
In the ‘MBCT only’ condition participants are invited to take part in the 
MBCT course as described above. In addition, they are asked to taper off 
their mADM from session 7 of the MBCT course onwards. The protocol 
specifies a tapering scheme lasting 5 weeks for all common ADMs, especially 
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addressing procedures to handle symptoms characteristic for discontinuation 
(Rosenbaum, Fava, Hoog, Ascroft, & Krebs, 1998) (available on request). In 
case of more exceptional treatments (e.g. lithium addition) withdrawal is 
based on the shared opinion of the authors of the medication protocol. Clients 
are seen by a consultant psychiatrist for a minimum of 3 and a maximum of 
12 appointments. The first three consultations are scheduled around session 
1 (informing and preparing participants), session 7 (initiating withdrawal) 
and approximately four weeks after session 7 (evaluation of withdrawal). 
If more guidance is needed, additional appointments can be scheduled. 
Patients are reassured that they can restart ADM as soon as they suffer a 
relapse/recurrence, or when withdrawal proves to be unfeasible.
Outcome measures
Table 2.1 presents an overview of the outcome measures and the time points 
of assessments.
Table 2.1. Overview of the measures and corresponding time points.ew of the measures and corr
Measure Target concept T0 MBCT T1 T2 T3 T4 T5
SCID-I* Diagnosis of MDD ● ● ● ● ● ●
IDS-C Current depressive symptoms ● ● ● ● ● ●
CSRI (Mental) health service use ● ● ● ● ● ●
MMAS Medication adherence ● ● ● ● ● ●
RRS Rumination ● ● ●
LEIDS Cognitive reactivity ● ● ●
FFMQ Mindfulness skills ● ● ●
SCS Self-compassion ● ● ●
WHOQOL-bref Quality of Life ● ● ●
EQ-5D Quality of Life ● ● ● ● ● ●
NEO-PI-R Personality ● ●
MAAS Daily awareness/attention ●
I-PANAS-SF Positive and negative affect ●
Calendar Mindfulness and medication 
adherence, absence from 
work and health service use
Monthly during 15-month study 
period.
 
Note. * Module depression (current and/or in the past).    
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Primary outcome measure
Relapse/recurrence. Relapse/recurrence is defined as meeting the DSM-IV 
criteria for a depressive episode at any moment during follow-up assessed 
by research assistants using the SCID-I. Our follow-up period has a duration 
of 15 months, therefore both relapse and recurrence can be observed. We 
refer to ‘relapse’ in case of a depressive episode occurring within 6 months 
after full remission and we refer to ‘recurrence’ in case of a depressive 
episode occurring after 6 months of full remission. In general, we refer to 
‘relapse/recurrence’ to indicate a depressive episode within the study 
period. In order to prevent attrition and recall bias, the interviews (either 
face-to-face or by telephone) are performed at 3 months intervals (T1-
T5). At any interview assistants review the previous 3 months since the 
previous contact. The research assistants received one full day of training 
to use the SCID-I. Interviews are audio taped to allow second-rating by an 
independent and blind assessor in cases of actual, borderline or probable 
relapse/recurrence. Previous studies on inter-rater reliability of the SCID-I 
have reported Cronbach’s alpha values between 0.61 and 0.80 (Lobbestael, 
Leurgans, & Arntz, 2010; Zanarini et al., 2000).
Secondary outcome measures
Time to relapse/recurrence is calculated from baseline to first relapse or 
recurrence. Number of relapses/recurrences during the follow-up period is 
calculated. Duration of relapse/recurrence is expressed in two ways: first as 
the duration of the first relapse/recurrence and second, as the percentage 
depressed days (including multiple depressive episodes) of the total number 
of follow-up days. Severity of depressive symptoms at follow-up contacts is 
assessed using the Dutch version of the IDS-C (Akkerhuis, 1997). The IDS-C 
has good psychometric qualities (Rush, Gullion, Basco, Jarrett, & Trivedi, 
1996; Trivedi et al., 2004). When the IDS-C is not administered during a 
depressive episode which falls in between assessments, the number of 
depressive symptoms according to the SCID-I (5 to 9) is used as a measure 
of severity. Quality of life is assessed using the 26-item self-report WHOQOL 
short version (WHOQOL-bref; The WHOQOL Group, 1998) which assesses 
subjective quality of life in four domains: physical, psychological, social and 
environmental. Personality is measured with the NEO Personality Inventory 
Revised (NEO-PI-R; Costa & McCrae, 1992) which consists of five domains: 
neuroticism, extraversion, openness, altruism, and conscientiousness.
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Process data
Adherence to MBCT and adherence to mADM is assessed during the entire 
study period using a calendar on which patients register on a daily basis 
their adherence to mindfulness exercises formal, informal, or none - and 
their adherence to mADM - full adherence, partial adherence (e.g. lower 
dosage than prescribed), or no adherence. This information is combined 
with the 4-item Morisky Medication Adherence Scale (MMAS; Morisky, 
Green, & Levine, 1986) with scores ranging from 0 (perfect adherence) to 
4 (low adherence). Rumination is measured with the extended version of 
the Ruminative Response Scale (RRS-EXT; Raes, Dewulf, van Heeringen, & 
Williams, 2009). The RRS-EXT enables distinction between ‘reflection’ and 
‘brooding’, the former referring to a more adaptive, and the latter to a more 
maladaptive way of thinking about depression. Cognitive reactivity is assessed 
using the Leiden Index of Depression Sensitivity – Revised (LEIDS-R; Van der 
Does, 2002). This scale consists of six subscales: hopelessness/suicidality, 
acceptance/coping, aggression, control/perfectionism, risk aversion, and 
rumination. To examine mindfulness skills, we administer the Dutch Five 
Facet Mindfulness Questionnaire (FFMQ; Baer, Smith, Hopkins, Krietemeyer, 
& Toney, 2006). The scale consists of 39 items divided into the subscales 
observing, describing, acting with awareness, nonjudging and nonreactivity. 
Self- compassion is measured with the Self Compassion Scale (SCS; Neff, 
2003). The SCS has 26 items measuring three concepts that are related 
to self-compassion: a) self-kindness versus self-judgment, b) common 
humanity versus isolation, and c) mindfulness versus over-identification. 
Daily attention. The Mindful Attention Awareness Scale (MAAS; Brown & 
Ryan, 2003) is administered before each MBCT session to assess mindful 
attention in daily life. Positive and negative affect is assessed before each 
MBCT session using the International Positive and Negative Affect Scale - 
Short Form (I-PANAS-SF; Thompson, 2007).
Cost-effectiveness
The cost-effectiveness evaluation is carried out from a societal perspective 
considering direct as well as indirect health costs. Data on health and social 
care utilisation are collected prospectively for each individual patient using 
an adapted version of the Client Service Receipt Inventory (CSRI; Beecham 
& Knapp, 1992). The CSRI includes production losses and family support. 
In addition prospective data are collected using a daily calendar on which 
participants register a) depression-related absence from work: full absence, 
partial absence or no absence, and b) any contacts with health care: the type 
of care and its duration. Unit cost estimates are derived from the national 
manual for cost prices in the health care sector (Oostenbrink, Bouwmans, 
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Koopmanschap, & Rutten, 2004). Costs of reduced ability to work are 
estimated using the friction costs method, which results in a more realistic 
estimate than the human capital approach (Koopmanschap, Rutten, van 
Ineveld, & van Roijen, 1995). Treatment costs of MBCT are calculated using 
activity-based-costing methods, thus measuring actual resources (time of 
therapist, time of patients, facilities) used. All unit cost prices are adjusted 
to 2012 prices. Unit cost estimates are combined with resource utilisation 
data to obtain a net cost per patient over the entire follow-up period. The 
EuroQoL-5 Dimensions instrument (EQ-5D; The EuroQol Group, 1990) 
is administered to provide utilities. The EQ-5D consists of 5 dimensions: 
mobility, self-care, daily activities, pain/discomfort and anxiety/depression. 
In addition, it contains a Visual Analogue Scale to determine Quality Adjusted 
Life Years (QALYs).
Procedure
Assessment of eligibility informed consent and baseline assessment
Figure 2.1 provides an overview of the recruitment and study procedure. 
After informed consent is obtained eligibility is assessed during the baseline 
interview (T0) using the SCID I depression module, the IDS-C, and the MINI 
(modules bipolar disorder, psychotic disorder, alcohol and drug dependency). 
After randomisation, the participant is informed about the condition to 
which he or she has been randomized. Also, the baseline questionnaires are 
administered at T0 (see Table 2.1).
Randomisation
Randomisation is computerized using a minimisation strategy while 
stratifying over the following variables: a) research centre, b) full versus 
partial remission (IDS-C score ≤ 11 versus > 11), c) number of depressive 
episodes in the past (3-4 versus ≥ 5), d) prior CBT (yes/no) and e) gender. 
Sub–threshold symptoms (partial remission) and number of past episodes 
are stratified because both are associated with relapse/recurrence risk 
(Hardeveld, Spijker, De Graaf, Nolen, & Beekman, 2010). Also, prior CBT is 
stratified because this has been shown to decrease relapse/recurrence risk 
(Bockting et al., 2005). Randomisation is performed online by the research 
assistant who conducts the baseline assessment by entering the required 
information on a randomisation website specifically designed for this study. 
The research assistant then communicates the treatment allocation to the 
patient, which means that he or she is no longer blind to the treatment 
condition. Unblinding of patients and research-assistants could not be 
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avoided because the different conditions required different arrangements 
for treatment appointments, and separating this task from the assessments 
was logistically impossible in most research centers. To assess the reliability 
of the follow-up assessments, all interviews are audio taped and a random 
selection of actual, borderline or probable cases of relapse/recurrence is 
rated by an independent assistant blind to treatment allocation.
Follow-up assessments
In accordance with previous trials (Kuyken et al., 2008; Ma & Teasdale, 2004; 
Teasdale et al., 2000), follow-up assessments take place at 3, 6, 9, 12 and 
15 months post randomisation (Table 2.1). The follow-up assessments at T2, 
T3 and T4 are administered by telephone and consist of only an interview 
part. If participants miss one or more assessments, research assistants 
examine the entire period from the last contact. In case of drop-out, we 
send a short questionnaire to gather essential information about depressive 
relapse/recurrence (if applicable) and the main reason for drop-out.
Statistical analysis
Primary analyses
Our primary analyses will be based on intention-to-treat. Subsequently per-
protocol analyses will be conducted. All analyses will be performed with and 
without covariates (i.e. the stratification factors research centre, depressive 
symptoms at baseline, and number of depressive episodes in the past, as well 
as other variables that might inadvertently be unevenly distributed over the 
conditions at baseline). Trial 1: mADM versus mADM + MBCT. The primary 
outcome measure will be relapse and/or recurrence meeting DSM-IV criteria 
for a major depressive episode during the 15-month study period. Relapse/
recurrence rates will be compared with a Chi-square test. Trial 2: MBCT 
versus mADM + MBCT. The primary outcome measure will be relapse and/or 
recurrence meeting DSM-IV criteria for a major depressive episode during 
the 15-month study period. Relapse/recurrence rates will be compared 
with a General Linear Model using a binomial family with an identity link. 
We will use the confidence interval (one-sided) of the difference in relapse/
recurrence between the two conditions (MBCT versus mADM + MBCT): if a 
difference of 25% can be excluded, then we will conclude non-inferiority of 
MBCT in comparison with mADM.
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Secondary analyses
Time to relapse and number, duration and severity of relapse/recurrence
Differences in time to relapse/recurrence between mADM versus 
mADM + MBCT (trial 1) and between MBCT versus mADM + MBCT (trial 
2) will be analyzed using a Cox Regression Proportional Hazards Model. 
In case of drop-out from the trial we will use the available measures and 
censor the participant at the time of the last assessment or informative 
contact. In patients suffering a relapse/recurrence during the study period 
we will compare the number, duration and severity of relapse/recurrence 
between mADM versus mADM + MBCT (trial 1) and between MBCT versus 
mADM + MBCT (trial 2) using a General Linear Model. We will perform 
additional analyses comparing different subgroups, for example patients 
who were in full remission at baseline (IDS-C ≤ 11) with patients who were 
in partial remission at baseline (IDS-C > 11) for both trials.
 
Mechanisms of change
Mediation analyses will be used to investigate the possible underlying 
mechanisms of change in MBCT. In accordance with other trials, these 
analyses will only include patients who have received an ‘adequate dose’ of 
MBCT, which is defined as participation in ≥ 4 of 8 MBCT sessions (Kuyken et 
al., 2010; Teasdale et al., 2000). In this subsample, we will test the mediating 
effect of adherence to MBCT, rumination, cognitive reactivity, mindfulness 
skills, and self-compassion, on depressive relapse/recurrence and depression 
severity as outcomes, using a multiple mediation model following the 
approach suggested by Preacher and Hayes (2008). In addition, we will use 
Hierarchical Linear Modeling techniques to investigate whether change in 
daily attention/awareness causally influences positive and negative effect. 
We will perform multilevel mediational analyses following the procedure 
reported by Kenny, Korchmaros & Bolger (2003). We will ‘lag’ the mediator 
variable (daily attention/awareness) by examining whether changes on the 
MAAS at time t-1 account for changes in the outcome variable (i.e. positive 
and negative affect) at time t for every MBCT session.
Cost-effectiveness
Cost-effectiveness of mADM versus mADM + MBCT will be analyzed in trial 1 
and cost-effectiveness of MBCT versus mADM + MBCT will be analyzed in trial 
2. A non-parametric bootstrapping method will be used, performing 1000 
replications of the original data to produce confidence intervals. Changes in 
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health-related quality of life from baseline will be used to calculate QALYs 
in each group. Incremental cost-effectiveness will be expressed in terms 
of incremental costs per QALY gained. A cost-acceptability curve will be 
constructed for statistical analysis of the incremental cost-effectiveness ratio. 
In case of dominance a full cost analysis will be conducted to estimate the 
mean savings per patient per year. To estimate the long-term consequences 
of introducing MBCT in the prevention of relapse/recurrence, decision 
analytic modeling (TreeAge) will be used, comparing mADM, MBCT, and 
the combination of mADM and MBCT in patients with recurrent depression, 
over a period of 5 years. Estimates of costs, utilities, and probabilities will be 
derived from the trial (extrapolation) and, where available, the literature, or 
from experts. Sensitivity analyses will be conducted to explore sensitivity of 
the outcomes to various model assumptions.
DISCUSSION
The prevention of relapse and recurrence in depression is considered 
a key target in mental health care given the high prevalence of relapse/
recurrence of MDD and the accompanying (societal) costs. Previous studies 
have shown that MBCT significantly reduces the relapse/recurrence risk as 
compared to treatment as usual (Piet & Hougaard, 2011), but MBCT has not 
yet been studied as an additional treatment to mADM. Therefore, our first 
trial will inform health care professionals and patients about the relapse/
recurrence risks associated with MBCT in addition to mADM compared 
with continuing mADM on its own. However, given the large amount of 
patients who prefer psychological treatment instead of ADM (van Schaik et 
al., 2004) and the difficulties that many patients have with long term use of 
ADM (ten Doesschate et al., 2009), it seems useful to investigate whether a 
relatively short, group-based course such as MBCT can help patients taper 
off their antidepressants. Therefore, our second trial will inform patients 
and clinicians about the relapse/recurrence risks associated with tapering 
off mADM after MBCT, compared with continuing mADM after MBCT. This 
trial is based on non-inferiority because we reasoned that the effectiveness 
of MBCT on its own (i.e. discontinuing antidepressants after MBCT) should 
be at least comparable to the effectiveness of mADM on its own. 
 The original study design was an RCT comparing mADM, MBCT, and 
mADM + MBCT. However, because of the strong treatment preferences 
that patients expressed during the beginning of the recruitment phase 
which hampered the randomisation possibilities, we adapted our design. 
Instead of a direct comparison between the three treatment options (three-
way randomisation) we now allocate the patients to different RCTs based 
on their preference for either mADM (allocation between mADM and 
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mADM + MBCT) or for MBCT (allocation between MBCT and mADM + MBCT). 
A methodological consequence of this adaptation is that we cannot directly 
compare MBCT to mADM because the MBCT preference group may differ 
from the mADM preference group with respect to known as well as unknown 
variables. The advantage that comes along with this design however, is an 
increase in the ecological validity of both trials. In our adapted design, the 
included patient groups probably more closely reflect the population(s) 
that we are interested in, since these preferences are obviously present in 
the population of remitted recurrently depressed adults who use mADM. 
Moreover, if we had continued using the original three-way randomisation 
procedure, we would have lost all participants who were not willing to be 
randomly assigned to mADM only or to MBCT only, resulting in a highly 
selective sample with low generalizability. 
 In summary, more detailed knowledge about the effectiveness of MBCT 
in addition to mADM, and about MBCT as a possible alternative to mADM 
is needed. Taking into account patient preferences, the MOMENT study will 
address these questions to support patients and clinicians in finding the 
optimal strategy to prevent depressive relapse and recurrence.
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ABSTRACT
Background
Mindfulness-based cognitive therapy (MBCT) and maintenance 
antidepressant medication (mADM) both reduce the risk of relapse in 
recurrent depression, but their combination has not been studied.
Aims
To investigate whether MBCT with discontinuation of mADM is non-inferior 
to MBCT+mADM.
Methods
A multicentre randomised controlled non-inferiority trial (ClinicalTrials.
gov: NCT00928980). Adults with recurrent depression in remission, using 
mADM for 6 months or longer (n = 249), were randomly allocated to either 
discontinue (n = 128) or continue (n = 121) mADM after MBCT. The primary 
outcome was depressive relapse/recurrence within 15 months. A confidence 
interval approach with a margin of 25% was used to test non-inferiority. 
Key secondary outcomes were time to relapse/recurrence and depression 
severity.
Results
The difference in relapse/recurrence rates exceeded the non-inferiority 
margin and time to relapse/recurrence was significantly shorter after 
discontinuation of mADM. There were only minor differences in depression 
severity.
Conclusions
Our findings suggest an increased risk of relapse/recurrence in patients 
withdrawing from mADM after MBCT. 
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INTRODUCTION
Major depressive disorder is one of the most common mental disorders. 
Many patients with major depressive disorder experience one or more 
relapses or recurrences (Richards, 2011). For patients with recurrent 
depression, maintenance antidepressant medication (mADM) helps to 
reduce the risk of relapse/recurrence (Borges et al., 2014; Geddes et al., 
2003; Viguera, Baldessarini, & Friedberg, 1998). Hence, clinical guidelines 
typically recommend that they should continue their medication for at least 
1 or 2 years (American Psychiatric Association, 2010; National Institute 
for Health and Care Excellence, 2009). Although mADM can be effective, 
it has several disadvantages. First, patients often experience side-effects 
(American Psychiatric Association, 2010) and long-term adherence is 
typically low (Bockting et al., 2008). Second, the protective effects of mADM 
do not persist after discontinuation whereas psychological interventions 
appear to have long-term beneficial effects (Dobson et al., 2008). In addition, 
many patients prefer psychological treatment (van Schaik et al., 2004). 
Therefore, developing alternative strategies for prevention of depressive 
relapse/recurrence is important. 
 Mindfulness-based cognitive therapy (MBCT) is an innovative 
psychological approach for relapse/recurrence prevention in recurrent 
depression developed by Segal, Williams & Teasdale (2012). It is an 8-week 
group-based treatment that integrates elements from mindfulness-based 
stress reduction (MBSR; Kabat-Zinn, 2013) and cognitive–behavioural 
therapy (CBT; Beck, Rush, Shaw, & Emery, 1979). A meta-analysis (Piet 
& Hougaard, 2011) showed that MBCT reduces the 12-month relapse/
recurrence risk compared with usual care or placebo, with a relative risk 
reduction of 43%, in patients with a history of three or more episodes of 
depression. Based on this evidence, MBCT is recommended for patients in 
remission who are at high risk of depressive relapse/recurrence (National 
Institute for Health and Care Excellence, 2009; Spijker et al., 2013). In their 
meta-analytic paper, Piet & Hougaard (2011) also addressed the comparison 
between MBCT and mADM, based on two studies (Kuyken et al., 2008; Segal et 
al., 2010) with a total of 177 participants. For patients with a history of three 
or more depressive episodes, MBCT with discontinuation of mADM was at 
least as effective as mADM alone in reducing relapse/recurrence (risk ratio 
(RR) = 0.80, 95% CI 0.60–1.08). This finding has recently been replicated in a 
large trial including 424 patients (Kuyken et al., 2015). These findings suggest 
that MBCT could be a viable alternative to mADM for patients who would like 
to withdraw from their medication. However, previous trials did not directly 
compare MBCT alone with the combination of MBCT and mADM. Therefore, 
the main aim of this multicentre, non-inferiority effectiveness trial was to 
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examine whether patients who receive MBCT for recurrent depression in 
remission could safely withdraw from mADM, i.e. without increased relapse/
recurrence risk, compared with the combination of these interventions. 
Patients were randomly allocated to MBCT followed by discontinuation 
of mADM or MBCT+mADM. The study had a follow-up of 15 months. Our 
primary hypothesis was that discontinuing mADM after MBCT would be 
non-inferior, i.e. would not lead to an unacceptably higher risk of relapse/
recurrence, compared with the combination of MBCT+mADM. In addition, 
we explored whether there was a difference between the groups in terms 
of time to relapse/recurrence, severity of (residual) depressive symptoms 
during follow-up, number, duration and severity of relapse/recurrence, and 
quality of life.
METHODS
The study design and procedures are presented in full in the study protocol 
(Huijbers et al., 2012) (ClinicalTrials.gov: NCT00928980). They are described 
in brief below. Originally we intended to conduct a three-armed randomised 
controlled trial (RCT) of MBCT alone, mADM alone or MBCT+mADM, 
but this turned out to be too complicated because of strong treatment 
preferences expressed by patients. Therefore, we decided to conduct two 
parallel RCTs: an RCT comparing MBCT followed by discontinuation of 
mADM v. MBCT+mADM for patients wanting MBCT (current trial), and an 
RCT comparing MBCT+mADM v. mADM alone for patients wanting to hold 
on to their medication (parallel trial; Huijbers et al., 2015). Thereby we 
acknowledged patients’ preferences while maintaining the experimental 
rigor of randomisation. This change has been described in the study protocol 
(Huijbers et al., 2012). The study was approved by the Medical Ethics 
Committee Arnhem-Nijmegen (nr. 2008/242) for all participating sites. After 
a complete description of the study, written informed consent was obtained 
from all participants.
Participants
Patients were recruited in 12 secondary and tertiary psychiatric out-patient 
clinics across The Netherlands between September 2009 and January 2012. 
Patients were referred by mental healthcare professionals or recruited 
by advertisements in the media (television, magazines and newspapers). 
Inclusion criteria were a history of at least three depressive episodes 
according to the DSM-IV (American Psychiatric Association, 2000); in full 
or partial remission, defined as not currently meeting the DSM-IV criteria 
for major depressive disorder; currently treated with antidepressants for 
49
Meditation or medication?
3
at least 6 months; 18 years of age or older; and Dutch speaking. Exclusion 
criteria were: bipolar disorder; any primary psychotic disorder (current 
and previous); clinically relevant neurological/somatic illness; current 
alcohol or drug dependency; high dosage of benzodiazepines (>2 mg 
lorazepam equivalents daily); recent electroconvulsive therapy (<3 months 
ago); previous MBCT and/or extensive meditation experience (for example 
retreats); current psychological treatment with a frequency of more than 
once per 3 weeks; and inability to complete interviews and self-report 
questionnaires.
Procedure
Eligibility was assessed with the Structured Clinical Interview for DSM-
IV (SCID) Axis 1 Disorders (First, Gibbon, Spitzer, & Williams, 1996) in a 
research interview performed by independent, trained research assistants. 
Eligible patients were randomly assigned to MBCT followed by guided 
discontinuation of mADM (‘MBCT+discontinuation’) or to MBCT with 
continuation of mADM (‘MBCT+mADM’). Randomisation was performed 
using a website-based application, developed specifically for this study by an 
independent statistician, with a minimisation procedure per research centre, 
stratified for full v. partial remission (scoring respectively ⩽11 or >11 on the 
Inventory of Depressive Symptomatology – Clinician rated (IDS-C; Akkerhuis, 
1997; Rush, Gullion, Basco, Jarrett, & Trivedi, 1996), number of past episodes 
(3–4 v. ⩾5), prior CBT (yes/no) and gender. Allocation was performed 
with a 1:1 ratio. Randomisation took place after the clinical interview and 
participants were informed about the assigned treatment immediately by 
the research assistant. The research assistants conducting the assessments 
could not be masked to treatment group since they were also involved in 
the practical organization of the trial. The baseline assessment took place 
after randomisation and participants started MBCT within 2 months of 
randomisation. The date of the first scheduled MBCT was considered the 
start date of the study. Follow-up assessments took place 3, 6, 9, 12 and 15 
months after this start date. Participants were assessed to the end of the 
follow-up period irrespective of relapse/recurrence. The assessments took 
place between September 2009 and June 2013.
Interventions
MBCT+discontinuation group
MBCT was largely based on the protocol by Segal, Williams & Teasdale 
(2002) with some adaptations. The intervention consisted of 8 weekly 
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sessions of 2.5 h (instead of 2 h) and 1 day of silent practice between the 
sixth and seventh session (which originates from the MBSR curriculum 
(Kabat-Zinn, 2013) and is suggested in the most recent version of the MBCT 
protocol (Segal et al., 2013). It was delivered in groups of 8–12 participants. 
MBCT included formal meditation exercises, such as the body scan, sitting 
meditation, walking meditation and mindful movement as well as informal 
exercises, such as bringing present-moment awareness to everyday activities. 
Cognitive–behavioural techniques included education, monitoring and 
scheduling of activities, identification of negative automatic thoughts and 
devising a relapse prevention plan. Participants were encouraged to practice 
meditation at home for about an hour a day using CDs.
 MBCT was provided in 12 different centres across The Netherlands, with 
a total of 19 teachers and 111 MBCT courses. Groups were mixed comprising 
patients from both treatment groups as well as patients not included in 
the trial. Videotapes of the MBCT sessions were available for 15 teachers. 
Two tapes per teacher were randomly selected. Teacher competency was 
examined by two independent expert raters using the Mindfulness-Based 
Interventions: Teaching Assessment Criteria comprising six domains (Crane 
et al., 2013). We report the average rating of these domains on a scale from 
1 to 6 (incompetent, beginner, advanced beginner, competent, proficient, 
advanced).
 Patients were asked and recommended to withdraw gradually from their 
antidepressants over a period of 5 weeks, starting after the seventh session 
of MBCT. This was supervised by psychiatrists. A protocol for medication 
tapering developed for this study by two experts in pharmacological 
treatment of major depressive disorder (W.A.N. and M.B.J.B.) was provided. 
For discontinuation we recommended a minimum of 3 and a maximum of 12 
consultations during the follow-up period. Adherence to the study protocol 
was defined as attending four or more MBCT sessions, as in previous studies 
(Kuyken et al., 2008; Teasdale et al., 2000), and having fully discontinued 
mADM before the 6-month follow-up assessment (i.e. within 6 months after 
baseline and within approximately 3–4 months after the last MBCT session).
MBCT+mADM group
MBCT was provided as described above. For continuation of mADM, a minimum 
of one consultation with a psychiatrist was recommended. Psychiatrists were 
instructed to maintain or reinstate an adequate dose of antidepressants, and 
recommendations to manage side-effects were provided. Adherence to the 
study protocol was defined as attending four or more MBCT sessions and using 
a therapeutic dose of mADM at each follow-up contact during the observed 
time period (using last observation carried forward for participants who did 
not complete all assessments).
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Outcome measures
Primary outcome
The primary outcome measure was relapse/recurrence as measured with 
the SCID-I by trained research assistants every 3 months during the follow-
up period (Huijbers et al., 2012). We purposively selected a sample of 
audiotaped SCID-I interviews (n = 35) across all study centres and across 
different levels of depression severity (mild, moderate or severe). These 
were rated by masked raters. The interrater agreement between first and 
second ratings was found to be substantial (kappa (κ) = 0.70, 95% CI 0.46–
0.94, P = 0.001) (Landis & Koch, 1977).
Secondary outcomes
Time to relapse/recurrence was calculated in weeks from the start of the 
study until the start of the first relapse/recurrence. Patients whose follow-
up data were unavailable or who did not experience a relapse/recurrence 
before the end of the follow-up period were treated as censored observations 
(with relapse/recurrence status set at 0 (‘no’) and time to event set at the 
number of weeks in the study with a maximum of 65 weeks). Severity of 
(residual) depressive symptoms was measured with the Dutch version of the 
IDS-C (Akkerhuis, 1997) at every assessment during the 15-month follow-
up period. The IDS-C has good psychometric qualities (Rush et al., 1996; 
Trivedi et al., 2004). In addition, number of relapses/recurrences (1 v. >1) 
and duration (in weeks) and severity (mild, moderate or severe) of the first 
relapse/recurrence were examined.
 Quality of life was assessed at baseline, 3 and 15 months using the 26-
item self-report WHOQOL short version (The WHOQOL Group, 1998). 
The WHOQOL assesses subjective quality of life in four domains: physical, 
psychological, social and environmental. Two questions with regard to 
overall perception of quality of life and health are included as well.
Statistical analysis
For the sample size calculation we refer to the published protocol (Huijbers et 
al., 2012). In line with this protocol, we first report analyses based on intention-
to-treat (ITT), followed by per-protocol analyses. The ITTsample included 
all participants as randomised; the per-protocol sample included those 
participants who adhered to both treatment protocols (see ‘Interventions’). 
For the primary outcome (relapse/recurrence) we calculated the one-
sided 95% confidence interval of the difference in relapse/recurrence rates 
between the groups using R version 3.1.1. To conclude non-inferiority, the 
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upper margin of the 95% confidence interval, i.e. the maximum difference 
between groups within this 95% confidence interval, should not exceed our 
non-inferiority margin of 25%. In line with regulatory guidelines on non-
inferiority trials (EMA Committee for Proprietary Medicinal Products, 2001; 
Food and Drug Administration, 2010), this should be the case for both ITT 
and per-protocol, as per-protocol analysis may be more conservative in non-
inferiority studies. In addition, a generalised linear model using a binomial 
family with an identity link was used to compare relapse/recurrence rates.
 Differences in time to relapse/recurrence were analysed using a Cox 
regression proportional hazards model using SPSS 20.0. Regression analyses 
were performed with and without adjustment for depressive symptoms at 
baseline and number of depressive episodes in the past (Log transformed), 
factors known to predict relapse/recurrence (Hardeveld, Spijker, De Graaf, 
Nolen, & Beekman, 2010). As there were no effects of research site on 
relapse/recurrence, we did not include this factor in our statistical models. 
 Severity of (residual) depressive symptoms (IDS-C) during the 15-month 
follow-up period was analysed using a latent growth curve model in MPlus 
version 7 with six time points, a random intercept and a random slope for 
group. Participants who did not complete all assessments were included 
in the analyses using full information maximum likelihood estimation for 
missing data.
 In patients who had a relapse/recurrence, number and severity were 
analysed using Pearson χ2 tests. Differences in duration of (first) relapse/
recurrence were analysed with independent-samples t-tests. 
 Quality of life was analysed with a repeated-measures ANOVA for both 
the observed data-set and the imputed data-set, using multiple imputation 
for missing data. 
 Moderation analyses were performed using Cox regression analyses for 
the stratification factors (a) full v. partial remission, (b) number of prior 
depressive episodes (3 or 4 v. 5+), (c) prior CBT (yes v. no), and (d) gender. 
Probability values lower than 0.05 were considered significant for all 
analyses.
RESULTS
Patient characteristics, flow and adherence
Table 3.1 shows the baseline demographic and clinical characteristics of the 
participants (MBCT+discontinuation group: n = 128, MBCT+mADM group: 
n = 121). There were no major imbalances between the groups. Within the 
MBCT+discontinuation group, patients who did not adhere to the protocol, 
i.e. attending fewer than four MBCT sessions and/or staying on medication, 
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had higher levels of residual depressive symptoms at baseline (14.4, s.d. = 
10.5) than those who followed the protocol (10.9, s.d. = 8.6; t = 2.09, P = 0.04, 
d = 0.37).
 Figure 3.1 shows the flow of participants from screening to analysis. 
Follow-up assessments were incomplete for 74/249 participants (30%) of 
which 41/249 (16%) did not complete any follow-up assessment. Adherence 
to MBCT was higher in the MBCT+discontinuation group (116/128, 91%) 
than in the MBCT+mADM group (96/121, 79%; χ2 = 6.26, P = 0.01). The 
number of patients adhering to the discontinuation regimen was 68/128 
(53%) and 78/121 patients (64%) adhered to the continuation regimen (χ2 
= 3.30, P = 0.07). No unexpected harms were reported.
 The teacher competency ratings showed that none of the teachers was 
incompetent, two teachers (13%) were characterised as beginners, six 
(40%) as advanced beginners, four (27%) as competent, three (20%) as 
proficient, and none as advanced. The mean teacher competency score was 
3.5 (s.d. = 0.9, range 2.0–5.2). Further details will be published elsewhere.
Primary outcome: relapse/recurrence
In the ITT sample, 69/128 participants in the MBCT+discontinuation group 
(54%) and 47/121 in the MBCT+mADM group (39%) experienced a relapse/
recurrence (RR = 1.38, 95% CI 1.05–1.83). The upper margin of the one-sided 
95% confidence interval of the difference between the groups was 25.3%, 
which exceeded our predefined non-inferiority margin of 25% (Figure 3.2). 
In the per-protocol sample, relapse/recurrence during the 15-month follow-
up occurred in 46/67 patients (69%) randomised to MBCT+discontinuation 
compared with 31/68 patients (46%) randomised to MBCT+mADM (RR = 
1.5, 95% CI 1.11–2.05). The upper margin of the one-sided 95% confidence 
interval was 36.7%, which also exceeded the non-inferiority margin. This 
implies that non-inferiority could not be shown. In addition, relapse/
recurrence rates were significantly different between the groups for the ITT 
sample (Wald χ2 = 5.81, P = 0.02) and for the per-protocol sample (Wald χ2 
= 7.76, P = 0.005).
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Table 3.1. Baseline demographic and clinical characteristics of patients with recurrent depression 
receiving mindfulness-based cognitive therapy followed by discontinuation of maintenance 
antidepressant medication (MBCT+Discontinuation) or mindfulness-based cognitive therapy plus 
maintenance antidepressant medication (MBCT+mADM).
Variable MBCT+Discontinuation MBCT+mADM
ITT (n=128) PP (n=67) ITT (n=121) PP (n=68)
N % N % N % N %
Female 92 72 52 78 76 63 40 59
Educational level 
   Low 9 7 6 9 8 6 5 7
   Middle 40 31 19 28 25 21 13 19
   High 73 57 41 61 81 67 48 71
   Missing 6 5 1 2 7 6 2 3
Marital status 
   Single 31 24 17 25 25 21 14 21
   Married/cohabiting 72 56 38 57 69 57 44 65
   Divorced/widowed 20 16 11 16 21 17 9 13
   Missing 5 4 1 2 6 5 1 1
Employed 84 66 50 75 75 62 39 57
Remission
   Full, IDS-C ≤ 11 70 55 40 60 63 52 31 46
   Partial, IDS-C > 11 58 45 27 40 58 48 37 54
Type of mADM 
   SSRI 92 72 53 79 98 81 54 79
   TCA 26 20 11 16 16 13 10 15
   Other a 10 8 3 5 7 6 4 6
Previous CBT treatment 76 59 36 54 72 60 40 59
Suicide attempt (lifetime) 25 20 14 21 22 18 13 19
Mean SD Mean SD Mean SD Mean SD
Age (years) 50.7 10.6 50.0 11.3 49.9 10.5 50.6 10.7
Baseline depression (IDS-C) 12.6 9.6 10.9 8.6 12.6 10.5 13.5 10.2
Nr. previous episodes 5.9 5.3 6.0 5.3 5.6 4.1 5.5 3.5
Age at MDD onset b 25.0 11.7 26.9 12.1 25.0 11.8 25.9 12.6
ITT, intention-to-treat; PP, per-protocol; IDS-C, Inventory of Depressive Symptomatology – Clinician rated; 
SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant; CBT, cognitive-behavioural 
therapy; MDE, major depressive episode; MDD, major depressive disorder. 
a. Including serotonin-norepinephrine reuptake inhibitors, monoamine oxidase-inhibitors, and 
mirtazapine.  b. Based on self-report.
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Enrollment 1003 Assessed for eligibility
• 1003 Telephone screens
• 373 Research interviews 686 Excluded
• 429 Not eligible
• 257 Declined participation
68 Randomised in parallel triala
249 Randomised
128 MBCT+Discontinuation
• 68 (53%) Discontinued mADM
   2 (2%) Discontinued mADM after 6 months
   17 (13%) Reduced mADM
   30 (23%) Continued mADM
   11 (9%) No information due to dropout
• 116 (91%) Completed ≥ 4 MBCT sessions
• 67 (52%) Adhered to both interventions
121 MBCT+mADM
• 78 (64%) Continued mADM
   17 (14%) Reduced mADM
   14 (12%) Discontinued mADM
   12 (10%) No information due to dropout
• 96 (79%) Completed ≥ 4 MBCT sessions
• 68 (56%) Adhered to both interventions
36 (28%) Lost to follow-up:
• 3 months: 22 (17%)
• 6 months: 3 (2%)
• 9 months: 1 (1%)
• 12 months: 7 (6%)
• 15 months: 3 (2%)
38 (31%) Lost to follow-up:
• 3 months: 19 (16%)
• 6 months: 8 (6%)
• 9 months: 6 (5%)
• 12 months: 4 (3%)
• 15 months: 1 (1%)
128 Analyzed intention-to-treat
• 61 Excluded from pre-protocol analysis
121 Analyzed intention-to-treat
• 53 Excluded from pre-protocol analysis
Random 
allocation
Follow-up
Analysis
Figure 3.1. Flow of participants from screening to analysis, comparing mindfulness-based cognitive therapy 
(MBCT) followed by discontinuation of maintenance antidepressant medication (MBCT+discontinuation) 
with MBCT plus maintenance antidepressant medication (MBCT+mADM).
 a Patients with a relative preference for MBCT were included in the current trial, whereas patients with 
a relative preference for mADM were included in a parallel trial (MBCT+mADM v. mADM alone; Huijbers 
et al., 2015).
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To examine whether there was differential drop-out based on relapse/
recurrence, we assessed whether participants who did not complete the 
entire follow-up period showed a higher rate of relapse/recurrence at the 
last observation than individuals who completed follow-up at the final 
assessment. In this procedure we excluded the participants who dropped 
out before the first follow-up assessment (n = 22 in the MBCT+discontinua-
tion group and n = 19 in the MBCT+mADM group). Of all the patients with 
one to four follow-up assessments, 9/33 (27%) had a relapse/recurrence at 
the last assessment, and in the complete case group, 43/175 (25%) had a 
relapse/recurrence at 15-month follow-up. These proportions were 
comparable (χ2 = 0.12, P = 0.74).
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Figure 3.2. Plot showing the differences in relapse/recurrence rates and corresponding one-sided 
95% confidence intervals exceeding the non-inferiority margin, for patients with recurrent depression 
receiving either mindfulness-based cognitive therapy (MBCT) followed by discontinuation of maintenance 
antidepressant medication (MBCT+discontinuation group, n = 128) or MBCT plus maintenance 
antidepressant medication (MBCT+mADM, n = 121).
Secondary outcomes
Figure 3.3 shows the survival (i.e. non-relapse/recurrence) curves over 
the 15-month follow-up period for the ITT and per-protocol samples. The 
MBCT+discontinuation group was associated with an increased relapse/
recurrence risk over the 15-month follow-up period (ITT: hazard ratio (HR) = 
1.59, 95% CI 1.10–2.31, P = 0.01 and per-protocol: HR = 1.59, 95% CI 1.01–2.51, 
P = 0.05). Results were similar for analyses adjusted for baseline depression 
severity and number of previous episodes. Results of the moderation analyses 
are shown in supplementary table S1. In summary, no moderation effects of 
full v. partial remission, number of prior depressive episodes (3 or 4 v. 5+), 
prior CBT or gender on the effect of group were observed.
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Figure 3.3. Survival curves over 15-month follow-up (65 weeks) for patients with recurrent depression 
receiving either mindfulness-based cognitive therapy (MBCT) followed by discontinuation of maintenance 
antidepressant medication (MBCT+discontinuation, n = 128) or MBCT plus maintenance antidepressant 
medication (MBCT+mADM, n = 121).
(A) Intention-to-treat analysis, (B) per-protocol analysis.
The latent growth curve analysis for severity of (residual) depressive 
symptoms (IDS-C) over the 15-month follow-up period showed an acceptable 
model fit, χ2(d.f. = 20) = 39.85 (n = 249), P = 0.005, comparative fit index 
(CFI) = 0.95, root mean square error of approximation (RMSEA) = 0.06, 
standardised root mean square residual (SRMR) = 0.06. On average, patients 
maintained mild levels of depression throughout the study period (Figure 
3.4). The course of depression did not significantly vary between the groups 
(β = −0.05, P = 0.66 and β = −0.10, P = 0.43 for the ITT and per-protocol 
analyses, respectively). However, when looking at the individual follow-up 
assessments separately, the MBCT+discontinuation group had higher levels 
of depression at 3-month follow-up (15.4) than the MBCT+mADM group 
(12.2). This difference was small but significant (F(188) = 5.8, P = 0.02, d = 
0.28). Depression levels did not differ between groups at the other follow-up 
assessments. In the per-protocol sample, there was a smaller difference at 
3-month follow-up, indicated by a trend (F(117) = 3.1, P = 0.08, d = 0.20).
 For those patients experiencing a relapse/recurrence, there were no 
differences between the groups in terms of number of relapses/recurrences 
(ITT: χ2 = 0.02, P = 0.89; per-protocol: χ2 = 1.43, P = 0.23), duration of (first) 
relapse (ITT: t = 0.03, P = 0.97; per-protocol: t = 0.18, P = 0.86) or severity 
of (first) relapse/recurrence (ITT: χ2 = 1.07, P = 0.59; per-protocol: χ2 = 
3.32, P = 0.19). Supplementary table S2 shows the results for the analyses 
on quality of life. In summary, there were no differences between the groups 
with regard to quality of life at 3-months and 15-months follow-up.
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Figure 3.4. Severity of (residual) depressive symptoms over 15-month follow-up for patients with 
recurrent depression receiving either mindfulness-based cognitive therapy (MBCT) followed by 
discontinuation of maintenance antidepressant medication (MBCT+discontinuation, n = 128) or MBCT 
plus maintenance antidepressant medication (MBCT+mADM, n = 121).
(A) Intention-to-treat analysis, (B) per-protocol analysis.
a Inventory of Depressive Symptomatology – Clinician rated (IDS-C) cut-off points for depression severity: 
0–11 none, 12–23 mild, 24–36 moderate, 37–46 severe and 47–84 very severe.
DISCUSSION
Principal findings and comparison with other studies
This is the first study comparing MBCT followed by discontinuation of mADM 
with the combination of these interventions (MBCT+mADM). The findings 
of this effectiveness study reflect an increased risk of relapse/recurrence 
for patients withdrawing from mADM after having participated in MBCT 
for recurrent depression. The overall course of depression severity during 
the 15-month follow-up period was similar in both groups, although a small 
difference was observed at 3-month follow-up. At that point, parallel with 
the moment of discontinuation, patients in the withdrawal group had higher 
depression levels. In addition, this study found no differences between the 
groups in terms of number, duration and severity of relapse in those patients 
who relapsed. Moreover, quality of life did not differ between the groups.
 Our results seem to be in line with evidence that combination therapy is 
more effective than monotherapy in the acute treatment of major depressive 
disorder (Cuijpers et al., 2014) and also for prevention of relapse/recurrence 
(Guidi, Fava, Fava, & Papakostas, 2011). On the other hand, earlier studies 
demonstrated that the efficacy of MBCT followed by withdrawal from 
mADM, performed in carefully controlled research circumstances, was 
similar to that of mADM alone (Kuyken et al., 2008; Kuyken et al., 2015; 
Segal et al., 2010). These findings suggest that MBCT might protect patients 
with recurrent depression from relapse/recurrence. In those studies, the 
withdrawal process took place as part of the intervention at the same time 
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in the whole group. Under those circumstances, there may have been more 
emphasis on using mindfulness skills to accept the symptoms as they were 
and to disengage from anticipatory fears and worries. In contrast, MBCT was 
delivered in mixed groups in the current study. Consequently, patients might 
have felt more insecure, have lacked support compared with other studies 
and might even have been actively discouraged to pursue discontinuation by 
fellow-participants and/or their attending psychiatrists.
 In addition, relapse/recurrence rates after discontinuation of 
antidepressants were somewhat higher in the current study (ITT 54% 
and per-protocol 69%) compared with earlier studies reporting estimates 
around 45% within 12–15 months (Fava et al., 2004; Kuyken et al., 2008; 
Viguera et al., 1998). Participants in the current study may have been more 
at risk for relapse as about half of them were in partial (rather than full) 
remission and their level of baseline depressive symptoms was relatively 
high, for example compared with the studies by Kuyken and colleagues (2008; 
2015). In addition, a substantial number of the participants in this trial were 
reluctant to discontinue their mADM, partly based on previous unsuccessful 
attempts to do so, as were their attending psychiatrists. So, adherence to the 
discontinuation protocol was substantially lower in our study (53%) than in 
the studies by Kuyken and colleagues (75% and 71%) (2008; 2015). Patients 
who were not willing to withdraw may have been sensible to do so, given 
their higher levels of baseline depression in comparison with those who 
adhered to the protocol. On the other hand, previous studies have shown 
that discontinuation of antidepressants can be hampered by withdrawal 
effects (Haddad & Anderson, 2007; Lejoyeux & Ades, 1997) that may be 
misinterpreted as signs of a possible relapse/recurrence (Rosenbaum, Fava, 
Hoog, Ascroft, & Krebs, 1998; Verbeek-Heida & Mathot, 2006).
Strengths and limitations
The great strength of the study is that MBCT was delivered in a ‘real-life’ 
setting, from university hospitals to community mental health centres across 
The Netherlands, by teachers with varying experience and competence, and 
in groups mixed with other types of patients. In addition to the standard 
dichotomous classification of relapse/recurrence we also assessed 
depressive symptoms over time as a continuous measure. In contrast with the 
higher relapse/recurrence rate, the overall course of depressive symptoms 
was similar between groups. This raises the question what parameter might 
be the better measure of the patients’ suffering. Some authors have argued 
for the latter (Goldberg, 2000; Kraemer, Noda, & O’Hara, 2004). A limitation 
of our approach was that the intervals between assessments were relatively 
long and that we did not include a self-report measure of depression.
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In terms of patient selection, a limitation of the current study is that the 
results may apply to patients in secondary and tertiary care, but cannot be 
assumed to extrapolate to primary care patients or patients with less severe 
forms of depression. Discontinuation may be particularly unfavourable for 
patients who are at highest risk for relapse/recurrence because of residual 
symptoms and several previous episodes, as sampled in the current study.
 A methodological limitation was that it was practically impossible to 
keep the research assistants at the different sites masked to group. However, 
a substantial interrater agreement (κ = 0.70) was found for the primary 
outcome measure (relapse/recurrence according to SCID-I) when compared 
with a second rater who was truly masked to group. Moreover, the relapse/
recurrence rates in ITT analysis may have been biased because of incomplete 
follow-ups, assuming no relapse at the time of censoring. Estimates obtained 
from complete case analysis were higher, i.e. 61/92 (66%) relapse/recurrence 
in the MBCT+discontinuation group and 40/83 (48%) in the MBCT+mADM 
group, and probably more realistic.
Clinical and research implications
In summary, in routine clinical practice, patients with recurrent depression 
should be generally recommended to stay on medication and be informed 
that discontinuation of mADM may be associated with an increased risk of 
relapse/recurrence. This does not necessarily mean, however, that patients 
who do want to discontinue their mADM should not be supported to have a 
try or that they could not benefit from MBCT. A recommendation for future 
research and clinical practice would be to ensure that the clinician who 
supports the process of discontinuation is also trained in the mindfulness 
model so that the difficulties that come up can be managed within this 
framework. Given the many psychological factors that may influence 
discontinuation, placebo-controlled studies might inform us on the relative 
contributions of physical and psychological barriers that patients encounter. 
In addition, further qualitative research on the barriers and facilitators that 
patients experience during the discontinuation process might help us to 
better tailor our interventions to support them.
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SUPPLEMENTARY TABLE S1
Table S1 (supplementary file). Cox regression proportional hazards analyses for time to relapse/
recurrence in patients with recurrent depression receiving mindfulness-based cognitive therapy followed 
by discontinuation of maintenance antidepressant medication (MBCT+Discontinuation) or mindfulness-
based cognitive therapy plus maintenance antidepressant medication (MBCT+mADM), with moderator 
variables of interest.
Variable Intention-to-treat 
analysis (N=249)
Per-protocol analysis 
(N=135)
Hazard 
ratio
95% 
confi-
dence 
interval
p Hazard 
ratio 
95% 
confi-
dence 
interval
p
Condition 
(MBCT+Discontinuation 
vs. MBCT+mADM)
1.59 1.10 to 
2.31
.01 1.59 1.01 to 
2.51
.05
Condition, adjusteda 1.60 1.11 to 
2.33
.01 1.69 1.07 to 
2.68
.03
Remission (full vs. partial) 0.64 0.45 to 
0.93
.02 0.61 0.39 to 
0.96
.03
   Remission x Condition 1.17 0.55 to 
2.45
.69 1.06 0.42 to 
2.67
.91
Nr of episodes (3-4 vs. 5+) 1.00 0.70 to 
1.44
.99 0.91 0.58 to 
1.43
.69
   Episodes x Condition 0.58 0.28 to 
1.23
.16 0.93 0.37 to 
2.32
.88
Prior CBT (no vs. yes) 0.68 0.46 to 
1.00
.05 0.73 0.46 to 
1.15
.17
   CBT x Condition 0.70 0.32 to 
1.52
.36 0.56 0.22 to 
1.43
.22
Gender (male vs. female) 0.75 0.50 to 
1.11
.15 0.81 0.50 to 
1.32
.40
   Gender x Condition 0.61 0.27 to 
1.35
.22 0.50 0.18 to 
1.38
.18
CBT, cognitive-behavioural therapy.
a Adjusted for depressive symptoms (Inventory of Depressive Symptomatology, Clinican Rated) at baseline 
and number of depressive episodes in the past. 
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SUPPLEMENTARY TABLE S2
Table S2 (supplementary file). Quality of life for the MBCT+Discontinuation group (N = 128) and 
MBCT+mADM group (N = 121) at baseline, 3 and 15 months.
Variable Baseline 3 months 15 months
Mean 
(SD)
N Mean 
(SD)
N Mean 
(SD)
N pa pb
WHO-QoL – Q1: overall perception 
of quality of life
.36 .24
    MBCT+Discontinuation 3.5 
(0.8)
116 3.4 
(0.9)
93 3.6 
(0.8)
83
    MBCT+mADM 3.5 
(0.8)
113 3.6 
(0.8)
86 3.7 
(0.9)
68
WHO-QoL – Q2: overall perception 
of health
.55 .29
    MBCT+Discontinuation 3.5 
(1.0)
116 3.3 
(1.0)
92 3.4 
(1.0)
83
    MBCT+mADM 3.4 
(1.0)
113 3.3 
(1.0)
85 3.4 
(1.1)
68
WHO-QoL – physical domain .48 .36
    MBCT+Discontinuation 24.6 
(4.3)
116 24.4 
(4.5)
93 25.4 
(4.9)
83
    MBCT+mADM 24.2 
(4.4)
113 24.6 
(4.7)
86 25.6 
(4.5)
67
WHO-QoL – psychological domain .21 .22
    MBCT+Discontinuation 19.1 
(3.1)
116 18.8 
(3.7)
93 19.7 
(3.6)
82
    MBCT+mADM 18.7 
(3.2)
113 19.9 
(3.6)
86 20.0 
(3.8)
68
WHO-QoL – social domain .94 .60
    MBCT+Discontinuation 10.1 
(2.2)
115 10.1 
(2.1)
93 10.5 
(2.3)
83
    MBCT+mADM 9.8 
(2.2)
113 10.0 
(2.2)
86 10.1 
(2.2)
68
WHO-QoL – environmental domain .60 .65
    MBCT+Discontinuation 30.9 
(4.2)
115 30.7 
(4.9)
93 31.6 
(4.5)
83
    MBCT+mADM 30.6 
(4.0)
113 30.5 
(4.2)
86 31.9 
(4.0)
68
WHO-QoL = WHO Quality of Life. a p-value reported for the repeated measures analysis on condition 
– time interaction based on observed data. b p-value reported for the repeated measures analysis on 
condition – time interaction based on imputed data.
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ABSTRACT
Background
Mindfulness-based cognitive therapy (MBCT) and maintenance 
antidepressant medication (mADM) both reduce the risk of relapse in 
recurrent depression, but their combination has not been studied. Our aim 
was to investigate whether the addition of MBCT to mADM is a more effective 
prevention strategy than mADM alone.
Methods
This study is one of two multicenter randomised trials comparing the 
combination of MBCT and mADM to either intervention on its own. In the 
current trial, recurrently depressed patients in remission who had been 
using mADM for 6 months or longer (n = 68), were randomly allocated to 
either MBCT+mADM (n = 33) or mADM alone (n = 35). Primary outcome was 
depressive relapse/recurrence within 15 months. Key secondary outcomes 
were time to relapse/recurrence and depression severity. Analyses were 
based on intention-to-treat.
Results
There were no significant differences between the groups on any of the 
outcome measures.
Limitations
The current study included patients who had recovered from depression 
with mADM and who preferred the certainty of continuing medication to the 
possibility of participating in MBCT. Lower expectations of mindfulness in 
the current trial, compared with the parallel trial, may have caused selection 
bias. In addition, recruitment was hampered by the increasing availability of 
MBCT in the Netherlands, and even about a quarter of participants included 
in the trial who were allocated to the control group chose to get MBCT 
elsewhere.
Conclusions
For this selection of recurrently depressed patients in remission and using 
mADM for 6 months or longer, MBCT did not further reduce their risk for 
relapse/recurrence or their (residual) depressive symptoms.
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INTRODUCTION
Major depressive disorder (MDD) is one of the most common mental 
disorders, characterised by high rates of relapse and recurrence (Richards, 
2011). The most common strategy to prevent relapse/recurrence after a 
depressive episode is maintenance antidepressant medication (mADM), 
which has been found more effective than placebo (Kaymaz et al., 2008). A 
different strategy for relapse/recurrence prevention in recurrent depression 
is mindfulness-based cognitive therapy (MBCT; Segal et al., 2002). It is 
a group based psychosocial intervention that integrates elements from 
mindfulness-based stress reduction (Kabat-Zinn, 1990) and cognitive 
behavioural therapy (CBT; Beck et al., 1979). A meta-analysis showed that in 
patients with three or more previous episodes of depression, MBCT reduces 
the 12-month relapse/recurrence risk compared with usual care or placebo, 
with a relative risk reduction of 43% (Piet & Hougaard, 2011). Based on this 
evidence, MBCT is recommended for patients in remission who are at high 
risk of depressive relapse/recurrence (National Institute for Health and Care 
Excellence, 2009; Spijker et al., 2013). In addition, MBCT appears to be at 
least as effective as mADM (Kuyken et al., 2008; Kuyken et al., 2015; Segal 
et al., 2010). However, for patients with a high relapse/recurrence risk, a 
combination of medication and psychotherapy may be recommended (Keller 
et al., 2000; Thase, 2014). The combination of two different interventions 
might be helpful as they might be complementary to each other, work in 
synergy or one treatment might have a positive influence on the adherence 
to the other treatment (Craighead & Dunlop, 2014). Previous neuroimaging 
research indeed suggested that medication and psychotherapy for depression 
involve different neural pathways (Goldapple et al., 2004). In addition, mADM 
might improve cognitive functions such as concentration and memory which 
might facilitate patients’ learning processes during MBCT. In turn, MBCT 
might result in accepting and acknowledging their depression more which 
might enhance compliance with mADM. Meta-analyses indeed showed that 
the combination of medication and psychological therapy was more effective 
than monotherapy in both current MDD (Cuijpers et al., 2014, de Maat et al., 
2008; Pampallona et al., 2004) and prevention of relapse/recurrence (Guidi 
et al., 2011).
 The combination of MBCT and mADM for prevention of relapse/
recurrence has not been studied yet. Earlier trials (Godfrin & van Heeringen, 
2010; Ma and Teasdale, 2004; Teasdale et al., 2000) investigating the 
additional value of MBCT to usual care excluded patients who were using 
ADM at baseline, but results from a more recent trial indicate that MBCT 
may be particularly useful for patients who are using ADM (Meadows et al., 
2014). Hence, the aim of the current study was to investigate whether the 
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combination of MBCT and mADM is superior to mADM alone. In this paper 
we present the results of a randomised controlled trial (RCT) assessing the 
15-month relapse/recurrence rate in 68 patients remitted from recurrent 
depression, who were randomly allocated to either MBCT+mADM (n = 
33) or continuation of mADM alone (n = 35). Our primary hypothesis was 
that MBCT+mADM would result in a reduction of the relapse/recurrence 
risk compared to mADM. In addition, we hypothesised that MBCT+mADM 
would be superior to mADM on the secondary outcomes time to relapse/
recurrence, severity of (residual) depressive symptoms during follow-up, 
number, duration, and severity of relapse/recurrence, and quality of life.
METHODS
Design
The study design and procedures are presented in full in the published 
study protocol (Huijbers et al., 2012) and are summarised below. Originally 
we intended to conduct a three-armed RCT of MBCT alone, mADM alone 
or MBCT+mADM, but this turned out to be not feasible due to strong 
treatment preferences expressed by patients. Treatment preferences may be 
associated with treatment outcomes (Kocsis et al., 2009; Swift et al., 2011) 
and patients with strong preferences are less likely to enter RCTs if their 
preferences are not supported (van Schaik et al., 2004). Therefore we ended 
up conducting two parallel RCTs. Patients preferring MBCT participated in 
an RCT comparing the combination of MBCT and mADM with MBCT followed 
by discontinuation of mADM (Huijbers et al., 2016). Patients preferring to 
hold on to their mADM participated in an RCT comparing the combination of 
MBCT and mADM with mADM alone (current trial). The study was approved 
by the Medical Ethics Committee Arnhem-Nijmegen (nr. 2008/242) for all 
participating sites. After complete description of the study, written informed 
consent was obtained from all participants.
Participants
Patients were recruited in twelve university and secondary mental health 
centres across the Netherlands between September 2009 and January 
2012. Patients were referred by mental healthcare professionals, general 
practitioners, or recruited via advertisements in the media (TV, magazines, 
and newspapers). Inclusion criteria were a history of at least three 
depressive episodes according to the Diagnostic and Statistical Manual of 
Mental Disorders-4th edition (DSM-IV); in full or partial remission, defined 
as not currently meeting the DSM-IV criteria for MDD; currently treated with 
ADM for at least 6 months; 18 years of age or older; and Dutch speaking. 
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Exclusion criteria were: bipolar disorder; any primary psychotic disorder 
(current and previous); clinically relevant neurological/somatic illness; 
current alcohol or drug dependency; high dosage of benzodiazepines (>2 
mg lorazepam equivalents daily); recent electroconvulsive therapy (<3 
months ago); previous MBCT and/or extensive meditation experience (i.e. 
retreats); current psychological treatment with a frequency of more than 
once per three weeks; and inability to complete interviews and self-report 
questionnaires.
Procedure
Eligibility was assessed with the Structured Clinical Interview for DSM-
IV (SCID) Axis 1 Disorders (First et al., 1996) in a research interview 
performed by independent, trained research assistants. Research assistants 
were employees within the participating centres, mostly research nurses 
and psychologists. They received 2 days of training in using the SCID, and 
subsequently there were regular meetings to discuss possible difficulties 
and questions about the assessments. Eligible patients were randomly 
assigned to MBCT combined with mADM or to mADM alone. Randomisation 
was performed using a website-based application, developed specifically for 
this study by an independent statistician, with a minimisation procedure 
for research centre, full versus partial remission (scoring respectively ≤11 
or >11; Epidemiology Data Center, 2015) on the Inventory of Depressive 
Symptomatology – Clinician rated (IDS-C; Akkerhuis, 1997; Rush et al., 1996), 
number of past episodes (3–4 versus ≥5), prior CBT (yes/no), and gender. 
Allocation was performed with a 1:1 ratio. Randomisation took place after 
the clinical interview and participants were informed about the assigned 
treatment immediately by the research assistant. The research assistants 
conducting the assessments could not be blinded to treatment condition 
since they were also involved in the practical organization of the trial. 
The baseline assessment took place after randomisation, and participants 
started MBCT within two months after randomisation. The date of the first 
scheduled MBCT was considered the start date of the study. Follow-up 
assessments took place 3, 6, 9, 12, and 15 months after this start date. The 
assessments took place between September 2009 and June 2013.
Interventions
Mindfulness-based cognitive therapy (MBCT)
MBCT was largely based on the protocol by Segal et al. (2002) with some 
adaptations. The intervention consisted of 8 weekly sessions of 2.5 (instead 
of 2) h and one day of silent practice between the 6th and 7th session (which 
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originates from the MBSR curriculum (Kabat-Zinn, 1990) and is suggested 
in the most recent version of the MBCT protocol (Segal et al., 2012)). It 
was delivered in groups of 8–12 participants. MBCT included both formal 
meditation exercises, such as the body scan, sitting meditation, walking 
meditation and mindful movement, and informal exercises, such as bringing 
present-moment awareness to everyday activities. Cognitive-behavioural 
techniques included education, monitoring and scheduling of activities, 
identification of negative automatic thoughts, and devising a relapse 
prevention plan. Participants were encouraged to practise meditation at 
home for about an hour a day using CDs. MBCT was offered in nine different 
sites across the Netherlands by nine teachers providing 32 MBCT courses. 
Groups were mixed comprising patients from both the current and parallel 
trial as well as regular patients. Video tapes of the MBCT sessions were 
available for nine teachers. Two tapes per teacher were randomly selected 
and teacher competency was examined by two independent expert raters 
using the Mindfulness-Based Interventions: Teaching Assessment Criteria 
(English version) (Crane et al., 2013). We report the average rating of its six 
domains on a scale from 1 to 6 (incompetent - beginner - advanced beginner 
– competent – proficient - advanced).
 In addition, patients were asked to continue their mADM as described 
below. Adherence to the study protocol was defined as attending four or 
more MBCT sessions (Kuyken et al., 2008; Teasdale et al., 2000) and using 
a therapeutic dose of mADM (Van der Kuy, 2000) at each follow-up contact 
during the observed time period. We did not place restrictions on utilisation 
of usual care. Usual care was assessed every three months using an adapted 
version of the Client Service Receipt Inventory (Beecham and Knapp,1992).
Maintenance of antidepressant medication (mADM)
Patients attended at least one visit with study psychiatrists for a review of 
their mADM. A protocol for optimisation was developed by two experts in 
pharmacological treatment of MDD (WN and MB) (Huijbers et al., 2012). 
Psychiatrists were instructed to maintain or reinstate an adequate dose 
of mADM, and recommendations to manage side effects were provided. 
Adherence to the study protocol was defined as using a therapeutic dose 
of mADM at each follow-up contact during the observed time period (using 
last observation carried forward for participants who did not complete all 
assessments) and not attending MBCT.
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Outcome measures
Primary outcome
The primary outcome measure was relapse/recurrence as measured with 
the SCID-I by trained research assistants every three months during the 
15-month follow-up period. We purposively selected a sample of audio taped 
SCID-I interviews (n = 35) across all study centres and across different levels 
of depression severity (mild, moderate, or severe). These were rated by 
blind raters. The inter-rater agreement between first and second ratings was 
found to be substantial (Landis and Koch, 1977), κ = 0.70, 95% confidence 
interval 0.46–0.94.
Secondary outcomes
Time to relapse/recurrence was calculated in weeks from the start of the 
study until the start of the first relapse/recurrence. Severity of (residual) 
depressive symptoms was measured with the IDS-C at every assessment 
during the 15-month follow-up period. The IDS-C has good psychometric 
qualities (Rush et al., 1996). In addition, number of relapses/recurrences 
(one versus >one) and duration (in weeks) and severity (mild, moderate, or 
severe) of the first relapse/recurrence were examined.
 Quality of life was assessed at baseline, 3 and 15 months using the 26-
item self-report WHOQOL short version (The WHOQOL Group, 1998). 
The WHOQOL assesses subjective quality of life in four domains: physical, 
psychological, social and environmental. Two questions with regard to 
overall perception of quality of life and health are included as well.
Statistical analysis
For the sample size calculation we refer to the published protocol (Huijbers 
et al., 2012). A total of 96 participants (48 per group) was needed to 
demonstrate a difference of 25%, with a power of 0.80 and alpha of 0.05. In 
line with the protocol, we primarily report analyses based on intention-to-
treat (ITT), followed by per-protocol (PP) analyses.
 Relapse/recurrence rates were compared with a Pearson χ2 test. 
Differences in time to relapse/recurrence were analysed using a Cox 
regression proportional hazards model using IBM SPSS Statistics 20. Patients 
whose follow-up data were unavailable or who did not experience a relapse/
recurrence before the end of the follow-up period were treated as censored 
observations. Regression analyses were performed with and without 
adjustment for depressive symptoms at baseline and number of depressive 
episodes in the past (log transformed), factors known to predict relapse/
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recurrence (Hardeveld et al., 2010). As there were no effects of research site 
on relapse/recurrence, we did not include site in our statistical models.
 Severity of (residual) depressive symptoms (IDS-C) during the 15-month 
follow-up period was analysed using a latent growth curve model in MPlus 
version 7 (Muthén and Muthén, 1998) with 6 time points, a random intercept, 
and a random slope for condition. Participants who did not complete all 
assessments were included in the analyses using full information maximum 
likelihood estimation for missing data.
 In patients who had a relapse/recurrence, number (one versus >one) 
and severity (mild, moderate, or severe) were analysed using the Pearson 
χ2 tests. Differences in duration of (first) relapse/recurrence were analysed 
with independent samples t-tests. Quality of life was analysed with a repeated 
measures ANOVA in IBM SPSS Statistics 20 for both the observed dataset and 
the imputed dataset, using multiple imputation for missing data (Asendorpf 
et al., 2014).
RESULTS
Patient characteristics, flow, and adherence
From all included patients in the two RCTs, the majority was referred by 
clinicians from within the participating centres, approximately 40% of 
the patients were recruited via self-referral after advertisements in the 
media (including an announcement on television), and a small number of 
patients was referred by general practitioners. As shown in Figure 4.1, most 
recurrently depressed patients preferred MBCT and chose to participate in 
the parallel trial (n = 249; Huijbers et al., 2016). A minority preferring to 
hold on to their mADM chose to participate in the current trial (n = 68).
 There were no major imbalances in demographic or clinical characteristics 
between the combination and mADM only group (see Table 4.1), except for 
type of antidepressant. In the mADM group, more patients used selective 
serotonine reuptake inhibitors, whereas in the combination group, more 
patients used tricyclic antidepressants, serotonin-norepinephrine reuptake 
inhibitors, monoamine oxidase-inhibitors, or mirtazapine. 
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Table 4.1. Baseline demographic and clinical characteristics of participants in the MBCT+mADM and 
mADM group.
Variable MBCT+mADM 
(N=33)
mADM 
(N=35)
pa
Female 73 % 71 % .91
Age (years) 51.9 ± 14.4 51.6 ± 14.2 .94
Educational level .97
   Low 12 % 11 %
   Middle 33 % 34 %
   High 55 % 49 %
   Missing 0 % 6 %
Marital status .35
   Single 30 % 20 %
   Married/cohabiting 61 % 57 %
   Divorced/widowed 9 % 20 %
   Missing 0 % 3 %
Employed 64 % 49 % .21
Baseline depression (IDS-C) 12.8 ± 10.5 11.5 ± 8.9 .59
Remission .84
   Full, IDS-C ≤ 11 58 % 60 %
   Partial, IDS-C > 11 42 % 40 %
Type of mADM .03
   Selective serotonine reuptake inhibitor 61 % 89 %
   Tricyclic antidepressant 24 % 8 %
   Other b 15 % 3 %
Nr. previous episodes 7.4 ± 8.8 
(median 5)
7.4 ± 5.2 
(median 5)
.98
Previous CBT treatment 52 % 51 % .99
Suicide attempt (lifetime) 21 % 11 % .27
Age at MDD onset c 23.7 ± 10.5 25.1 ± 12.5 .64
IDS-C, Inventory of Depressive Symptomatology – Clinician rated; CBT, cognitive-behavioural therapy; 
MDE, major depressive episode; MDD, major depressive disorder. a Pearson χ2 tests for categorical 
variables and independent samples t-tests for continuous variables; b Including serotonin-norepinephrine 
reuptake inhibitors, monoamine oxidase-inhibitors, and mirtazapine; c Based on self-report.
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Enrollment 1003 Assessed for eligibility
• 1003 Telephone screens
• 373 Research interviews
686 Excluded
• 429 Not eligible
   - 96 Less then 3 episodes
   - 80 Currently depressed
   - 165 Not using ADM ≥ 6 months
   - 88 Met exclusion criteria
• 257 Declined participation
   - 79 Refused randomisation
   - 178 Practical or unknown reasons
249 Randomised in parallel trial
(Huijbers et al., 2016)68 Randomised
33 MBCT+mADM
• 28 (85%) Continued mADM
   4 (12%) Reduced/discontinued mADM
   1 (3%) No information due to dropout
• 28 (85%) Completed ≥ 4 MBCT sessions
• 23 (70%) Adhered to both interventions
35 mADM
• 28 (80%) Continued mADM
   2 (6%) Discontinued mADM
   5 (14%) No information due to dropout
• 8 (23%) Attended ≥ 4 MBCT sessions 
   (protocol violation)
• 21 (60%) Adhered to both interventions 
   (including not attending MBCT)
5 (15%) Lost to follow-up:
• 3 months: 3 (9%)
• 6 months: 1 (3%)
• 9 months: 1 (3%)
• 12 months: 0 (0%)
• 15 months: 0 (0%)
7 (20%) Lost to follow-up:
• 3 months: 5 (14%)
• 6 months: 0 (0%)
• 9 months: 0 (0%)
• 12 months: 0 (0%)
• 15 months: 2 (6%)
33 Analyzed intention-to-treat
• 10 Excluded from pre-protocol analysis
35 Analyzed intention-to-treat
• 14 Excluded from pre-protocol analysis
Random 
allocation
Follow-up
Analysis
Figure 4.1. Flow of participants from screening to analysis.
Figure 4.1 shows the flow of participants from screening to analysis. In the 
MBCT+mADM condition, 28/33 patients (85%) completed MBCT. In the 
mADM condition, 8/35 patients (23%) received MBCT (protocol violation). 
Adherence to mADM did not differ between MBCT+mADM (n = 28/33, 85%) 
and mADM (n = 28/35, 80%). Follow-up assessments were incomplete for 
12/68 participants (18%) of whom 8/68 (12%) did not complete any follow-
up assessment. There were no significant differences between the groups 
with regard to utilisation of usual care during the study period (see Table 
4.3). No unexpected harms were reported.
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The teacher competency assessment showed that one teacher was 
characterised as beginner, four as advanced beginners, and four as competent. 
The mean teacher competency score was 3.4 (SD 0.7, range 2.2–4.3).
Primary outcome: relapse/recurrence
No differences in relapse/recurrence rates were observed between 
MBCT+mADM and mADM. In the ITT sample, the relapse/recurrence rate 
was 36% (12/33) in the combination group and 37% (13/35) in the mADM 
only group (χ2 = 0.004; p = 0.95). In the PP sample, the difference in relapse/
recurrence rates was somewhat greater, but not significantly so: 39% (9/23) 
in the combination group and 48% (10/21) in the medication only group (χ2 
= 0.32; p = 0.57).
Secondary outcomes: time to relapse/recurrence, severity of (residual) 
depressive symptoms during follow-up, number, duration, and severity 
of relapse/recurrence, and quality of life
Figure 4.2 shows the survival (i.e. non-relapse/recurrence) curves over the 
15-month follow-up period. Cox regression analyses showed that there was 
no difference in time to relapse/recurrence between the two conditions for 
both ITT (hazard ratio = 0.87, 95% confidence interval 0.40–1.90; p = 0.72) 
and PP (hazard ratio = 0.75, 95% confidence interval 0.31–1.85; p = 0.53) 
samples. Results were similar for analyses adjusted for baseline depression 
severity and number of previous episodes.
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Figure 4.2. Survival curves over 15-month follow-up (65 weeks) for MBCT+mADM (n = 33) and mADM (n = 35).
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The latent growth curve analysis for severity of (residual) depressive 
symptoms (IDS-C) over the 15-month follow-up period showed a good 
model fit with χ2 (df=20)=16.18 (n = 68), p = 0.71, comparative fit index 
= 1.00, root mean square error of approximation = 0.00 and standardised 
root mean square residual = 0.07. On average, patients maintained mild 
levels of depression throughout the study period (Figure 4.3). The course of 
depression did not significantly vary between the conditions (β = −0.07, p = 
0.69 and β = 0.16, p = 0.53 for the ITT and PP analyses, respectively). 
 For those patients experiencing a relapse/recurrence, there were 
no differences between the conditions in terms of number of relapses/
recurrences during the 15-month follow up period (ITT: χ2=0.10, p=0.75; 
PP: χ2=0.02, p=0.88), duration of (first) relapse (ITT: t=0.01, p=0.99; PP: 
t=−0.02, p=0.98), or severity of (first) relapse/recurrence (ITT: χ2=3.44, 
p=0.18; PP: χ2=0.57, p=0.75).
 Table 4.2 shows the results for the analyses on quality of life. In summary, 
there were no differences between the conditions with regard to quality of life.
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Figure 4.3. Severity of (residual) depressive symptoms over 15-month follow-up for MBCT+mADM (n = 
33) and mADM (n = 35). 
a IDS-C=Inventory of Depressive Symptomatology – Clinician Rated; cut-off points for depression severity: 
0–1 none, 12–23 mild, 24–36 moderate, 37–46 severe, 47–84 very severe (Epidemiology Data Center, 
2015).
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Table 4.2. Quality of life for the MBCT+mADM (n = 33) and mADM group (n = 35) at baseline, 3 and 15 
months.
Variable Baseline 3 months 15 months
Mean 
(SD)
N Mean 
(SD)
N Mean 
(SD)
N pa pb
WHO-QoL – Q1: overall percep-
tion of quality of life
.68 .38
    MBCT+mADM 3.7 
(0.7)
32 3.8 
(0.7)
27 3.8 
(0.8)
26
    mADM 3.8 
(0.8)
33 3.8 
(1.0)
27 4.0 
(0.5)
24
WHO-QoL – Q2: overall percep-
tion of health
.55 .23
    MBCT+mADM 3.3 
(0.9)
32 3.5 
(1.1)
26 3.5 
(0.9)
26
    mADM 3.7 
(0.8)
33 3.7 
(1.0)
27 3.9 
(0.7)
24
WHO-QoL – physical domain .25 .14
    MBCT+mADM 24.3 
(3.3)
32 25.3 
(3.9)
27 26.2 
(4.2)
26
    mADM 25.0 
(4.5)
32 24.4 
(4.5)
27 25.4 
(4.7)
24
WHO-QoL – psychological 
domain
.28 .17
    MBCT+mADM 19.3 
(3.2)
32 20.5 
(3.3)
27 20.2 
(3.6)
26
    mADM 20.1 
(3.9)
32 20.4 
(3.7)
27 21.2 
(2.8)
24
WHO-QoL – social domain .10 .10
    MBCT+mADM 10.4 
(2.4)
32 10.9 
(1.9)
27 10.5 
(2.5)
26
    mADM 11.1 
(2.3)
32 10.4 
(2.3)
28 10.6 
(2.4)
24
WHO-QoL – environmental 
domain
.82 .82
    MBCT+mADM 31.2 
(3.8)
32 30.4 
(4.0)
27 31.6 
(3.5)
26
    mADM 31.9 
(4.6)
32 31.4 
(4.5)
27 32.2 
(3.1)
24
WHO-QoL = WHO Quality of Life. a p-value reported for the repeated measures analysis on condition 
– time interaction based on observed data. b p-value reported for the repeated measures analysis on 
condition – time interaction based on imputed data.
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Table 4.3. Utilisation of usual care, other than trial interventions, in the MBCT+mADM and mADM group 
during the 15-month study period.
Type of care MBCT+mADM (n=28a) mADM (n=28a)
Users; 
n (%)
Mean 
cumulative 
duration b 
(SD)
Users; 
n (%)
Mean 
cumulative 
durationb  
(SD)
pc
General practitioner 26 (93%) 1.8 hours 
(2.4)
27 (96%) 1.5 hours 
(2.0)
.70
Psychiatrist 17 (61%) 2.3 hours 
(2.4)
16 (57%) 2.5 hours 
(3.5)
.85
Psychologist/ 
   psychotherapist
12 (43%) 13.7 hours 
(16.0)
11 (39%) 7.4 hours 
(6.6)
.23
Social worker 3 (11%) 12.0 hours 
(10.6)
2 (7%) 9.8 hours 
(10.2)
.83
Psychiatric nurse 5 (18%) 1.6 hours 
(2.1)
5 (18%) 4.6 hours 
(2.9)
.09
Hospitalisation 2 (7%) 26.5 days 
(31.8)
2 (7%) 50.0 days 
(28.3)
.52
Other d 4 (14%) 2.5 hours 
(1.9)
6 (21%) 5.0 hours 
(6.2)
.47
a Based on complete cases; b Calculated for the group of users; c p-value reported for independent samples 
t-tests of mean cumulative duration; d Including company doctor, insurance doctor, addiction treatment, 
(job)coach.
DISCUSSION
Based on the results of the current study, adding MBCT to mADM for patients 
with recurrent depression in remission does not seem to reduce relapse/
recurrence rate, time to relapse, number, duration and severity of relapse/
recurrence, severity of depressive symptoms, or quality of life.
 Previous studies comparing MBCT and treatment as usual (TAU) in 
patients with recurrent depression concluded that MBCT was an effective 
intervention to reduce relapse/recurrence (Piet & Hougaard, 2011). 
However, some of these trials included in this meta-analysis have been 
criticised for only including patients who were free of ADM (Teasdale et al., 
2000; Ma and Teasdale, 2004; Bondolfi et al., 2010). This might have led to 
a higher relapse/recurrence rate in the TAU condition, thus inadvertently 
contributing to the the superiority of MBCT.
 Studies comparing MBCT with mADM (Kuyken et al., 2008; Segal et 
al., 2010; Kuyken et al., 2015) did not show any differences between the 
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effectiveness of MBCT and that of mADM either. However, these studies 
are not quite comparable to ours as patients in the MBCT condition were 
withdrawn from their medication. So, we do not know whether the relapse/
recurrence rates might have been better in the MBCT condition if patients 
had been allowed to stay on their mADM.
 There are a few studies comparing MBCT and TAU in recurrent depression 
which did allow their participants to stay on their mADM (Godfrin & van 
Heeringen, 2010; van Aalderen et al., 2012; Meadows et al., 2014). These 
studies showed that patients on mADM appeared to benefit as much from 
MBCT as their counterparts (van Aalderen et al., 2012). Indeed, Meadows 
et al. (2014) demonstrated that particularly those on medication seemed to 
benefit from MBCT.
 So, our findings contrast unfavourably with the above mentioned studies. 
What might explain these discrepancies? In our view, the first and most 
probable explanation for this finding is selection bias. As already mentioned, 
the study population of this trial consisted of a minority preferring the 
certainty of holding on to their medication over the possibility to participate 
in the MBCT course. Most of the patients interested in the study chose to 
participate in the parallel trial examining the possible difference between 
the combination of MBCT and mADM and MBCT alone. Hence, patients 
participating in the current trial might have had lower expectations and 
less commitment to MBCT. As it is well known that patients’ preferences 
may contribute to the effectiveness of an intervention (Swift et al., 2011), 
this might have attenuated the possible effect of the MBCT condition. This 
might have been even strengthened by the increasing availability of MBCT 
in the Netherlands in recent years. Individuals who were most interested in 
MBCT among those wanting to hold on to their mADM decided to get MBCT 
elsewhere rather than participate in the trial. In fact, this tendency hampered 
the recruitment of the trial to the extent that we had to finish it before reaching 
the number of patients required by our power analysis. To make matters 
worse, almost a quarter of those who had consented to participate in the 
trial but were randomised to the control condition decided to nevertheless 
participate in an MBCT course elsewhere, thus further compromising the 
ITT analyses. Indeed, the difference between the intervention and control 
groups in the PP analyses was greater than that in the ITT analyses. This 
difference was not significant, but this might also be related to the study 
being underpowered.
 There are some additional options to consider as well. The overall 
teacher competency in our study was lower than in previous studies 
(Kuyken et al., 2008; Kuyken et al., 2015; Segal et al., 2010), which might 
have attenuated the effect of MBCT. However, this is intrinsically linked 
to our trial being an “effectiveness” rather than “efficacy” study, with the 
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intervention being carried out in a ‘real world’ setting with more different 
sites and more teachers with a wider range of competencies participating. In 
terms of generalisability, the wide range of teachers with different levels of 
experience can also be considered as a strength. It does however underscore 
the importance of a careful implementation of MBCT in routine clinical 
practice, including proper training and continuous professional development 
of future mindfulness teachers (Crane & Kuyken, 2013). On the other hand, 
possibly as a consequence of our optimisation of mADM in the control 
condition, the adherence rate with mADM seems to be rather high compared 
with some other studies (Bockting et al., 2008; Kuyken et al., 2008; Olfson et 
al., 2006). This might have left relatively little room for further improvement. 
This hypothesis is supported by the fact that the relapse/recurrence rates of 
36% in our combination condition is pretty similar to that of other trials, but 
the relapse/recurrence rate in our medication only condition of 37% was 
substantially lower than that of comparable studies (Kuyken et al., 2008; 
Kuyken et al., 2015; Segal et al., 2010).
 So, what are the implications of our study of both clinical practiceand 
research? For clinical practice, the implications of the study are that MBCT 
is not necessarily of additional benefit for all patients. Particularly for those 
who are stable and content with their mADM, there is no need to offer 
additional MBCT. We might preserve MBCT for those patients who on the 
basis of previous research seem to benefit most. To scientifically address 
the question whether MBCT is of additional value to patients with recurrent 
depression who are using mADM, one should conduct a properly powered 
RCT in a population where MBCT is not yet readily available to this patient 
group, possibly in other countries such as the US. More research needs to 
be conducted on possible predictors of MBCT, such as use of antidepressant 
medication. In this way, we can offer costly interventions such as MBCT 
to those who might benefit most. Literature on patient factors predicting 
treatment response to MBCT is emerging but still in its infancy, particularly 
compared to predictors of outcome of cognitive therapy (DeRubeis et al., 
2014). Factors that have been associated with better treatment response 
to MBCT are a higher number of previous episodes (Ma & Teasdale, 2004; 
Teasdale et al., 2000), residual symptoms (Segal et al., 2010), higher severity 
of childhood trauma (Williams et al., 2014), treatment in a specialist setting 
versus primary care and the use of antidepressant medication (Meadows et 
al., 2014). This seems to suggest that MBCT is particularly helpful for patients 
who are more vulnerable.
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ABSTRACT
Background
Previous studies have suggested that patients’ treatment preferences may 
influence treatment outcome. The current study investigated whether 
preference for either mindfulness-based cognitive therapy (MBCT) or 
maintenance antidepressant medication (mADM) to prevent relapse in 
recurrent depression was associated with patients’ characteristics, treatment 
adherence, or treatment outcome of MBCT.
Methods
The data originated from two parallel randomised controlled trials, the 
first comparing the combination of MBCT and mADM to MBCT in patients 
preferring MBCT (n = 249), the second comparing the combination to mADM 
alone in patients preferring mADM (n = 68). Patients’ characteristics were 
compared across the trials (n = 317). Subsequently, adherence and clinical 
outcomes were compared for patients who all received the combination (n 
= 154).
Results
Patients with a preference for mADM reported more previous depressive 
episodes and higher levels of mindfulness at baseline. Preference did not 
affect adherence to either MBCT or mADM. With regard to treatment outcome 
of MBCT added to mADM, preference was not associated with relapse/
recurrence (χ(2) = 0.07; p = .80), severity of (residual) depressive symptoms 
during the 15-month follow-up period (β = -0.08, p = .49), or quality of life.
Limitations
The group preferring mADM was relatively small. The influence of 
preferences on outcome may have been limited in the current study because 
both preference groups received both interventions.
Conclusions
The fact that patients with a preference for medication did equally well as 
those with a preference for mindfulness supports the applicability of MBCT 
for recurrent depression. Future studies of MBCT should include measures 
of preferences to increase knowledge in this area.
89
Meditation or medication?
5
INTRODUCTION
Major depressive disorder (MDD) is a common and highly debilitating 
mental disorder that is characterized by high rates of relapse or recurrence 
(Richards, 2011). To date, the most commonly used treatment to prevent 
future episodes of MDD is the use of maintenance antidepressant medication 
(mADM). Although there is evidence that mADM are more effective than 
placebo in reducing the risk of relapse (Borges et al., 2014; Kaymaz et al., 
2008), adherence to mADM is generally low (Bockting et al., 2008) and the 
prophylactic effectiveness seems to decrease with the number of previous 
episodes (Kaymaz et al., 2008). Therefore, alternative preventive strategies 
have been developed. For example, Mindfulness-Based Cognitive Therapy 
(MBCT; Segal et al., 2012) significantly reduces relapse risk in patients with 
three or more previous depressive episodes (Piet & Hougaard, 2011) and 
appears to be at least as effective as mADM in the prevention of relapse 
(Kuyken et al., 2008; Kuyken et al., 2015; Segal et al., 2010). This suggests 
that MBCT offers a viable alternative for patients preferring a psychological 
intervention to prevent relapse.
 In general, practice guidelines recommend that patients’ treatment 
preferences should play an important role in the selection of a treatment 
modality (American Psychiatric Association, 2010). In the context of the 
acute phase of depression treatment, depressed patients have been shown 
to generally prefer psychological rather than pharmacological treatment 
(Steidtmann et al., 2012; van Schaik et al., 2004). This suggests that many 
patients with recurrent depression might prefer psychological treatment, 
such as MBCT, over mADM to prevent relapse/recurrence.
 Treatment preferences seem to be related to treatment expectations 
and therefore, may contribute to adherence and outcomes as a non-
specific therapeutic factor (Rutherford et al., 2010). Although several 
studies on the acute treatment of depression have examined the impact of 
preferences on outcome, results are inconclusive. A systematic review on 
treatment preferences in MDD concluded that preferences may positively 
affect treatment initiation and the therapeutic alliance, but have minimal 
impact on depression severity outcomes (Gelhorn et al., 2011). In contrast, 
a simultaneous meta-analysis indicated a small (Cohen’s d=0.31) but 
significant benefit of preference-match in patients with psychiatric problems 
receiving psychological or pharmacological therapies (Swift et al., 2011). For 
the subset of studies specifically looking at depression (k=12), this effect was 
also small (d=0.35) but significant. The inconsistency in the literature on the 
effects of preference on treatment outcome may be related to differences 
in methodology. For example, in an RCT comparing behavioural activation 
and antidepressant medication, preference for psychotherapy influenced 
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treatment outcome in terms of clinician-rated depression, but not self-rated 
depression (Moradveisi et al., 2014). In addition, the strength of patient 
preference on a continuous measure may be more predictive of outcome 
than preference-match as a categorical predictor (Raue et al., 2009).
 Unlike most patient characteristics, preferences cannot be randomly 
allocated because of their intrinsic relationship with the received treatment. 
In this way, preferences can affect the external and internal validity of 
randomised controlled trials (RCTs) (Corrigan & Salzer, 2003). For instance 
patients with a strong preference for psychological treatment are likely 
to decline RCTs precluding their preference (van Schaik et al., 2004). 
Consequently, RCTs may underestimate the effect of preferences on outcome. 
In addition, preferences may affect the internal validity of a trial, for example 
because patients who receive a treatment concordant with their preference 
are less likely to drop out, show higher rates of attendance and have a better 
working alliance with the therapist (Elkin et al., 1999; Iacoviello et al., 2007; 
Kwan et al., 2010; Raue et al., 2009). These methodological problems related 
to preferences may lead to a gap between results obtained in RCTs and 
routine practice (TenHave et al., 2003).
 To our knowledge, no studies have explicitly examined patient preferences 
and their possible relation with treatment adherence and treatment outcome 
in relapse/recurrence prevention of MDD. In two parallel randomised 
controlled trials (the first comparing the combination of MBCT and mADM to 
MBCT alone, the second comparing the combination to mADM alone), patients 
could choose to participate in either study, according to their preference for 
either mADM or MBCT. The current post-hoc study aims to investigate: (a) 
possible differences in demographic and clinical characteristics between 
patients with a preference for MBCT and those with a preference for mADM; 
(b) whether patients’ preferences are associated with adherence to MBCT or 
adherence to mADM; and (c) whether patients’ preferences are associated 
with relapse/recurrence risk, severity of depressive symptoms, or quality 
of life, over the 15 months follow-up. We had no specific a priori hypotheses 
with regard to possible differences in patients’ baseline characteristics, but 
we expected MBCT treatment adherence and clinical outcome to be better 
for patients preferring MBCT than for patients preferring mADM.
METHODS
Study design
The study design and procedures are presented in full in the published 
study protocol (Huijbers et al., 2012) and are summarised below. Originally 
we intended to conduct a three-armed RCT of MBCT alone, mADM alone or 
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MBCT+mADM, but due to strong treatment preferences this turned out not 
to be feasible. Therefore we ended up conducting two parallel RCTs (see 
Figure 5.1). Patients preferring MBCT participated in an RCT comparing the 
combination of MBCT and mADM to MBCT alone, i.e. with discontinuation of 
mADM (Huijbers et al., 2016). Patients preferring to continue their mADM 
participated in an RCT comparing the combination of MBCT and mADM 
to mADM alone (Huijbers et al., 2015). This change in design enabled us 
to acknowledge patients’ preferences while maintaining the experimental 
rigour of randomisation. In addition, it provided the opportunity to study 
the possible effect of treatment preference in depression relapse/recurrence 
prevention.
Enrollment
1003 Telephone 
screens
373 Research 
interviews
630 Excluded
• 406 Not eligible
• 224 Declined participation
56 Excluded
• 23 Not eligible
• 33 Declined participation
317 Included in study
Allocated by preference
Trial A (N = 249)
MBCT preference
Random allocation
Trial B (N = 68)
mADM preference
Random allocation
Comparison of 
patients’ 
characteristics
MBCT alonea
N = 128
MBCT + mADM
N = 121
MBCT + mADM
N = 33
mADM alone
N = 35
Comparison of patients’ outcomes
Figure 5.1. Schematic overview of the two trials and random allocation to treatments.
Participants and procedure
Patients were recruited in 12 secondary and tertiary psychiatric outpatient 
clinics across the Netherlands between September 2009 and January 2012. 
Patients were referred by mental health care professionals or recruited by 
advertisements in the media (TV, magazines and newspapers). Inclusion 
criteria were a history of at least three previous depressive episodes 
according to the Diagnostic and Statistical Manual of Mental Disorders-4th 
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edition (DSM-IV), being in full or partial remission; currently treated with 
mADM for at least 6 months; 18 years of age or older; and Dutch speaking. 
The study was approved by the Medical Ethics Committee Arnhem-Nijmegen 
(nr. 2008/242) for all participating sites. After full explanation of the study, 
written informed consent was obtained from all participants. The study 
period was 15 months with assessments at 0 (baseline), 3, 6, 9, 12 and 
15 months. For the possible differences between patients who preferred 
to participate in trial A (preference for MBCT) and trial B (preference for 
medication) we used data of all participants (n = 317). For all others analyses 
we only used data from the participants who received the combination of 
MBCT and mADM (n = 121+33).
Intervention: MBCT plus maintenance ADM (MBCT+mADM)
MBCT was delivered in 12 different centres across the Netherlands according 
to the, slightly adapted, protocol by Segal, Williams and Teasdale (2002). It 
was delivered in groups of 8–12 participants and consisted of eight weekly 
sessions of 2.5 h plus one day of silent practice between the 6th and 7th 
session (Kabat-Zinn, 2013). Participants were encouraged to practice 
meditation at home for about an hour a day with the support of CDs.
For continuation of mADM, a minimum of one consultation with a 
psychiatrist was recommended. Psychiatrists were instructed to maintain or 
reinstate a therapeutic dosage of mADM, and recommendations to manage 
side effects were provided. Adherence to the mADM protocol was defined as 
using a therapeutic dose at each follow-up contact during the observed time 
period (using last observation carried forward for participants who did not 
complete all assessments).
Preference measures
Preference for MBCT was operationalised as choosing to participate in trial 
A (MBCT+mADM versus MBCT alone) and preference for mADM as choosing 
to participate in trial B (MBCT+mADM versus mADM alone).
 Preference strength was measured at baseline with an adapted version 
of the Treatment Credibility Questionnaire (TCQ; Borkovec & Nau, 1972) by 
Addis et al. (2004), with one additional item from the Credibility Expectancy 
Questionnaire (Devilly & Borkovec, 2000). The TCQ that was used in this 
study originally consisted of 7 items that focus on credibility and expectancy: 
“To what extent do you think this treatment will help you?”, “How logical 
does this treatment appear to you?”, “How scientific does this treatment 
appear to you?”, “To what extent do you think that this treatment will help 
you to better understand the causes of your problems?”, “To what extent do 
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you think that you will learn effective strategies to cope with your problems 
in this treatment?”, “To what extent does this treatment correspond to your 
ideas about what helps people in treatments?” and “To what extent do you 
feel that this treatment will reduce your complaints?”. For the current study, 
we excluded items 4 and 5 from the analyses because these seemed to be 
less applicable to mADM, resulting in an adapted 5-item version of the scale. 
Items were scored on a 7-point rating scale, ranging from 1 (not at all) to 
7 (very much) with a total score ranging between 5 and 35. The TCQ was 
administered for both aspects of the intervention: MBCT and mADM. Internal 
consistencies in the current study were α=.87 for the TCQ about MBCT and 
α=.85 for the TCQ about mADM. In the analyses, the difference between the 
credibility of MBCT and that of mADM (TCQ MBCT – TCQ mADM) was used as 
a predictor of treatment outcome, referred to as “MBCT preference strength”.
Outcome measures
Adherence to MBCT included two aspects: the number of sessions attended 
and the average percentage of days per month at which patients practiced 
at home during the first three months. Home practice was assessed using 
calendars specifically designed for the study, on which participants could 
indicate their home practice (yes or no) on a daily basis.
 Adherence to mADM also included two aspects: the dichotomous 
classification of using a therapeutic dose according to the Dutch 
pharmacotherapeutic compass (Health Insurance Board, 2000) at each 
follow-up contact during the observed time period (yes or no) and the average 
percentage of days per month at which patients used their medication during 
the first three months. This average percentage of medication use was 
calculated from the study calendars, on which patients indicated whether 
they had used medication (yes or no) on a daily basis, similar to the daily 
registration of mindfulness practice.
 Primary outcome was relapse/recurrence as measured with the 
Structured Clinical Interview for DSM (SCID-I; First et al. (1996)) by trained 
research assistants every three months during the 15-month follow-up 
period. The interrater reliability between first and second (blind) ratings 
was found to be substantial (Kappa=0.70, p<.001, 95% CI 0.456–0.942).
 Secondary outcomes were time to relapse/recurrence, the severity of 
depressive symptoms during follow-up and quality of life. The Inventory 
of Depressive Symptomatology – Clinician rated (IDS-C; Rush et al., 1996) 
was used to assess severity of depressive symptoms at baseline, 3, 6, 9, 12 
and 15 months. The IDS-C has good psychometric qualities (Rush et al., 
1996; Trivedi et al., 2004). The internal consistency in the current study 
ranged between α=.85 and α=.92 across the six assessments. Quality of life 
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was assessed at baseline, 3 and 15 months using the 26-item self-report 
WHOQOL short version (The WHOQOL Group, 1998). The WHOQOL assesses 
subjective quality of life in four domains: physical, psychological, social and 
environmental. Two questions with regard to overall perception of quality of 
life and health were included as well.
Statistical analysis
All analyses were performed using IBM SPSS Statistics version 20.0 (IBM 
Corporation, 2011) unless stated otherwise. Probability values lower than .05 
(two-tailed) were considered significant for all analyses. Possible differences 
in baseline characteristics between participants with a preference for MBCT 
or mADM were examined using independent samples t-tests for continuous 
and Pearson χ2 tests for categorical variables. For these analyses, we used 
data from the complete sample (N = 317). For all other analyses we used the 
total number of patients who received MBCT and mADM (N = 154). Analyses 
were based on intention-to-treat.
 The association between preference type (MBCT versus mADM) and 
adherence to MBCT was examined with separate ANOVAs for (a) number 
of sessions and (b) percentage of home practice in the first three months. 
For MBCT preference strength as a predictor, we used linear regression 
analyses for (a) number of sessions and (b) amount of home practice, in 
separate analyses. The association between preference type (MBCT versus 
mADM) and adherence to mADM was examined with a Pearson Chi-square 
test (two-tailed) for the dichotomous adherence measure (yes or no) and 
ANOVA for the percentage of mADM adherence (days per month) in the first 
three months. MBCT preference strength was used as a predictor in a logistic 
regression model for the dichotomous measure and in a linear regression 
model for percentage adherence.
 Relapse/recurrence rates in the two preference groups were compared 
with a Pearson χ2 test and differences in time to relapse/recurrence were 
analysed using a Cox regression proportional hazards model. We used the 
same model to examine whether MBCT preference strength was a predictor 
of relapse risk. The severity of depression at baseline and the number of 
previous episodes (log transformed) were included as covariates because 
these factors have been consistently associated with an increased relapse 
risk (Hardeveld et al., 2010). In addition, we included baseline characteristics 
that were not balanced between the groups as covariates. Patients whose 
follow-up data were unavailable or who did not experience a relapse/
recurrence before the end of the follow-up period were treated as censored 
observations.
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The course of (residual) depressive symptoms (IDS-C) during the 15-month 
follow-up period was analysed using a latent growth curve model (LGCM) 
in MPlus version 7 (Muthén & Muthén, 1998) with 6 time points, a random 
intercept and a random slope for preference. To examine the predictive value 
of preference type and MBCT preference strength for symptom trajectory, 
both were added as covariates to the unconditional base model in separate 
analyses. In this way we could evaluate to what extent they predicted rate 
of change independent of initial level of depressive symptom severity. In 
both analyses, the number of previous episodes and mindfulness skills were 
included as covariates. Participants who did not complete all assessments 
were included in the analyses using full information maximum likelihood 
estimation for missing data.
 Quality of life was analysed with a repeated measures ANOVA for both the 
observed dataset (complete case analysis) and the imputed dataset, using 
multiple imputation for missing data (Asendorpf et al., 2014).
RESULTS
Patient preferences and associated factors
The flow of participants has been described in detail in the original 
publications (Huijbers et al., 2015; Huijbers et al., 2016). As shown in Figure 
5.1, the majority of the included patients in both RCTs (n = 317) preferred 
MBCT (n = 249; 79%) and a minority preferred mADM (n = 68; 21%). Table 5.1 
shows the comparison of baseline demographic and clinical characteristics 
of those who preferred MBCT and those who preferred mADM. The group 
that preferred MBCT reported a higher MBCT preference strength (TCQ 
MBCT – TCQ mADM) than the mADM preference group (Cohen’s d = 0.69). 
The relation between preference type and MBCT preference strength is 
displayed in Figure 5.2, showing that there was considerable variability in 
preference strength in both preference groups. Patients preferring mADM 
reported more previous episodes (d = 0.27) and, interestingly, higher 
baseline levels of mindfulness skills (d = 0.31). No other differences were 
found between the groups.
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Table 5.1. Baseline demographic and clinical characteristics of patients with recurrent depression in 
remission participating in either trial A (MBCT preference; comparing MBCT+mADM versus MBCT alone) 
or trial B (mADM preference; comparing MBCT+mADM versus mADM alone).
Variable (A) MBCT pre-
ference (N=249)
(B) mADM pre-
ference (N=68)
Comparison
N % N % χ2 p
Female 168 67 49 72 0.52 .47
Educational level 3.68 .16
   Low 17 7 8 12
   Middle 65 26 23 34
   High 154 62 35 51
   Missing 13 5 2 3
Marital status 0.24 .89
   Single 56 23 17 25
   Married/cohabiting 141 57 40 59
   Divorced/widowed 41 16 10 15
   Missing 11 4 1 1
Employed 159 64 38 56 1.54 .22
Remission 0.63 .43
   Full, IDS-C ≤ 11 133 53 40 59
   Partial, IDS-C > 11 116 47 28 41
Type of mADM 0.32 .85
   SSRI 190 76 51 75
   TCA 42 17 11 16
   Othera 17 7 6 9
Previous CBT treatment 148 59 35 51 1.39 .24
Suicide attempt (lifetime) 47 19 11 16 0.27 .60
Mean SD Mean SD t p
Age (years) 50.3 10.6 51.8 14.2 -0.93 .35
Baseline depression (IDS-C) 12.6 10.0 12.1 9.6 0.34 .73
Nr. previous episodes 5.9 5.0 7.4 7.1 -2.02 .045
Age at MDD onsetb 25.0 11.7 24.4 11.5 0.37 .71
MBCT preference strengthc 1.4 5.8 -2.9 7.9 3.92 .00
Mindfulness skills (FFMQ)d 116.4 16.4 121.4 14.6 -2.22 .027
a Including serotonin-norepinephrine reuptake inhibitors, monoamine oxidase-inhibitors, and 
mirtazapine. b Based on self-report. c Treatment Credibility Questionnaire (TCQ; Addis, Hatgis, 2004, 
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Figure 5.2. The distribution of preference strength for mindfulness-based cognitive therapy (MBCT) over 
maintenance antidepressant medication (mADM) in patients preferring MBCT (n = 249) and those 
preferring mADM (n = 68). Distributions were similar for the subsample that was selected for the analyses 
of adherence and outcome.
Prognostic significance of preference type (MBCT versus mADM) and 
MBCT preference strength
MBCT adherence and mADM adherence
Table 5.2 shows the results for the comparisons between the preference 
groups for adherence to treatment. There were no differences between the 
groups on any of the included measures.
Borkovec and Nau, 1972) was assessed twice: once for MBCT and once for mADM. Reported is the 
difference between these scores (TCQ MBCT – TCQ mADM), data available for n=225 in the MBCT 
preference group, and for n=59 in the mADM preference group. d Total score, available for n=228 (MBCT 
preference group) and n=64 (mADM preference group). 
MBCT = mindfulness-based cognitive therapy; mADM = maintenance antidepressant medication; 
IDS-C=Inventory of Depressive Symptomatology – Clinician rated; SSRI=selective serotonin reuptake 
inhibitor; TCA=tricyclic antidepressant; CBT=cognitive-behavioural therapy; MDD=major depressive 
disorder; FFMQ=Five Facet Mindfulness Questionnaire.
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Table 5.2. Comparisons between the MBCT preference and mADM preference groups for adherence to 
treatment.
MBCT pref-
erence
N mADM 
preference
N Comparison
Adherence to MBCT
  Number of sessions;   
  mean (SD), median
5.9 (2.6), 7 121 6.2 (2.5), 7 33 F (1,152) = 
0.45, p = .51
  Home practice, % of days  
  per month; mean (SD)
0.83 (0.15) 79 0.82 (0.13) 26 F (1,103) = 
0.07, p = .80
Adherence to mADM
  Adhered to protocol (yes/ 
  no); N (%)
87 (72) 121 28 (85) 33 χ2 = 2.30, p 
= .13
  mADM use, % of days per  
  month; mean (SD)
0.95 (0.01) 78 0.97 (0.02) 26 F (1,102) = 
1.54, p = .22
MBCT = mindfulness-based cognitive therapy; mADM = maintenance antidepressant medication; SD = 
standard deviation.
MBCT preference strength was not a predictor of the number of MBCT 
sessions attended (β = −0.03, p = .70) or the amount of home practice 
reported (β = 0.08, p = .42). It did not predict adherence to mADM (odds 
ratio = 0.95, 95% CI = 0.89–1.01, p = .10) or the percentage of adherent days 
per month (β = −0.15, p = .14) either.
Primary outcome: relapse/recurrence of depression
No differences in relapse/recurrence rates were observed between the two 
preference groups. The relapse/recurrence rate was 39% (47/121) in the 
MBCT preference group and 36% (12/33) in the mADM preference group 
(χ2 = 0.07; p = .80).
 As illustrated in Figure 5.3, Cox regression analysis showed that preference 
for MBCT or mADM, corrected for baseline depression severity, number of 
previous episodes and mindfulness skills, did not predict the time to relapse/
recurrence (hazard ratio = 1.32, 95% confidence interval 0.70–2.51, p = .41).
 In addition, MBCT preference strength, corrected for baseline depression 
severity, number of previous episodes and mindfulness skills, did not predict 
time to relapse/recurrence either (hazard ratio = 1.00, 95% confidence 
interval 0.97–1.05, p = .85).
Secondary outcomes: depression severity and quality of life
The latent growth curve analysis for severity of (residual) depressive 
symptoms (IDS-C) over the 15-month follow-up period showed an acceptable
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Figure 5.3. Survival curves over 15-month follow-up (65 weeks) for the mindfulness-based cognitive 
therapy (MBCT) preference group (n = 121) and maintenance antidepressant medication (mADM) 
preference group (n = 33). a Using Cox regression analysis. HR=hazard ratio for MBCT preference 
compared to mADM; CI=confidence interval.
model fit for a linear growth model: comparative fit index=0.96, root mean 
square error of approximation = 0.07, standardised root mean square 
residual = 0.07. As shown in Figure 5.4, patients more or less maintained 
mild levels of depression throughout the study period. Adding preference 
group, previous episodes, mindfulness skills, and intercept as predictors 
to the unconditional base model showed that the course of depression 
did not significantly vary between the preference groups (β = −0.08, se = 
.12, p = .49). In this analysis, 11 cases were excluded due to missing data 
on the covariates. Adding MBCT preference strength, previous episodes, 
mindfulness skills and intercept as predictors to the unconditional base 
model showed that the course of depression did not significantly vary with 
MBCT preference strength (β=0.17, se=.12, p =.15). Cases with missing data 
on any of the predictors were excluded from this analysis (n =13).
 Table 5.3 shows the results for the analyses of quality of life. In summary, 
there were no differences between the preference groups with regard to 
quality of life.
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Table 5.3. Quality of life at baseline, 3 and 15 months for the MBCT preference group (n = 121) and 
mADM preference group (n = 33), both receiving MBCT+mADM.
Variable Baseline 3 months 15 months
Mean 
(SD)
N Mean 
(SD)
N Mean 
(SD)
N pa pb
WHO-QoL – Q1: overall 
perception of quality of life
.71 .50
    MBCT preference 3.5 
(0.8)
113 3.6 
(0.8)
86 3.7 
(0.9)
68
    mADM preference 3.7 
(0.7)
32 3.8 
(0.7)
27 3.8 
(0.8)
26
WHO-QoL – Q2: overall 
perception of health
.53 .10
    MBCT preference 3.4 
(1.0)
113 3.3 
(1.0)
85 3.4 
(1.1)
68
    mADM preference 3.3 
(0.9)
32 3.5 
(1.1)
26 3.5 
(0.9)
26
WHO-QoL – physical domain .87 .56
    MBCT preference 24.2 
(4.4)
113 24.6 
(4.7)
86 25.6 
(4.5)
67
    mADM preference 24.3 
(3.3)
32 25.3 
(3.9)
27 26.2 
(4.2)
26
WHO-QoL – psychological 
domain
.70 .36
    MBCT preference 18.7 
(3.2)
113 19.9 
(3.6)
86 20.0 
(3.8)
68
    mADM preference 19.3 
(3.2)
32 20.5 
(3.3)
27 20.2 
(3.6)
26
WHO-QoL – social domain .47 .27
    MBCT preference 9.8 
(2.2)
113 10.0 
(2.2)
86 10.1 
(2.2)
68
    mADM preference 10.4 
(2.4)
32 10.9 
(1.9)
27 10.5 
(2.5)
26
WHO-QoL – environmental 
domain
.56 .44
    MBCT preference 30.6 
(4.0)
113 30.5 
(4.2)
86 31.9 
(4.0)
68
    mADM preference 31.2 
(3.8)
32 30.4 
(4.0)
27 31.6 
(3.5)
26
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MBCT = mindfulness-based cognitive therapy; mADM = maintenance antidepressant medication; WHO-
QoL = World Health Organization Quality of Life. a p-value reported for the repeated measures analysis 
on preference – time interaction based on complete cases (n=57 MBCT preference and n=24 mADM 
preference). b p-value reported for the repeated measures analysis on preference – time interaction based 
on imputed data.
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Figure 5.4. Severity of (residual) depressive symptoms over 15-month follow-up for the mindfulness-
based cognitive therapy (MBCT) preference group (n = 121) and maintenance antidepressant medication 
(mADM) preference group (n = 33). 
a IDS-C=Inventory of Depressive Symptomatology – Clinician Rated; cut-off points for depression severity: 
0–11 none, 12–23 mild, 24–36 moderate, 37–46 severe, 47–84 very severe (Epidemiology Data Center, 
2015). 
b Effect of preference group on the slope of depressive symptoms using a latent growth curve model.
DISCUSSION
The current study investigated patients’ treatment preferences for either 
MBCT or mADM to prevent relapse in recurrent depression, in two related 
RCTs. The majority of patients (79%) preferred trial A with MBCT in both 
study arms (MBCT+mADM or MBCT alone) over trial B with mADM in both 
study arms (MBCT+mADM or mADM alone). This finding is in accordance 
with previous studies indicating that most patients prefer psychological 
treatment or combined treatment over pharmacological treatment alone 
(Steidtmann et al., 2012; van Schaik et al., 2004).
 Regarding baseline characteristics of patients with different types of 
treatment preferences, two previous studies suggested that patients with 
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more severe depressive symptoms were more likely to prefer medication 
(Bedi et al., 2000; Dobscha et al., 2007). Although we did not replicate this 
finding in the current study, the higher number of previous episodes in the 
mADM preference group may indicate that patients with higher vulnerability 
for depression tend to stay on medication. Our finding that patients 
preferring mADM reported higher levels of mindfulness might indicate that 
they were more aware of, and more accepting towards their vulnerability for 
depression.
 Looking at the group of participants who had been allocated to the 
combination of MBCT and mADM in both RCTs, patients with a preference 
for MBCT were not less adherent to mADM or more adherent to MBCT than 
those with a preference for mADM. Likewise, preference strength was not 
a predictor of adherence. Thus, our results are not in line with previous 
findings that preferences affect adherence and, consequently, internal study 
validity (Elkin et al., 1999; Iacoviello et al., 2007; Kwan et al., 2010; Raue et 
al., 2009). It is important to bear in mind, however, that despite differences in 
MBCT preference strength, patients in the mADM trial were also interested 
in mindfulness. The mADM preference group might represent a group of 
patients who are reluctant to discontinue their mADM, but actually willing 
to try MBCT as an add-on-treatment. This corresponds with previous 
findings that a large majority of patients preferred a combination of ADM 
and psychotherapy (Steidtmann et al., 2012). In addition, several patients 
allocated to mADM alone in trial B (Huijbers et al., 2015) did not adhere to the 
protocol: they participated in MBCT anyway. This points to the possibility that 
many patients actually preferred the combination treatment. Unfortunately 
we only asked patients’ preferences for either MBCT or mADM, and not 
specifically for the combination therapy, MBCT alone or mADM alone.
 Furthermore, preference type and strength of MBCT preference were not 
associated with treatment outcome. These findings correspond with previous 
studies comparing antidepressants and psychological interventions for MDD 
(Dunlop et al., 2012; Gelhorn et al., 2011) but contrast with the results of 
others (Raue et al., 2009; Swift et al., 2011). One explanation for our findings 
is that the subsample of patients in our outcome analyses was allocated to 
the combination of MBCT and mADM, which meant that they all received 
their preferred treatment. On the other hand, the key change from baseline 
was the addition of MBCT, as all patients were already using mADM for a 
longer period. Therefore, one would expect this addition of MBCT to be more 
beneficial for patients with a preference for it. The advantage of our approach 
is that patients were not demoralised by being allocated to a non-preferred 
treatment. The disadvantage, within the context of our research questions, 
is that the influence of patients’ preferences may have been relatively small. 
In addition, different types of study design may lead to different results. For 
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example, our study was different from most studies as our primary aim was 
prevention of relapse/recurrence. Given that patients were thus in remission 
at baseline, there was probably less room for improvement in terms of 
depression severity and quality of life as our secondary outcome measures. 
We cannot rule out the possibility that a preference for MBCT versus mADM 
would affect outcome in therapeutic studies. Nevertheless, the results of the 
current study suggest that the influence of preference on the internal study 
validity and outcome of MBCT (added to mADM) is limited.
 This study provided a unique opportunity to investigate the impact of 
patient preference on the outcome of MBCT+mADM in remitted recurrently 
depressed patients. Patients from both preference groups were recruited in 
the same research sites and all assessments and interventions took place 
in the same way by the same people. Thus, the only apparent difference 
between them was their relative preference for MBCT or mADM. Of course, 
the comparisons that were made in the current study did not involve 
randomly allocated groups, so these groups did indeed differ for the number 
of previous episodes and level of mindfulness skills and may have differed 
in other aspects we did not assess. However, as the two preference groups 
did not differ on adherence or outcome, confounding factors explaining a 
possible difference are not particularly relevant. Furthermore, we used a 
clinician-rated instrument (IDS-C) to assess depression severity, which may 
be more objective than a self-report measure.
 An important limitation of the current study is that the sample of 
patients with a preference for mADM was small. Hence, we may not have 
been able to detect possible differences between the groups. For example, 
there was some indication that patients in the mADM preference group 
were somewhat more likely to adhere to mADM (85%) compared with the 
MBCT preference group (72%). With the current sample size, we could have 
detected a difference of approximately 25% with 80% power. With the actual 
difference of 13%, the power was only 42%. Another limitation is that our 
study population probably consisted of a selected subsample of the larger 
population of patients with recurrent MDD. Patients not willing to take ADM 
at all, or those who had decided to withdraw from them before, were not part 
of our sample. Similarly, patients not interested in participating in MBCT will 
not have opted for the trial at all, so the study participants will have had a 
more than average interest in MBCT. As a consequence, it is likely that the 
difference in preference strength was relatively small in this study, compared 
to clinical practice. In patients with stronger and more specific preferences, 
for example for MBCT alone or mADM alone, the results of our comparison 
might have been different. Moreover, we cannot exclude the possibility that 
cultural or regional factors, such as attitudes towards MBCT or mADM, or 
availability of MBCT also influence patients’ preferences. Hence, our results 
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may only be generalisable to the Dutch mental health care system. It would be 
interesting to see whether our findings can be replicated in other countries.
 The fact that we did not find an association between preference for either 
MBCT or mADM and treatment outcome is, in fact, pretty reassuring. Thus, 
patients who prefer to continue using their medication and who might not 
have high expectations from mindfulness may benefit to the same extent 
from MBCT as those who expect more. The current study also found no 
evidence for the idea that the internal validity had been affected by the 
patients’ preference. That does not take away the fact that the external 
validity of the study may have been restricted by treatment preferences. We 
cannot extrapolate our findings to patients with stronger preferences for one 
of the monotherapies (i.e. MBCT without medication, or medication alone). 
For obvious reasons, it will not be easy if not impossible, to recruit these 
groups for future studies on treatment preference. It would nevertheless 
be interesting to include measures of patient preference in other studies of 
MBCT, where the design or population might be different.
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ABSTRACT
As Mindfulness-Based Cognitive Therapy (MBCT) becomes an increasingly 
mainstream approach for recurrent depression, there is growing need 
for practitioners who are able to teach MBCT. The requirements for being 
competent as a mindfulness-based teacher include personal meditation 
practice and at least a year of additional professional training. This study is 
the first to investigate the relationship between MBCT teacher competence 
and several key dimensions of MBCT treatment outcomes. Patients with 
recurrent depression in remission (N = 241) participated in a multi-center 
trial of MBCT, provided by 15 teachers. Teacher competence was assessed 
using the Mindfulness-Based Interventions: Teaching Assessment Criteria 
(MBI:TAC) based on two to four randomly selected video-recorded sessions 
of each of the 15 teachers, evaluated by 16 trained assessors. Results showed 
that teacher competence was not significantly associated with adherence 
(number of MBCT sessions attended), possible mechanisms of change 
(rumination, cognitive reactivity, mindfulness, and self-compassion) or key 
outcomes (depressive symptoms at post treatment and depressive relapse/
recurrence during the 15-month follow-up). Thus, findings from the current 
study indicate no robust effects of teacher competence, as measured by the 
MBI:TAC, on possible mediators and outcome variables in MBCT for recurrent 
depression. Possible explanations are the standardised delivery of MBCT, 
the strong emphasis on self-reliance within the MBCT learning process, 
the importance of participant-related factors, the difficulties in assessing 
teacher competence, absence of main treatment effects in terms of reducing 
depressive symptoms,and the relatively small selection of videotapes. 
Further work is required to systematically investigate these explanations.  
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INTRODUCTION
Mindfulness-Based Cognitive Therapy (MBCT) is an increasingly popular 
intervention in mental health care and beyond. It was developed by Segal, 
Williams and Teasdale (2002) as a relapse prevention method for patients 
with recurrent Major Depressive Disorder (MDD). The evidence base of 
MBCT is growing and a recent individual patient data meta-analysis suggests 
it is superior to usual care and at least as effective as other active treatments 
(Kuyken et al., 2016). It is recommended by guidelines on depression 
prevention such as those by the American Psychiatric Association (American 
Psychiatric Association, 2006), the National Institute for Health and Clinical 
Excellence (NICE; 2004) and the Dutch guidelines on evidence-based practice 
(Spijker et al., 2012). MBCT is based on the rationale that people become 
more vulnerable to developing depression when they have strong automatic 
patterns of (negative) thinking or behaving in response to a stressful event 
or a decrease in mood, referred to as cognitive reactivity (Scher et al., 2005). 
Cognitive reactivity often leads to a further lowering of mood, eventually 
turning into a depressive relapse/recurrence (Segal et al., 1999). In MBCT, 
participants learn to become aware of their automatic cognitive reactions 
to low mood or stress, and to observe these reactions with kindness and 
curiosity (Segal et al., 2012). There is evidence that MBCT diminishes the 
‘toxic’ relationship between cognitive reactivity and poor outcome (Kuyken 
et al., 2010) - i.e. cognitive reactivity no longer predicted depression severity 
at one-year follow-up in patients who participated in MBCT, in contrast with 
those receiving antidepressant medication. Other studies have suggested 
that rumination, which refers to the recurrent thinking about one’s own 
depressive symptoms and their possible causes and implications, may 
also be an important mediating factor (van Aalderen et al., 2012b; Hawley 
et al., 2014; Ramel et al., 2004). In addition, evidence suggests that both 
mindfulness skills and self-compassion mediate the effect of MBCT on 
clinical outcome (van der Velden et al., 2015).
 Up till now, the teachers in the trials included in the meta-analysis on 
MBCT for recurrent MDD (Kuyken et al., 2016) were either the developers 
of MBCT or were trained by the developers of MBCT. However, the field is 
rapidly developing, with a growing need for qualified teachers. Concerns 
have been expressed about organizations or individuals responding to 
this need before engaging in or completing the required teacher training 
(Santorelli et al., 2011; Crane et al., 2010). In parallel, some consensus 
has emerged concerning minimum training standards and good practice 
guidelines (Kabat-Zinn et al., 2011; UK Network of Mindfulness-Based 
Teacher Trainers, 2010). Additionally, some measures have been developed 
to operationalize the adherence and competence of the teachers who 
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deliver mindfulness-based interventions, such as the MBCT-Adherence Scale 
(Segal et al., 2002a), the Mindfulness-Based Relapse Prevention (MBRP) 
Adherence and Competence Scale (Chawla et al., 2010) and the Mindfulness-
Based Interventions: Teaching Assessment Criteria (MBI:TAC; Crane et al., 
2013). However, research investigating the relationship between therapist 
competence in MBCT/MBSR and intervention outcomes is still lacking. In 
fact, “engaging the thorny question of clinician training” has been formulated 
as one of the important gaps in the current evidence base for mindfulness-
based interventions (Dimidjian & Segal, 2015, p. 605).
 Therapist competence has been defined as ‘the extent to which a 
therapist has the knowledge and skill required to deliver a treatment to the 
standard needed for it to achieve its expected effects’ (Fairburn & Cooper, 
2011). It has been described as a component of intervention integrity 
(Perepletchikova & Kazdin, 2005). There are several reasons why therapist 
competence is important to address (Fairburn & Cooper, 2011; Sharpless & 
Barber, 2009; Barber et al., 2007), including the responsibility of clinicians 
to provide their patients with the best possible care, the need to disseminate 
high-quality evidence-based psychological treatments, and the possible 
influence of therapist competence on the validity of clinical trials. The UK 
Medical Research Council recommends that process evaluations, including 
assessment of integrity, should be nested within clinical trials of complex 
interventions to better understand the outcomes and interpret the results of 
these trials in light of the observed integrity (Craig et al., 2008). In addition, 
the information that is generated by such integrity checks can be used to 
differentiate between sites (e.g. in a multi-centre trial) and to further develop 
and refine treatment (Waltz et al., 1993). 
 A meta-analytic review (Webb et al., 2010) showed that in studies 
targeting depression (n = 5), therapist competence was significantly related 
to outcome with a medium effect size (r = 0.28). These studies included 
cognitive behavioural therapy (CBT; n = 3), interpersonal therapy (n = 1) and 
dynamic psychotherapy (n = 1). For example, Kuyken and Tsivrikos (2009) 
studied the therapy outcomes of 69 patients with depressive disorders who 
were treated with CBT by one of 18 therapists, whose audio recordings of 
therapy sessions were evaluated by an expert. The results of this study 
indicated that greater therapist competence was associated with improved 
outcomes. Similar findings were reported by Strunk and colleagues (2010). 
However, a recent study did not find an association between competence 
and outcome in a group of 43 CBT therapists and 1247 patients treated for 
depression and/or anxiety in routine clinical practice (Branson et al., 2015). 
In summary, there is evidence for a relationship between competence and 
outcome in psychotherapy for depression, but this effect is not as consistent 
or robust as might be expected.
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Within the context of MBCT, the effect of teacher1 competence on treatment 
outcome has not yet been investigated. The role of the teacher in MBCT is 
different from the therapist’s role in (individual) psychotherapy, with more 
emphasis on the patients’ self-efficacy and less knowledge of their personal 
stories. However, it is generally assumed that the quality of the teaching is 
important to ensure that patients receive the intervention as it is intended. 
Therefore, the aim of the current study was to investigate the possible 
influence of teacher competence in the delivery of MBCT for recurrent 
depression on several dimensions relevant to MBCT process and outcome: 
adherence to treatment (i.e. number of sessions), possible mechanisms of 
change (rumination, cognitive reactivity, mindfulness, and self-compassion) 
and key outcome variables (depressive symptoms at post treatment and 
depressive relapse/recurrence during the 15-month follow-up). We included 
patient adherence and some of the mediators of MBCT as reported in a 
systematic review (van der Velden et al., 2015) as intermediate outcomes 
of teaching because we expected these to be most sensitive to the teacher’s 
influence. To assess competence, we chose the MBI:TAC as it includes both 
adherence and competence (in contrast to the MBCT-Adherence Scale) and 
it can be used for mindfulness-based interventions in general (in contrast to 
the MBRP Adherence and Competence Scale that is more specifically aimed 
at a mindfulness intervention for substance use disorders). In addition, the 
MBI:TAC is accompanied by a detailed manual. The study was part of two 
randomized controlled trials (RCTs) including MBCT as a relapse prevention 
strategy for patients with recurrent depression (Huijbers et al., 2015; Huijbers 
et al., 2016). We applied a two-level modeling approach to assess the amount 
of variance at the level of participant outcomes that could be explained at the 
teacher level, and whether expert-ratings of MBCT teacher competence could 
predict these outcomes. In addition, Cox regression analysis was used to test 
whether competence scores could predict depressive relapse/recurrence. 
We hypothesized that there would be differences between teachers with 
regard to levels of competence, and that higher levels of teacher competence 
would be associated with better adherence, decreases in rumination and 
cognitive reactivity, increases in mindfulness and self-compassion, lower 
levels of depression post treatment and a lower risk of relapse/recurrence 
in the year after MBCT.
1 In the context of mindfulness-based interventions, the word ‘teacher’ is more common 
than the word ‘therapist’.
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METHODS
Design
This study was based on two parallel randomized controlled trials, the first 
one comparing the combination of MBCT and antidepressant medication 
with medication alone (Huijbers et al., 2015) and the second comparing the 
combination of MBCT and antidepressant medication with MBCT alone, i.e. 
with discontinuation of medication (Huijbers et al., 2016). Both RCTs were 
multicentre trials involving relatively large numbers of MBCT teachers, 
which allowed us to investigate the possible effect of teacher competence 
on patient outcomes. Thus, the current study followed a quasi-experimental, 
prospective design, comparing adherence, possible mediators and depression 
outcomes for different teachers.
Participants
Patients
The patient sample consisted of patients with three or more previous 
depressive episodes, who were currently in full or partial remission and 
were using maintenance antidepressants for at least 6 months (Huijbers et 
al., 2012). The sample of the current study was restricted to patients who 
were allocated to MBCT. Patients had to have attended at least 1 session 
by a teacher whose competence data were available (see below). In total, 
241 of the 317 patients in the two trials met these criteria. Seventy-nine 
(33%) were male. The mean age of the participants was 51.0 (ranging from 
23 to 89). The median number of past episodes of depression was four. 
All patients provided informed consent to participation in the RCT; the 
study was approved by the Medical Ethics Committee Arnhem-Nijmegen 
(nr. 2008/242) for all participating sites. Patients and teachers provided 
additional informed consent to recording of the sessions on videotape.
Teachers
A total number of 21 teachers participated in the trial delivering 113 MBCT 
classes. Videotapes were available for 15 primary teachers (if classes 
were taught by two teachers together, we considered the level of the most 
proficient teacher to reflect the overall competence of the teaching). Seven of 
the 15 teachers met the advanced criteria of the association of mindfulness-
based teachers in the Netherlands and Flanders (www.vmbn.nl), which 
are in accordance with the UK good practice guidelines (UK Network of 
Mindfulness-Based Teacher Trainers, 2010) and include a minimum of 150 
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hours of education in MBSR/MBCT (entailing theoretical background, skills 
practice, supervision and reflection), a minimum of three years of personal 
meditation practice and attending retreats (minimum of one 10-day retreat 
or two 5-day retreats), and providing a minimum of two courses per two 
years. All teachers received additional training in the MBCT study protocol 
during a three-day training retreat at the start of the project by some of the 
senior teachers who were involved in previous trials of MBCT (Kuyken et 
al., 2008; van Aalderen et al., 2012b). Ongoing peer supervision took place 
on each site. In addition, the research team organized full-day plenary 
supervision meetings every six months during the intervention phase of the 
trial, consisting of mindfulness practices, workshops, small group teachings 
and plenary discussions about difficulties or practical issues. Table 6.1 shows 
the professional and meditation experience of the teachers and assessors.
Table 6.1. Professional and meditation experience of the teachers and assessors
Variable Teachers (n=15) Assessors (n=16)
Gender (male/female) 3/12 7/9
Age M=54 ± 7.2; range 39 - 64 M=51 ± 9.5; range 34 - 67
Professional background Psychologist (8);
Occupational therapist 
(3);
Psychiatric nurse (3);
Psychiatrist (1)
Psychologist (7); 
Occupational therapist 
(3);
Psychiatrist (2); 
Counsellor (2), 
General practitioner (1);
Other (1)
Clinical experience 
(years)
M=21 ± 6.5; range 11.5 
- 31
M=19 ± 10.2; range 4.5 
- 35
Years of personal 
meditation practice
M=9.0 ± 8.0; range 3 - 35 M=16 ± 9.0; range 6 - 37
Meditation practice 
(hrs/week)
M=4.3 ± 3.3; range 0.5 - 
14
M=3.9 ± 1.2; range 2 - 7
Number of days spent in 
retreat 
M=57 ± 95; range 0 - 282 M=161 ± 227; range 11 
- 966
Total amount of 
personal practice (days)a
M=296 ± 231; range 24 
- 845
M=580 ± 532; range 150 
- 2333
Number of MBCT cours-
es taught
M=23 ± 16; range 6 - 60 M=33 ± 20; range 7 - 80
a This variable is an estimate of the amount of personal practice (lifetime) calculated from the time 
periods, frequency and duration of personal home practice (transformed to the corresponding number of 
8-hour days)  added to the number of days spent in silent retreats.
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Measures
Teacher competence
The Mindfulness-Based Interventions: Teaching Assessment Criteria (MBI:TAC) 
(Crane et al., 2013; Crane et al., 2012a; Crane et al., 2012b) were used to assess 
the competence of the teaching. These criteria have been developed through a 
consensus process by a group of expert mindfulness trainers in the context of 
MBSR and MBCT teacher training programmes in the UK, in the period from 
2008 to 2012. The MBI:TAC consists of six domains: 1) coverage, pacing and 
organization of session curriculum; 2) relational skills; 3) embodiment of 
mindfulness; 4) guiding mindfulness practices; 5) conveying course themes 
through interactive inquiry and didactic teaching; and 6) holding of group 
learning environment. Within each domain, three to five ‘key features’ are 
described. The manual, which is freely available online (Crane et al., 2012b), 
provides detailed descriptions of these key features and their components. 
Domains can be scored at six competence levels: incompetent (1), beginner 
(2), advanced beginner (3), competent (4), proficient (5) and advanced (6), 
analogous to the Dreyfus and Dreyfus competence scale (Dreyfus & Dreyfus, 
1986). An early study of the psychometric properties of the MBI:TAC suggests 
good reliability (Crane et al., 2013) in terms of good overall agreement (r = 
.81) and substantial agreement for the individual domains (ICCs ranging from 
.60 to .81). Good face validity, construct validity and concurrent validity was 
reported in terms of between-domain correlations (ranging from .60 to .84) 
and significant differences between teachers in their first year of training and 
those in their second year or beyond. 
Possible mediators
Rumination was measured with the ‘brooding’ subscale of the extended 
version of the Ruminative Response Scale (RRS-EXT) (Treynor et al., 2003). 
The authors reported adequate internal consistency α = .79 and test–retest 
stability (α = .62, 1 year time interval) for the brooding subscale, which 
consists of 5 items. We selected the brooding subscale because over time, 
brooding has been related to higher levels of depression, whereas the 
reflection subscale has been linked to lower levels of depression (Treynor et 
al., 2003). The internal consistency in the current study was α = .75.
 Cognitive reactivity was assessed using the Leiden Index of Depression 
Sensitivity – Revised (LEIDS-R) (Van der Does, 2002). This scale consists of 
34 items comprising six subscales of 5 or 6 items, which had the following 
internal consistencies in the current study: hopelessness/suicidality: α = .83, 
acceptance/coping: α = .63, aggression: α = .73, control/perfectionism: α = 
.64, risk aversion: α = .70, rumination: α = .73. The internal consistency of the 
total score was α = .85.
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Mindfulness skills were assessed using the Five Facet Mindfulness 
Questionnaire (FFMQ) (Baer et al., 2006), consisting of 39 items divided into 
the subscales observing, describing, acting with awareness, non-judging and 
non-reactivity. The FFMQ has been found reliable and valid in a Dutch sample 
of depressed individuals (Bohlmeijer et al., 2011). In the current study, the 
following internal consistencies were found: observing: α = .74, describing: 
α = .89, acting with awareness: α = .86, non-judging: α = .88, non-reactivity: 
α = .79, and total score: α = .87.
 Self-compassion was measured with the Self Compassion Scale (SCS) 
(Neff, 2003). The SCS has 26 items measuring three concepts that are related 
to self-compassion: a) self-kindness versus self-judgment, b) common 
humanity versus isolation, and c) mindfulness versus over-identification. 
Good validity for the SCS has been reported (Neff, 2003). In the current study, 
the following internal consistencies were found: self-kindness: α = .73, self-
judgment: α = .79, common humanity: α = .70, isolation: α = .76, mindfulness: 
α = .73, over-identification: α = .68, and total score: α = .72.
Outcome measures
Depressive symptoms. The Inventory of Depressive Symptomatology – 
Clinician rated (IDS-C) (Rush et al., 1996) was used to assess severity of 
depressive symptoms at post treatment. This clinician-rated scale consists 
of 30 items assessing the criterion symptoms designated by the Diagnostic 
and Statistical Manual of Mental Disorders - 4th edition (DSM-IV) (American 
Psychiatric Association, 2000) for major depressive disorder for the prior 7 
days. The IDS-C has good psychometric qualities (Rush et al., 1996; Trivedi 
et al., 2004). The IDS-C was administered by independent, trained research 
assistants (see Huijbers et al., 2012). Cronbach’s alpha in the current study 
was .84 for the baseline assessment and .89 at post treatment.
 Depressive relapse/recurrence. Relapse/recurrence of depression was 
defined as meeting the DSM-IV criteria for a depressive episode during the 
15-month study period using the Structured Clinical Interview for DSM 
disorders I (SCID-I) (First et al., 1996). See Huijbers et al., (2012) for more 
details. Fair to good reliability has been reported for SCID-I in depressed 
samples (Lobbestael et al., 2011; Zanarini et al., 2000). In the current study, 
the inter-rater reliability between first and second ratings was found to be 
substantial (Kappa = 0.70, p = .001, 95% CI 0.456 – 0.942).
Intervention
MBCT was largely based on the protocol by Segal, Williams, and Teasdale 
(2002) with some minor adaptations: it consisted of 8 weekly sessions of 
2.5 (rather than 2) hours and included one day of silent practice between 
the 6th and 7th session (which originates from the MBSR curriculum (Jon 
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Kabat-Zinn, 2013) and is suggested in the most recent version of the MBCT 
protocol (Segal et al., 2012). Classes were provided at 12 different locations 
in the Netherlands. All sites used the same materials (protocol, handouts, 
CDs). 
Procedure
Fifteen MBCT teachers who participated in the RCT as trial teachers provided 
video recordings of their teaching (two full MBCT courses). The tapes were 
recorded during the intervention phase of the study between September 2009 
and January 2012. From each teacher, two tapes were randomly selected 
via online list randomisation (www.random.org). These were evaluated on 
competence by two independent raters from a group of 16 assessors. 
 Initially, assessors were invited to take part in a two-day workshop on the 
use of the MBI:TAC, led by two of the developers (RC and WK). The assessors 
were all expert teachers of mindfulness-based interventions. Three assessors 
also participated as a trial teacher, the others were not involved in the RCTs. 
All assessors fulfilled the advanced criteria of the association of mindfulness 
based teachers in the Netherlands and Flanders. The workshop included a 
two and a half hour didactic session in which the background and domains of 
the MBI:TAC were explained, and assessors’ evaluations were benchmarked 
using two 30-minute video clips of MBCT teaching. Subsequently, assessors 
independently evaluated the video tapes in pairs. About two tapes per 
teacher were evaluated. The total number of evaluated tapes during this two-
day workshop was 31. Most tapes were evaluated by two assessors, 8 tapes 
were evaluated by one assessor only. No discussion between the assessors 
was allowed during initial assessment. After noting down individual scores, 
assessors discussed possible differences in scoring and completed a final form 
with consensus scores for each of the six domains. After each of these sessions, 
there was a plenary session with the developers of the scale to ask questions 
and discuss difficulties. 
 To maximize the reliability of the MBCT teacher competence ratings, two 
assessors who were also involved in the initial workshop were invited for 
further training in using the MBI:TAC and to evaluate 18 additional tapes. As 
part of this training, their ratings of two non-trial tapes were benchmarked 
against ratings of one of the developers of the MBI-TAC and discrepancies 
were discussed (RC). The additional trial tapes were selected from teachers 
with a minimum of 10 participants in their groups (n = 8). This resulted in a 
subsample of eight teachers for whom we had competence estimates based on 
four sessions rather than two. The final number of evaluated tapes was 47, of 
which 5 tapes were evaluated by one assessor. In addition, we collected notes 
from the assessors about the process of evaluation to aid our interpretation of 
the results.
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Statistical analysis
To assess inter-rater reliability of the MBI:TAC, Intraclass Correlation 
Coefficients (ICCs) were calculated using a two-way random consistency 
model with single measures, based on the independent ratings of two 
assessors per videotape (n = 42). For interpreting the strength of these ICCs, 
the following cut-off points are used: < 0.00 poor; 0.00 - 0.20 slight; 0.21 – 
0.40 fair; 0.41 – 0.60 moderate; 0.61 – 0.80 substantial; 0.81 – 1.00 almost 
perfect (Landis & Koch, 1977). In addition, exact agreement and agreement 
including adjacent scores was calculated per domain. As an external validity 
check, we calculated the correlations between the mean MBI:TAC scores 
and teacher experience (years of clinical experience, personal mindfulness 
practice and number of MBCT courses), and between MBI:TAC scores and 
teachers’ self-reported mindfulness skills. 
 For all analyses, we performed complete case analyses (see table 6.2 
for the numbers). Probability values lower than .05 (two-tailed) were 
considered significant in all analyses. We used separate analyses for each 
outcome measure. Linear regression analyses were used to examine the 
relationship between competence and MBCT adherence, with the MBI:TAC 
score as a predictor of the number of sessions attended. To investigate 
a possible association between teacher competence and continuous 
process and outcome measures, firstly multilevel analyses were used to 
investigate the amount of variance in the outcome measures at the level of 
the participants (n = 241) that could be explained at the level of the teacher 
(n = 15). This was expressed as an ICC, calculated as teacher variance / 
(teacher variance + residual variance). Baseline scores of the process and 
outcome variables were included as covariates in the respective analyses. 
In addition, we included age, gender, number of past episodes (log-
transformed), depressive symptomatology at baseline (for the outcomes 
other than depressive symptomatology), previous CBT experience (yes/
no) as covariates. Subsequently, MBI:TAC scores were added to the model to 
test whether teacher competence would have additional value in predicting 
the variance in outcomes. Competence was operationalized as the average 
of the six domains of the MBI:TAC, based on the mutually agreed (or if 
unavailable the individual) scores, yielding a single competence score per 
teacher. Cox regression analysis was performed to examine the association 
between teacher competence and depressive relapse/recurrence during the 
15-month study period. In case of drop-out of the study, participants were 
censored before drop-out, others were censored at the end of the study 
period. Analyses were performed both with and without covariates. 
 Sensitivity analyses were performed for the subsample of teachers for 
whom we had four videotapes evaluated (n = 8), i.e. for whom we expected 
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the MBI:TAC estimates to be more reliable than for teachers who were 
evaluated on two videotapes. We also performed all analyses on the original 
sample (n = 15, assessments from first two videotapes only). However, as 
the pattern of results in both sensitivity analyses was very similar to the 
complete sample (n = 15, using all available assessments), we only report 
the results from the complete sample. Another set of sensitivity analyses was 
performed using the average rather than the mutually agreed MBI:TAC score 
as a predictor. However, this led to highly similar results, and the correlation 
between the agreed and average score was very high (r = .99) so we only 
reported the results based on mutually agreed scores.
 Exploratory analyses were performed to differentiate between the 
individual domains of the MBI:TAC and to examine indicators of teachers’ 
experience (years of practice as a clinician, number of MBCT courses taught 
and the total amount of personal practice) as predictors of all process 
and outcome variables. Personal practice was calculated from teachers’ 
registrations (retrospectively) of the time periods, frequency and duration 
of personal home practice, transformed to the corresponding number of 
8-hour days, added to the number of days spent in silent retreats. For these 
analyses, we used the same model as for the primary analyses (i.e. multilevel 
model for the continuous variables and Cox regression analysis for relapse/
recurrence).
RESULTS
Treatment outcome
Table 6.2 shows the means and standard deviations of the continuous 
mediator and outcome variables. Cognitive reactivity and brooding 
decreased significantly from pre- to post treatment with small effect sizes, 
whereas mindfulness skills and self-compassion increased significantly 
with medium and small effect sizes, respectively. Depressive symptoms did 
not change from pre- to post treatment. Of the 241 participants, 115 (47.7 
%) experienced a relapse/recurrence in the observed time period. For the 
completer sample (attending at least 4 sessions; n = 221), the results were 
similar.
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Table 6.2. Means and standard deviations of the continuous mediator and outcome variables
Variable Pretreatment 
Mean (SD)n
Post
Mean (SD) n
F(df) Effect size 
(d)
RRS-Br 11.0 (3.0) 234 9.8 (3.2) 186 28.22 (1,180) *** 0.39
LEIDS-R 76.7 (14.3) 233 74.0 (15.0) 186 8.24 (1,180) ** 0.18
FFMQ 117.1 (15.5) 232 127.9 (16.9) 185 84.32 (1,177) *** 0.67
SCS 86.9 (14.4) 232 93.1 (15.2) 184 37.26 (1,176) *** 0.42
IDS-C 12.8 (9.7) 241 13.2 (10.9) 201 1.48 (1,200) -0.09
Note. RRS-Br = Ruminative Response Scale – Brooding subscale; LEIDS-R = Leiden Index of Depression 
Sensitivity – Revised; FFMQ = Five Facet Mindfulness Scale; SCS = Self Compassion Scale; IDS-C = Inventory 
of Depressive Symptomatology – Clinician Rated; ** p < .01; *** p < .001.
Teacher competence
Levels of competence
The mean MBI:TAC score (averaged across tapes; n = 15) was 3.53 (SD 0.92, 
range 2.00 – 5.15). The means and standard deviations for the individual 
domains were as follows: 3.58 ± 0.91 (coverage/organization); 3.62 ± 0.94 
(relational skills); 3.61 ± 1.04 (embodiment); 3.54 ± 0.95 (guiding practices); 
3.53 ± 1.13 (inquiry and teaching); and 3.29 ± 1.00 (group management). 
This suggests that the competence scores of the evaluated sessions were, 
on average, between ‘advanced beginner’ and ‘competent’ level. In terms 
of discrete competence levels, none of the teachers was incompetent, two 
teachers (13%) were characterized as beginners, six (40%) as advanced 
beginners, four (27%) as competent, three (20%) as proficient, and none as 
advanced.
Reliability and validity
The internal consistency of the MBI:TAC was high (Cronbach’s alpha = .96). 
The ICCs of the six domains were as follows: 0.55 (moderate) for domain 
1 ‘coverage/pacing’; 0.67 (substantial) for domain 2 ‘relational skills’; 0.45 
(moderate) for domain 3 ‘embodiment’; 0.68 (substantial) for domain 4 
‘guiding practices’; 0.63 (substantial) for domain 5 ‘inquiry and teaching’; 
and 0.58 (moderate) for domain 6 ‘group management’. Low agreement 
was observed for the percentages exact agreement, ranging between 29% 
and 40%. When adjacent scores were included as agreement, percentages 
ranged between 69% and 88%. 
 Correlations between the domains of the MBI:TAC were high, ranging 
from .76 to .94 (all p-values < .01). Table 6.3 shows the correlations 
between the MBI:TAC mean score and indicators of teachers’ experience 
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and mindfulness skills. MBI:TAC scores were not significantly correlated 
with clinical experience (in years). A trend was observed between personal 
meditation practice and the MBI:TAC domain ‘group management’. The 
number of MBCT courses was not significantly correlated with MBI:TAC 
scores, but correlations were all in the positive direction. Unexpectedly, 
albeit not significant, correlations between the MBI:TAC scores and FFMQ 
total scores were all in the negative direction, ranging between -.01 to -.56.
Table 6.3. Correlations (Pearson’s r) between the MBI:TAC domains and indicators of teachers’ experience 
and mindfulness skills
Variable Clinical 
experience 
(years)
Total 
amount of 
personal 
practice 
(days)
Number 
of MBCT 
courses 
Mindful-
ness Skills 
(FFMQ 
total)
MBI:TAC (mean) .03 .39 .32 -.43
1) Coverage / organization .22 .36 .45 -.01
2) Relational skills -.02 .39 .34 -.38
3) Embodiment .17 .35 .30 -.48
4) Guiding practices -.13 .40 .25 -.56†
5) Inquiry and teaching -.10 .31 .15 -.52
6) Group management .08 .45† .32 -.19
N=14 N=15 N=14 N=10
Note. † trend towards significance (p-values between .05 and .10). 
Teacher competence and adherence
The attrition rate, defined as attending fewer than four out of eight sessions 
in accordance with previous trials (Kuyken et al., 2008; Teasdale et al., 2000), 
was 8% (N = 20 / 241). The median number of sessions was seven. Linear 
regression analysis with the covariates in the first block and MBI:TAC score 
as a predictor the second block showed that MBI:TAC did not improve the 
model for number of sessions attended as an outcome measure (Model 1: 
R2 = .023, F(5,235) = 1.11, p = .358; Model 2: R2 change = .000, F change 
(1,234) = 0,92, p = .483). Similar results were obtained for analysis without 
covariates.
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Teacher competence and possible mediators
Figure 6.1 shows the changes in rumination, cognitive reactivity, mindfulness 
skills and self-compassion from pre- to post treatment, grouped by mean 
teacher competence score from lowest to highest. Based on visual inspection, 
the largely vertical orientation for the solid lines (indicating the group mean 
change scores) suggests that participants from different teachers did not 
have different outcomes. The results of the multilevel analyses indicated that 
the variance explained by the teacher was negligible for all outcomes (ICC 
values < .01). Analyses without the covariates, except for the baseline score 
of the outcome measure, yielded similar results (all p-values > 0.1). 
 Adding the MBI:TAC score to the model did not explain variance in any of 
the outcome measures (all p-values ≥ 0.1). Analyses without the covariates, 
except for the baseline score of the outcome measure, yielded similar results. 
 Exploratory analyses with the individual MBI:TAC domain scores showed 
that there were no significant associations between these domain scores 
and changes in the possible mediators. Exploratory analyses with years 
of clinical practice, number of MBCT courses taught and total amount of 
personal practice as individual predictors did not show a relationship with 
any of the mediators either. 
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Figure 6.1. Changes in depressive symptoms, rumination, cognitive reactivity, mindfulness skills, and 
self-compassion from pre- to post treatment, grouped by mean teacher competence score from lowest to 
highest. The solid line represents the mean.
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Teacher competence and outcomes: depressive symptoms and relapse/
recurrence
Figure 6.1 shows the changes in depression severity from pre- to post 
treatment grouped by mean teacher competence score from lowest to highest. 
Again, visual inspection of the solid lines showed a vertical orientation, 
indicating that the mean difference in depression severity between pre- and 
post treatment did not differ between patients of different teachers. The 
pattern of results was similar to that of the possible mediators: the variance 
in changes in depression severity could neither be explained by the teacher 
nor by the MBI:TAC score (including the individual domains). Depression 
outcomes could not be explained by years of clinical practice, number of 
MBCT courses taught and personal practice of the teacher as individual 
predictors either.
 Cox regression analysis with MBI:TAC as a predictor for relapse with age, 
gender, number of past episodes (log transformed), baseline depression 
score and CBT experience as covariates showed that the MBI:TAC score did 
not make a significant contribution to the model (Hazard ratio = 1.07, 95% 
CI 0.83 to 1.38, p = .60). The model without covariates yielded similar results 
(Hazard ratio = 1.00, 95% CI 0.78 to 1.28, p = .99). Exploratory analyses with 
a) the individual MBI:TAC domain scores and b) years of clinical practice, 
number of MBCT courses taught and personal practice as individual 
predictors did not show any relationship with relapse/recurrence either.
DISCUSSION
In the current study, we found that teacher competence as assessed by the 
MBI:TAC was not associated with patients’ adherence to MBCT sessions, 
changes in possible mediating variables (rumination, cognitive reactivity, 
mindfulness and self-compassion) or depression severity from pre- to post 
treatment, or with relapse/recurrence during one-year follow-up. Other 
indices of teacher competence, such as their level of experience as measured 
by the number of MBCT classes they had led, did not predict mediator and 
outcome variables either. 
 To our knowledge, this is the first study to systematically examine the 
relation between competence and outcome in MBCT. Interestingly, earlier 
studies of CBT in depression did indicate therapist competence to be related 
to treatment outcome (e.g. Kuyken & Tsivrikos, 2009). However, a more recent 
study of 43 CBT therapists and 1247 patients in routine clinical practice 
did not show an association between therapist competence and treatment 
outcome either (Branson et al., 2015). Our own study also took place in 
routine clinical care, with 12 centers around the Netherlands participating. 
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The 15 teachers included in our study were not taught or supervised by the 
developers of MBCT as in earlier trials (Kuyken et al., 2016) and showed a 
wider range of competence levels, including more beginner and advanced 
beginner scores than in other trials reporting teacher competence (Kuyken 
et al., 2015; Williams et al., 2014; Kuyken et al., 2008). That being said, the 
lowest and highest levels of competence were still underrepresented in the 
current study. There were only two teachers characterized as ‘beginner’, and 
none of the teachers were, on average, characterized as advanced. This may 
have caused some restriction of range, possibly undermining any association 
between competence and outcome.
 Another possible explanation for the absence of a relationship between 
competence and outcome in MBCT is that the MBCT program might “carry 
itself”. Participants are given standardized pre-recorded mindfulness 
practices, invited to take full responsibility for themselves and to develop 
self-efficacy. This is also reflected in the strong emphasis on doing homework 
practices and applying mindfulness to daily life. Most of the work takes place 
between the sessions (about six hours of home practice per week) rather than 
within the sessions (two and a half hours). Previous studies have suggested 
that the patients’ amount of home practice is related to the risk of relapse/
recurrence (Crane et al., 2014) and decrease of depressive symptoms (van 
Aalderen et al., 2012b) after MBCT, and to a decrease in rumination (Ramel 
et al., 2004) and an increase in wellbeing (Carmody & Baer, 2008) after 
MBSR. Thus, participants’ willingness to engage in practice and explore 
their experiences both in and between the sessions may be more important 
to change than MBCT teacher competence. In this and most other studies 
rates of patient engagement and adherence tend to be high. Therefore, the 
relationship between teacher and participant is possibly less influential than 
in other types of psychotherapy. Furthermore, MBCT is delivered in groups 
with group members providing a sense of group support which may decrease 
the importance of the therapeutic relationship. This has been suggested 
by several qualitative studies of MBCT participants (e.g. Allen et al., 2009; 
Mason & Hargreaves, 2001), including one study that focused exclusively on 
the role of the teacher in MBCT (van Aalderen et al., 2012a). Interestingly, all 
participants in this latter study mentioned the importance of peer support 
whereas this was mentioned by only a few teachers. 
 An additional explanation for the absence of a relationship might be the 
relatively uniform delivery of the intervention within the trial. MBCT is highly 
standardized (especially in the context of an RCT). All study participants 
received the same materials and participants’ home practice was led through 
the same mindfulness practice CDs.
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Assessing competence 
Another striking finding of our study is the complexity and difficulty 
of assessing practitioner competence of any complex intervention. The 
reliability of the MBI:TAC in our study was lower than reported by the 
developers of the instrument (Crane et al., 2013). ICCs were moderate to 
substantial, suggesting that a considerable amount of variance can be 
attributed to differences in ratings between assessors. There are several 
explanations for the relatively low agreement between assessors in our study. 
Unlike the assessors in the study by Crane et al., (2013), who collaborated in 
the development of the MBI:TAC for several years, the assessors in our study 
had no previous experience with the instrument, were trained in MBCT at 
different institutes, were less acquainted with each other and evaluated 
teachers of whose teaching they had no or little prior knowledge. A study by 
Keen and Freeston (2008) indicated that reliable assessment of competence 
is complex and resource intensive: in order to obtain adequate reliability for 
CBT competencies, 19 videotapes of one therapist evaluated by two assessors 
would be necessary. Although we increased the number of evaluated tapes 
from two to four for a substantial number of the teachers to begin to address 
this issue, we were not able to meet this stringent target. On the other hand, 
several indicators of teachers’ experience (years of practice as a clinician, 
number of MBCT courses taught and personal practice) were not associated 
with treatment outcome either, which supports the robustness of our 
findings independent of the MBI:TAC ratings. 
 An unexpected observation was that the teachers’ self reported levels 
of mindfulness skills, as measured with the FFMQ, were negatively (albeit 
not significantly) correlated with the MBI:TAC domains. This may suggest 
that teachers who are considered to be more competent are more aware of 
their lack of mindfulness than those considered less competent. However, 
this finding should be interpreted with caution as data on mindfulness skills 
were only available for 10/15 teachers. 
 Interestingly, Horvath and colleagues (2011) showed that patients’ 
perceptions of the therapeutic alliance are related to outcome in individual 
psychotherapies, but that these perceptions did not necessarily match those 
of the therapists. In future studies, it would be interesting to use triangulation, 
for example by using self reports, experts’ and patients’ perspectives on 
teacher competence in mindfulness-based interventions, to see how these 
correlate and possibly (differentially) predict outcome.
 On the basis of the notes from the expert teacher competence assessors, 
we identified some challenges in the process of assessing competence. 
First, the constituent trials often used two teachers and the presence of a 
co-teacher can significantly impact the teaching of the other. Although in 
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the current study only a minority of patients attended MBCT provided by 
two teachers (28%) and the competence ratings of these teachers differed 
less than 1 point (on a scale from 1-6), we cannot rule out that the presence 
of co-teachers may have influenced teacher competence and consequently, 
the results of this study. Thus, the possible impact of a co-teacher should be 
taken into account when assessing competence in future studies. A second 
challenge that came up was the difficulty of distinguishing between the 
different domains. For example, the assessors noted in a particular case 
that the lack of organization of the session seemed to stem from a lack of 
embodiment. The overlapping of domains sometimes led to confusion with 
regard to choosing whether to include the information in one domain or the 
other, or in both. Furthermore, the numerous and detailed descriptions of 
the domains (including key features and corresponding criteria) seemed 
challenging. Some elements or criteria may speak strongly to one assessor, 
whereas other elements may be more important to another assessor, 
resulting in different ‘weighting’ of the criteria. The assessors noticed that 
despite having similar overall impressions of a teacher, their individual 
scores could be different. In addition, the MBI:TAC criteria emphasize the 
use of interactive dialogue as a key method in mindfulness-based teaching, 
for example to explore participants’ experiences or to convey course themes. 
However, in some cases the assessors observed types of teaching, such as 
active listening or presenting psycho-education (without dialogue) in a 
very inspiring way, which seemed to deepen the learning process as well. In 
these cases, using the criteria led to lower scoring than when a more general 
impression of the teaching was followed. Finally, we have the impression 
that the assessments are also sensitive to cultural influences. 
Conclusion and implications
In conclusion, we did not find robust effects of teacher competence on several 
outcomes of MBCT. Explanations for the absence of such an association might 
be the standardized delivery of MBCT, the importance of participant-related 
factors, the difficulties in assessing teacher competence, and a relatively 
small selection of videotapes. It is possible that teachers and researchers 
overestimate the role of the teacher relative to the curriculum, the group, the 
mindfulness home practice and the participants themselves. However, to our 
knowledge, this is the first quantitative study examining teacher competence 
in MBCT. It is an area that is under investigated. Therefore, we encourage 
other researchers who conduct trials of mindfulness-based interventions 
to systematically assess teacher competence and its possible influence 
on treatment outcome so that the field can develop understanding of this 
nuanced and complex area.   
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In this chapter, I will first provide an overview of the findings in the current 
thesis, which will then be discussed in relation to the existing literature. I 
will also describe some strengths and limitations of the study, its clinical 
implications, and suggest some directions for future research.
Summary
Patients with major depressive disorder have a high risk of relapse/
recurrence. Maintenance antidepressant medication (mADM) is typically 
recommended to prevent relapse/recurrence. Many individuals, however, 
are unwilling to continue mADM for a long period, for example because of side 
effects. Besides, mADM is only effective as long as it is taken. So, a substantial 
proportion of patients prefer psychosocial interventions. Mindfulness-based 
cognitive therapy (MBCT) is an eight-week group intervention designed to 
help patients prevent depressive relapse/recurrence by developing non-
judgmental awareness of their automatic patterns of thinking and behaviour. 
Previous studies have shown that MBCT helps to prevent future depressive 
episodes in patients with recurrent depression, and that it can be a viable 
alternative to mADM. However, up till now, no studies have investigated 
whether the combination of MBCT and mADM is more effective than either 
of these treatments on its own. 
 The current thesis was designed to assess the effectiveness of MBCT, 
mADM and its combination in patients with recurrent depression (3 or more 
previous episodes) in full or partial remission who had been using mADM 
for at least six months. Chapter 2 describes the design and protocol of the 
two RCTs that constitute the backbone of this thesis, together referred to as 
the ‘MOMENT’ study. Originally we intended to conduct a three-armed RCT 
of MBCT alone, mADM alone or MBCT+mADM, but this turned out not to 
be feasible since almost all patients who were interested in the study either 
wanted to participate in MBCT, or hold on to their medication. Therefore 
we conducted two parallel RCTs. Patients preferring MBCT participated 
in trial A comparing the combination of MBCT+mADM to MBCT alone, i.e. 
with discontinuation of mADM. Patients preferring mADM participated in 
trial B comparing the combination of MBCT+mADM to mADM alone. This 
enabled us to acknowledge patients’ preferences while maintaining the 
experimental rigour of randomisation. An advantage of this new approach 
was that the study was more in line with clinical practice, as particular 
treatment preferences are very common. In addition, acknowledging patient 
preference is widely recognized as an important aspect of evidence-based 
practice (American Psychiatric Association, 2010).
 The primary finding of the current thesis is that patients who discontinued 
their mADM after having participated in MBCT had nevertheless an 
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increased risk of relapse/recurrence of depression, even having stated a 
preference for MBCT rather than mADM (chapter 3). In the intention-to-
treat sample, relapse rates were 54% for the discontinuation group and 39% 
for the combination group. In the per-protocol sample these numbers were 
even higher: 69% and 46%, respectively. Discontinuation seemed much 
more challenging than we had anticipated, resulting in a large percentage 
of patients (47%) who did not adhere to the study protocol, i.e. who did not 
proceed with the process of discontinuing their mADM to zero milligram. 
Thus, our hypothesis that MBCT followed by discontinuation of mADM 
would be non-inferior to the combination of MBCT and mADM was rejected. 
However, the overall course of depression severity during the 15-month 
follow-up period was similar in both groups, although a small but significant 
increase of depressive symptoms was observed in the discontinuation group 
at 3-month follow-up. At that point, patients in the discontinuation group 
were in the middle of tapering their medication, which may have led to 
elevated symptom levels. Probably related to this, we observed that besides 
the fact that almost half of the patients did not complete or even start the 
discontinuation process, those who did fully discontinue often restarted their 
mADM within the study period (56%). Other secondary outcomes, including 
the number, duration and severity of depressive episodes and quality of life 
during follow-up, did not differ between the groups.
 Another hypothesis was rejected in chapter 4, where we showed that 
adding MBCT to mADM did not further decrease the risk of relapse/recurrence 
compared with mADM alone (36% for MBCT+mADM and 37% for mADM 
alone). The groups also did not differ on any of the secondary outcomes. 
The relapse/recurrence rates in the per-protocol analysis (MBCT+mADM 
39% and mADM alone 48%) suggested that there may be a small benefit for 
adding MBCT to mADM in patients adhering to both interventions. However, 
a sample size of about 500 participants per group would be needed to detect 
such a difference with 80% power. One of the possible explanations for the 
absence of an additional effect of MBCT was that in this trial only patients 
with a preference for mADM were included, whereas those preferring MBCT 
were included in the previous trial (chapter 3). 
 The possible influence of preference was further explored in chapter 
5, where we hypothesized that patients preferring MBCT would benefit 
more from MBCT than those preferring mADM, in terms of adherence to 
the combination of treatments (MBCT+mADM) and its outcomes (risk 
of relapse/recurrence, severity of (residual) depressive symptoms and 
quality of life). However, neither preference type (MBCT versus mADM) nor 
preference strength (the score on a questionnaire about expectations of both 
treatments) affected adherence or outcomes. Again, our findings were in 
contrast with our expectations. 
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In chapter 6, we tested the hypothesis that higher levels of competence of the 
mindfulness teacher would be associated with better adherence (number of 
MBCT sessions attended), reduction of rumination and cognitive reactivity, 
improvement of mindfulness and self-compassion, and reduction of post 
treatment depressive symptoms and risk of relapse/recurrence in the year 
after MBCT. However, the results showed that despite a relatively wide range 
of competence levels in the sample of teachers in the MOMENT study (n = 
15), teacher competence was not related to any of these outcomes. This study 
also showed that it is fairly difficult to rate teacher competence reliably. The 
inter-rater reliability was only moderate for most of the subscales of the 
instrument that we used, the Mindfulness-Based Interventions: Teaching 
Assessment Criteria (MBI:TAC; Crane et al., 2013). Nevertheless, our findings 
seemed rather robust as other possible indices of competence, including 
years of clinical practice, number of MBCT courses taught and amount of 
personal practice, did not predict patient outcomes either.
Preventing relapse/recurrence in patients with recurrent depression
Comparing our results with previous studies of MBCT for preventing 
relapse/recurrence, the findings from our study were rather unexpected. 
For example, discontinuation of mADM after MBCT led to higher rates of 
relapse/recurrence than in previous studies (Kuyken et al., 2008; Kuyken et 
al., 2015; Segal et al., 2010). In the most recent meta-analysis, MBCT followed 
by discontinuation even appeared slightly more effective than mADM alone 
(Kuyken et al., 2016). In our view, however, it would be premature to say 
that MBCT is more effective than antidepressants. Discontinuation may be 
particularly challenging for patients who are at highest risk for relapse/
recurrence because of residual symptoms and several previous episodes, 
as sampled in the current study. In that regard, trial A could be considered 
a study about tapering antidepressants rather than a study about the 
effectiveness of MBCT. In terms of patient selection, the results may apply to 
patients in secondary and tertiary care, but cannot be assumed to extrapolate 
to primary care patients or patients with less severe forms of depression. 
 The fact that our study was the first to compare MBCT followed by 
mADM discontinuation with the combination of MBCT and mADM makes 
it difficult to weigh our results against the existing literature. The finding 
that the combination of MBCT and mADM performs better than MBCT alone, 
however, fits rather well with the literature on combining antidepressants 
with psychological interventions in general (Cuijpers et al., 2014; Guidi, 
Fava, Fava, & Papakostas, 2011). These meta-analyses have shown that 
the combination of antidepressants with psychological interventions is 
generally more effective in terms of both reduction of depressive symptoms 
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in current MDD and reducing relapse risk in MDD in remission. In contrast, 
the results from trial B are not in line with this idea, as adding MBCT to 
mADM did not reduce risk of relapse/recurrence compared with mADM 
alone. This is even more surprising considering that post hoc analyses 
of an effectiveness trial conducted in Australia showed that MBCT was 
particularly effective for patients on antidepressants (Meadows et al., 2014). 
Interpretation of our results was complicated by the fact that about a quarter 
of patients in the mADM group participated in MBCT anyway. They were able 
to do so, albeit violating the study protocol, due to the availability of MBCT 
in all participating research centers. Those patients apparently wanted to 
receive the combination of treatments despite the fact that they had stated 
a (relative) preference for mADM at baseline. Interestingly, this group 
reported more previous depressive episodes and had higher levels of self-
reported mindfulness skills at baseline (chapter 5). This might indicate that 
they were more aware of, and more accepting towards their vulnerability for 
depression.
 In sum, the current thesis suggests that the combination of MBCT and 
mADM is more effective than MBCT alone (i.e. with discontinuation), but not 
compared with mADM alone. We cannot directly compare MBCT and mADM 
alone, however, as the samples of our two RCTs consisted of patients with 
different treatment preferences.
Patients’ preferences
The majority of patients (79%) preferred trial A with MBCT in both study arms 
over trial B with mADM in both study arms. This finding is in accordance with 
previous studies indicating that most patients prefer psychological treatment 
or combined treatment over pharmacological treatment alone (Steidtmann 
et al., 2012; van Schaik et al., 2004). However, even within the separate trials 
of the MOMENT study, patients might have had a specific preference for the 
combination treatment. For example, patients in the mADM trial were also 
interested in mindfulness and did equally well when receiving MBCT added 
to mADM as those preferring MBCT. So, the mADM preference group might 
represent a group of patients who are reluctant to discontinue their mADM, 
but are actually interested in MBCT as an additional treatment. Hence, the 
difference in patients’ preferences may have been relatively small compared 
with routine clinical practice or other studies. 
 Another explanation for our finding that preferences did not impact 
outcome is that by design, our primary aim was prevention of relapse/
recurrence. Therefore, patients were in remission at baseline and as a result, 
there may have been less room for improvement, for example in terms of 
depression severity, compared with therapeutic studies.
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Interestingly, about a quarter of the patients in trial A who were allocated to 
the combination group actually tapered or discontinued their medication, 
in disagreement with the protocol. This subgroup supposedly had a strong 
preference for discontinuing their medication. We also observed that 
only 21% of these patients restarted mADM, whereas 56% of the patients 
who discontinued by allocation (in the discontinuation group) restarted. 
Interestingly, the risk of relapse/recurrence in the combination group was 
higher in those who adhered to both interventions (per-protocol: 46%) than 
in the entire sample (intention-to-treat: 39%). These findings may suggest 
that choosing a treatment strategy works better than being randomly 
allocated to it. On the other hand, studies that used a ‘partially randomized 
patient preference design’ did not show an influence of choosing treatment 
versus being randomized to it (e.g. Van et al., 2009). In our study, however, 
patients may have had stronger preferences than in previous studies as they 
even took the hurdle of tapering in disagreement with the study protocol.
Teacher competence
Contrary to our expectations, we found that teacher competence was not 
associated with patients’ adherence to MBCT sessions, changes in possible 
mediating variables (rumination, cognitive reactivity, mindfulness and self-
compassion), depression severity or relapse/recurrence. Our expectations 
were mainly based on a meta-analysis of the effect of therapist competence in 
different types of individual psychotherapy (Webb, DeRubeis, & Barber, 2010), 
as there were no such studies available for MBCT. In this meta-analysis, the 
mean weighted effect size for the relation between competence and outcome 
in all included studies (k = 15) was 0.07 (not significantly different from 0), 
but for the subset of studies investigating MDD (k = 5), the r-type effect size 
was 0.28 (p < .01). However, a more recent study including 43 CBT therapists 
and 1247 patients in routine clinical practice did not show an association 
between therapist competence and treatment outcome either (Branson et 
al., 2015). Our own study also took place in routine clinical care, with 12 
research sites around the Netherlands participating. In addition, MBCT takes 
place in a group, which may attenuate the influence of the teacher due to the 
support from group members. Other factors that may play a role include the 
emphasis on home practice and self-efficacy, and a relatively uniform delivery 
of the intervention within the trial (including a highly standardized protocol 
and materials such as CDs). As a result, to a certain extent the program might 
“carry itself” rather than depend heavily on the competency of the teacher. 
Finally, we have the impression that the assessments are also sensitive to 
cultural influences. Dutch assessors, for example, seemed to be less generous 
in their ratings than their UK counterparts.
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Methodological considerations
A major strength of the current study is its generalizability. Patients were 
broadly recruited (mental health professionals, general practitioners, self-
referral) and treated by 15 different teachers in nine mental health centers 
in urban as well as more rural areas of the Netherlands. In terms of the NIH 
stage model outlined in the general introduction, the current study can be 
considered an effectiveness study (stage IV). Adopting such a multi-centre 
effectiveness study has a number of consequences that can be regarded both 
as a strength and as a limitation. For example, the fact that so many patients 
did not adhere to the study protocol of discontinuing (47%) or continuing 
(36%) their mADM forms a major threat to the internal validity of the study. 
Indeed, per-protocol analysis showed that the relapse/recurrence rates 
were higher when including only those participants who discontinued fully 
(in the discontinuation group) or continued on the same dose of mADM (in 
the combination group), compared with the entire sample (intention-to-
treat). However, seeing that tapering medication caused so much difficulty 
is, in itself, an important observation. It might be that the numbers of 
‘discontinuation failure’ in our study are more realistic in terms of what 
to expect in routine clinical practice. Taking this one step further, the high 
percentage of relapse/recurrence after discontinuation, even with MBCT, 
may also be more realistic than that reported in highly controlled studies 
(e.g. (Segal et al., 2010). An important difference is that in the current study, 
MBCT was delivered in mixed groups, whereas in previous studies (Kuyken 
et al., 2008; Kuyken et al., 2015; Segal et al., 2010) the withdrawal process 
took place as part of the intervention at the same time in the whole group. 
Therefore, patients in this study may have lacked support within the training 
in using mindfulness skills to cope with anticipatory fears and worries, or 
withdrawal symptoms. Consequently, patients might have felt more insecure 
about discontinuation.
 A second major threat to the internal validity of the study is the relatively 
low level of teacher competence. On average, most of the teachers were 
characterized as advanced beginners on the basis of their scores on the 
MBI:TAC, and only half of them were characterized as competent or above. 
This may have attenuated the effectiveness of MBCT in general in the 
current study. In terms of external validity, however, this aspect of the study 
can be considered a strength. It gives an indication of the effectiveness of 
MBCT as provided in a ‘real-life’ setting and it stresses the importance of 
careful implementation of MBCT, including proper training and continuous 
professional development of future mindfulness teachers (Crane & Kuyken, 
2013). In addition, the relatively wide range of competence levels created 
an opportunity to study its influence on the outcomes of the patients. As a 
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result, this was the first study to systematically address this topic in MBCT 
for depression, using the best methodology that is currently available to 
assess it, i.e. scoring a random sample of videotapes from a relatively large 
number of teachers using a standardized measure by pairs of independent 
expert assessors. 
 Another possible methodological problem is the use of self-report 
questionnaires of which the validity is still under debate. For example, the 
Five Facet Mindfulness Questionnaire (FFMQ) that was used in this thesis 
has been criticized for delineating mindfulness into an overly simplified 
psychological construct, disregarding its philosophical (Buddhist) 
underpinnings (Grossman & Van Dam, 2011). These authors also raised the 
concern that participants may only adequately understand the items of the 
FFMQ after they have participated in MBCT, which might have a negative 
impact on the baseline assessment. Similarly, the Self Compassion Scale 
(SCS) that was used in the current thesis is also under debate, as a recent 
paper showed that its negative subscales (self-judgment, isolation, and 
over-identification) were stronger related to psychopathology than their 
positive counterparts (self-kindness, common humanity and mindfulness), 
which means that using the total score will probably result in an inflated 
relationship with symptoms of psychopathology and an overestimation of 
the treatment effect (Muris & Petrocchi, 2016). Despite these possible threats 
to the validity of assessing mindfulness and self-compassion, there are few 
alternatives so far. When the MOMENT study started, these were the best 
available and most commonly used measures, thus permitting comparison 
with previous studies. Nevertheless, further refinement of the construct 
of mindfulness and novel, creative ways to measure it are amongst the key 
priorities on the scientific agenda.
Reporting of ‘negative’ findings
The summary of the current thesis shows that none of our research 
hypotheses in chapters 3, 4, 5 and 6 were supported. In that regard, the 
MOMENT study has generated a series of “negative” findings. However, these 
unexpected findings also stimulate the scientific debate and generate new 
research questions, for example with regard to discontinuation of mADM, 
or teacher competence. Thus, these “negative” findings are as important 
as “positive” findings. In fact, a recent meta-analysis has shown that non-
significant or negative findings may be underrepresented in the field of 
mindfulness-based interventions. Coronado-Montoya and colleagues (2016) 
performed a search for all RCTs of mindfulness-based interventions and 
compared the proportion of RCTs with positive results with what would 
be expected if mindfulness were similarly effective compared to individual 
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psychotherapy (effect size d = 0.55). They also collected all registered 
(including unpublished) RCTs to examine possible reporting bias. Results 
showed that of the 124 included RCTs, almost 90% reported positive results, 
which was 1.6 times greater than the expected proportion. In addition, of 
the 21 trial registrations, 13 (62%) remained unpublished 30 months 
after completion of the trial. The authors conclude that the proportion of 
mindfulness-based intervention trials with statistically significant results 
may overstate what would occur in clinical practice. The current thesis may 
contribute to a more balanced perspective of what MBCT has to offer and 
what needs to be improved.
 A possible reason for the apparent imbalance is that authors often 
have conflicts of interest (Gorman, 2016). Such conflicts exist “when the 
individual has interests in the outcome of the research that may lead to a 
personal advantage and that might therefore, in actuality or appearance, 
compromise the integrity of the research” (Institute of Medicine, 2002). 
Important to note here is that conflicts of interest can instigate but do not 
necessarily result in compromised scientific integrity. Gorman (2016) shows 
that conflicts of interest have the potential to adversely affect the quality 
of research but also that the field has begun to respond to these concerns. 
Possible ways to improve the scientific integrity include more detailed 
disclosure of the conflicts of interest of all authors, using the CONSORT 
guidelines for reporting clinical trials (Moher, Schulz, & Altman, 2001), using 
the SPIRIT guidelines for publishing the protocols of RCTs (including its pre-
specified primary outcome measure) in an early stage (Chan et al., 2013), 
and increasing transparency by making data openly available. Fortunately, 
these practices are becoming increasingly commonplace. 
The paradox of mindfulness research: change versus acceptance
From a scientific and community perspective, researchers’ and funding 
agencies’ focus on “positive” outcomes of clinical trials, such as reduction 
of relapse risk or depressive symptoms, is very understandable. However, 
from a theoretical perspective, this may not be very suitable for mindfulness 
research. The aim of mindfulness practice is namely to change the relationship 
with experiences, rather than to change these experiences themselves. In 
fact, striving towards change, for example striving to get rid of depressive 
symptoms, is regarded as a hindrance rather than a facilitator for developing 
mindful awareness and insight. When striving towards change, people are in 
the ‘doing mode’ (see General Introduction), which is usually their default 
mode and characterized by thinking (“living inside your head”). In contrast, 
the ‘being mode’ is characterized by moment-to-moment awareness, 
allowing things to be as they are in that moment, including possible feelings 
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of sadness, guilt, shame or anxiety. The rationale behind the MBCT program 
is to purposively attend to these difficult experiences with an attitude of non-
judging, acceptance, and self-kindness, rather than self-criticism, in order to 
gain insight in the automatic patterns of thinking and behaviour that may 
lead to depression. This insight is assumed to create fexibility in thinking and 
choosing, and consequently to an increased sense of liberation. Although 
mental health often improves simultaneously or subsequently, this is not a 
direct aim of mindfulness training. Thus, one could question whether the 
outcome measures that are often used, such as risk of relapse/recurrence 
or levels of depressive symptoms, are sufficiently sensitive to ‘capture’ the 
change that MBCT might bring about. For example, in an RCT of mindfulness 
training for patients with medically unexplained symptoms (Van Ravesteijn, 
Lucassen, Bor, Van Weel, & Speckens, 2013), mindfulness did not change 
the patients’ physical functioning or general health status, but did increase 
mental functioning, especially vitality and social functioning as measured 
with the SF-36 Health Survey. Similarly in recurrent depression, measures 
that focus more on patients’ ability to maintain their occupational and social 
activities, even in the presence of depressive symptoms, might better suit 
MBCT’s rationale.
Implications and future directions
There are some implications and recommendations for future research 
that derive directly from the current thesis. First, our finding that 
discontinuation of mADM appeared so difficult for many patients requires 
further investigation. For the time being, patients with recurrent depression 
should be informed that, on a group level, discontinuation of mADM is 
associated with an increased risk of relapse/recurrence. However, given 
that a substantial number of patients is eligible and interested in tapering 
or discontinuing their medication, we should be able to provide them with 
better guidance than is currently available. Therefore, we need to know 
more about the factors that facilitate successful discontinuation. This may 
include mindfulness practice when emphasis is placed on using mindfulness 
skills to accept the (withdrawal) symptoms as they were and to disengage 
from anticipatory fears and worries, in homogeneous groups with patients 
who all taper their medication. Other possible factors include peer support, 
intensive support from clinicians during the ‘tricky’ parts of the tapering 
process, shared decision making, and individualized tapering schemes. 
In addition, patients may switch to a longer-acting antidepressant before 
starting withdrawal (Wilson & Lader, 2015). At the Radboudumc Center 
for Mindfulness, we have recently started a new research project with the 
aim of investigating the possible value of MBCT supporting antidepressant 
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medication tapering in primary care. Other groups are also working on the 
topic of discontinuation of ADM, supported by cognitive therapy (Bockting 
et al., 2011; Molenaar et al., 2016; Scholten, Batelaan, Van Oppen, Smit, 
& Van Balkom, 2013), so we seem to be heading towards an increased 
understanding of discontinuation of mADM in affective disorders.
 Secondly, it seems important to know for which patients MBCT is 
particularly effective. Trial B suggested that MBCT has little added value to 
mADM in patients preferring mADM, but this finding needs to be replicated, 
especially given the relatively small sample and high rates of non-adherence 
to the study protocol. Future studies addressing patients’ preferences might 
use more sophisticated measures than we did in the MOMENT study, and 
assess preferences for all aspects of an intervention. For example, in chapter 
5 we only assessed preferences for either MBCT or mADM, but not for the 
combination of these treatments, or to what extent patients were willing or 
apprehensive of discontinuation of mADM. It would have been interesting to 
look at these aspects separately.
 Third, we recommend that teacher competence in mindfulness-based 
interventions is systematically assessed so that we can learn more about 
its possible influence on treatment outcome. Although this type of research 
is very time-consuming and expensive, understanding the relationship 
between competence and patient outcome is of fundamental importance to 
the dissemination and implementation of MBCT. It would be interesting to 
include a group of teachers with an even larger range of competence levels 
than we did in the MOMENT study, at least adding the ‘advanced’ level. In 
addition, the field would benefit from future studies using triangulation 
by examining teachers’ self reports, experts’ and patients’ perspectives on 
teacher competence in mindfulness-based interventions, to see how these 
correlate and possibly (differentially) predict outcome.
 As outlined by Dimidjian and Segal (2015), a general recommendation 
for mindfulness research is to proceed to later stages in the NIH stage model, 
especially stages III, IV and V (efficacy in community clinics, effectiveness, 
and implementation and dissemination), which are highly underrepresented. 
In the discussion of their paper, they state: “If MBI approaches are to have a 
meaningful impact, they must overcome not only barriers to dissemination 
and implementation that are common to other approaches (e.g., service 
costs, waiting lists, and distance to access intervention), but also unique 
barriers due to instructor competencies” (p. 608). The authors also include 
a word of caution about “falling off the implementation cliff” and “getting 
caught in implementation-limbo”, the former referring to the phenomenon 
that interventions appear to lose some of their effectiveness when they are 
being offered to larger groups of people, and the latter referring to a situation 
in which the ‘bar’ for the level of therapist training is set lower and lower due 
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to financial and time constraints (Weisz, Ng, & Bearman, 2014). Although 
the findings of the current thesis (chapter 6) are not particularly inviting 
in terms of investing much time and money in training teachers to deliver 
mindfulness based interventions competently, it should be emphasized that 
our knowledge in this area is still preliminary and requires replication and 
further investigation. 
 In addition, although there is evidence that changes in mindfulness skills, 
rumination, worry, (self)compassion and meta-awareness are associated 
with improvements in MBCT treatment outcomes (van der Velden et al., 
2015), a more detailed understanding of how MBCT works is needed to 
refine and optimize treatment. This would also facilitate a better selection 
of the patients who may benefit most from MBCT. In addition, future studies 
are needed to examine whether the working mechanisms are different for 
different populations, such as patients with or without medication, or with 
or without current depression.
 With regard to scientific integrity, it seems important to move towards a 
science characterized by transparency, in order to banish reporting biases 
as much as possible. Reporting of “negative” findings should be as easy as 
reporting “positive” ones, given that the methodology is sound. Some ways 
to improve transparency and scientific integrity are to use the CONSORT 
guidelines for reporting clinical trials (Moher et al., 2001), to ‘upgrade’ and 
monitor conflict of interest policies, to make open access publishing of trial 
protocols mandatory so that submitted manuscripts can be compared with 
these protocols (for example by editors and reviewers) and reporting bias can 
be assessed more accurately, and to increase access to raw data. The Center 
for Open Science aims to increase openness, integrity, and reproducibility of 
scientific research, and has launched several projects to do so, for example 
development of an open science framework, the reproducibility project in 
which 100 papers published in the field of psychology were independently 
replicated, and the “$ 1,000,000 preregistration challenge” in which 1000 
researchers will be awarded with $ 1,000 if they preregister their study and 
report their results in accordance with their prespecified analysis plan. Thus, 
it seems that the academic society is slowly but steadily moving towards a 
more reliable evidence base, which is crucial for delivering the best possible 
care to our patients. 
Conclusion
The current thesis provides a series of studies investigating MBCT for recurrent 
depression. None of our hypotheses were supported: discontinuation of 
mADM after MBCT increased the risk of relapse/recurrence compared 
with the combination of these treatments, adding MBCT to mADM did not 
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further reduce relapse/recurrence risk compared to mADM alone, and we 
found no evidence that patients’ preferences or teacher competence had any 
influence on the outcomes of MBCT. These unexpected findings, however, 
have generated several new research questions and stimulated the scientific 
debate about issues that have received little attention so far, such as teacher 
competence and patient preference, in the field of mindfulness research. 
Consequently, our findings may contribute to a more balanced perspective 
of MBCT, including both its strengths and limitations. 
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Dit proefschrift is gebaseerd op een verzameling artikelen die voortkomen uit 
het MOMENT onderzoek dat in 2009 is opgestart. MOMENT is een acroniem 
voor ‘Mindfulness Of Medicatie EN Terugvalpreventie’ en het onderzoek 
was gericht op het voorkómen van terugval bij mensen met terugkerende 
depressie door middel van mindfulness, medicatie, of de combinatie daarvan. 
Hieronder volgt een Nederlandstalige samenvatting van de achtergrond van 
dit onderzoek, de methode en de resultaten ervan, alsmede een bespreking 
van de bevindingen vanuit een breder perspectief.
Depressie en het voorkomen van terugval
De depressieve stoornis is een veelvoorkomende maar toch ernstige 
psychische aandoening. In Nederland maakt ongeveer 1 op de 5 
volwassenen minstens eens in zijn of haar leven een depressie door. Een 
depressie wordt gekenmerkt door de volgende symptomen: een sombere, 
neerslachtige stemming, gebrek aan plezier of interesse in (gewoonlijk 
plezierige) activiteiten, verandering in eetlust of gewicht, slaapproblemen, 
psychomotorische geremdheid of agitatie, vermoeidheid of futloosheid, 
gevoelens van waardeloosheid of extreme schuldgevoelens, cognitieve 
problemen zoals gebrek aan concentratie of besluiteloosheid, en regelmatig 
terugkerende gedachten aan zelfdoding of een intentie daartoe. Om van een 
depressieve stoornis te spreken moeten 5 van de 9 bovenstaande symptomen 
gedurende minimaal 2 weken aanwezig zijn en tot significante problemen 
leiden in het beroepsmatig of sociaal functioneren. Behalve de lijdensdruk 
voor de patiënt heeft een depressie dus ook een negatieve invloed op diens 
omgeving, bijvoorbeeld doordat iemand zich sociaal terugtrekt of (tijdelijk) 
niet meer kan werken. Deze individuele en maatschappelijke lijdensdruk 
wordt nog versterkt door het feit dat depressie vaak terugkomt, namelijk in 
ongeveer de helft van de gevallen. Als mensen 3 of meer depressies hebben 
gehad in hun leven, is de kans zeer groot dat zij nog vaker een depressie 
zullen doormaken, zeker bij gebrek aan behandeling. Bovendien ervaren 
veel patiënten nog restklachten na een depressieve periode en herstellen 
dus slechts gedeeltelijk. Om deze redenen is het van groot belang dat er 
onderzoek wordt gedaan naar hoe we depressieve terugval het beste kunnen 
voorkomen.
 De meest gebruikelijke vorm van terugvalpreventie is het gebruik 
van antidepressieve onderhoudsmedicatie (in het Engels maintenance 
antidepressant medication, mADM). Uit onderzoek is gebleken dat dit 
de kans op een terugval vermindert met ongeveer 20-30%. Het is echter 
onduidelijk hoe lang men deze medicatie zou moeten blijven gebruiken. 
Ook willen veel patiënten niet langdurig antidepressiva slikken, waardoor 
de therapietrouw te wensen overlaat. Een ander nadeel van antidepressiva 
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is dat deze doorgaans weinig veranderen aan het onderliggende probleem 
dat ervoor zorgt dat men kwetsbaar is voor terugval. Bovendien hebben 
veel patiënten een voorkeur voor psychologische behandeling. Deze 
vormen een goed alternatief voor mADM: een recente meta-analyse liet 
zien dat psychologische behandelingen de kans op een terugval nog verder 
verminderen dan antidepressiva. Eén van die behandelingen is mindfulness-
based cognitieve therapie (MBCT).
Wat is MBCT en hoe kan het terugval helpen voorkomen?
MBCT is een groepsbehandeling voor 8-12 deelnemers per groep, bestaande 
uit 8 wekelijkse bijeenkomsten van 2½ uur plus een verdiepingsdag in stilte 
(6 uur). Het is gebaseerd op het mindfulness-based stress reduction (MBSR) 
programma van Jon Kabat-Zinn (1990), dat vervolgens in het begin van de 
21e eeuw door Zindel Segal, Mark Williams en John Teasdale werd aangepast 
voor mensen met terugkerende depressie, met als doel terugval te helpen 
voorkomen (Segal, Williams, & Teasdale, 2002; Segal, Williams, & Teasdale, 
2012). Daarom werden ook verschillende elementen uit de cognitieve therapie 
toegevoegd aan het programma. Een belangrijk aspect van de training is de 
thuisbeoefening: deelnemers worden aangemoedigd om dagelijks ongeveer 
45 minuten te besteden aan de mindfulness oefeningen. Een veelgebruikte 
definitie van mindfulness is die van Jon Kabat-Zinn: “mindfulness betekent 
aandacht geven op een speciale manier: bewust, op het moment zelf, en 
niet-oordelend”. Bijvoorbeeld tijdens de ‘bodyscan’ brengt men de aandacht 
bewust naar alle delen van het lichaam, opeenvolgend, en naar de lichamelijke 
sensaties die men daar kan opmerken. Men oefent om dit te doen met een 
vriendelijke houding ten opzichte van de ervaringen die zich van moment tot 
moment voordoen, ook als deze onprettig zijn (bijvoorbeeld rusteloosheid, 
spanning of pijn). Wanneer men afgeleid raakt, kan men zodra dit wordt 
opgemerkt, weer rustig met de aandacht terugkeren naar de lichamelijke 
gewaarwordingen zonder zichzelf te veroordelen voor het afgeleid zijn. Men 
oefent dus om telkens weer contact te maken met het hier en nu wanneer 
de geest afgedwaald was, meestal in gedachten over het verleden of de 
toekomst. Andere ‘formele’ oefeningen zijn de zitmeditatie, de (liggende en 
staande) bewegingsoefeningen en de ‘3-minuten ademruimte’. Ook tijdens 
de zitmeditatie is het de bedoeling om de aandacht te richten op de huidige 
ervaring, waarbij men begint met aandacht voor de adem, die vervolgens 
wordt uitgebreid naar aandacht voor het lichaam, geluiden, gedachten en 
gevoelens, en tot slot het ‘keuzeloos gewaarzijn’ waarin er geen specifieke 
focus is maar waarin men observeert wat er zoal de revue passeert in lichaam 
en geest. Tijdens de bewegingsoefeningen wordt de aandacht gevestigd op 
de lichamelijke gewaarwordingen van de bewegingen en houdingen, met 
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een speciale rol voor het verkennen en erkennen van grenzen. De 3-minuten 
ademruimte is een korte meditatie die op verschillende momenten van de 
dag kan worden ingezet, bijvoorbeeld tijdens een vergadering of in de rij 
bij de kassa, en die daardoor heel geschikt is om mindfulness te integreren 
in het dagelijkse leven. Deelnemers worden gestimuleerd om hun dagelijkse 
activiteiten zoveel mogelijk met aandacht te doen. Tijdens alle oefeningen 
worden deelnemers uitgenodigd om vanuit de ‘doe-modus’ over te schakelen 
naar de ‘zijnsmodus’. De doe-modus wordt gekenmerkt door doelgerichtheid 
(plannen, evalueren, problemen oplossen, dingen anders willen dan ze zijn) 
terwijl de zijnsmodus wordt gekenmerkt door (zintuiglijk) gewaarzijn van 
het huidige moment, waarbij ervaringen worden geaccepteerd zoals ze zijn. 
Het probleem van de doe-modus is dat veel mensen deze niet alleen inzetten 
voor praktische problemen zoals een lekke band of om van A naar B te komen, 
maar ook voor onprettige, negatieve gemoedstoestanden. Wanneer iemand 
zich bijvoorbeeld somber voelt, komt er doorgaans automatisch een mentale 
reactie op gang in de trant van “dit klopt niet, waar komt dit vandaan?” en 
“hier moet ik zo snel mogelijk vanaf”. Dit wordt ook wel ‘rumineren’ genoemd. 
Bij mensen die kwetsbaar zijn voor een depressie, bijvoorbeeld omdat ze in 
het verleden een depressie hebben doorgemaakt, komen daar vaak nog meer 
gedachten bij, zoals “het gebeurt me weer, ik kan het ook nooit goed doen, ik 
doe er niet toe”. Deze gedachten leiden vervolgens weer tot verslechtering van 
de stemming. Men ervaart zulke automatische negatieve gedachten vaak als 
‘waar’ en als onderdeel van het zelf, zeker in een negatieve gemoedstoestand. 
Uit onderzoek is gebleken dat rumineren een belangrijke factor is in het 
ontstaan, onderhouden en terugkeren van een depressieve stoornis. 
 Een belangrijk onderliggend theoretisch model voor de MBCT training 
betreft de ‘differentiële activatie hypothese’. Deze hypothese stelt dat 
negatieve gedachtepatronen tijdens een depressieve stemming eerder naar 
boven komen dan tijdens een neutrale of positieve gemoedstoestand, en dat 
het verband tussen een sombere stemming en deze negatieve gedachten 
steeds sterker wordt naarmate mensen vaker en ernstiger depressief zijn 
geweest. Daardoor kunnen kleine veranderingen in de stemming bij mensen 
die voorheen depressief zijn geweest tot een sterk negatief gedachtepatroon 
leiden, waardoor een neerwaartse spiraal ontstaat die uiteindelijk kan 
uitmonden in een nieuwe depressie. Dit wordt ook wel ‘cognitieve reactiviteit’ 
genoemd. Tijdens de MBCT training leren patiënten om deze neerwaartse 
spiraal in een vroeg stadium te herkennen waardoor de mogelijkheid ontstaat 
om deze in de kiem te smoren. Zo kan een depressie worden voorkomen of 
de ernst en duur daarvan worden beperkt. Een belangrijk aspect daarbij is 
dat mensen leren om zichzelf niet te veroordelen voor wat ze doormaken en 
in plaats daarvan vriendelijkheid en compassie voor zichzelf te ontwikkelen, 
zeker in moeilijke periodes.
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Verschillende onderzoeken hebben inmiddels uitgewezen dat MBCT een 
effectieve manier is om de kans op terugval te verminderen. In de meest 
recente meta-analyse van de tot nu toe beschikbare gerandomiseerd 
gecontroleerde studies gericht op terugvalpreventie bij depressie werden 
alle data van in totaal 1258 deelnemers ‘op één hoop gegooid’ (Kuyken et 
al., 2016). Uit de analyses bleek dat MBCT in vergelijking met ‘gebruikelijke 
zorg’ effectiever was, en zelfs in vergelijking met mADM. Het verschil in 
effectiviteit tussen MBCT en mADM was weliswaar klein, maar significant. 
Uit ander onderzoek, uitgevoerd door onze eigen afdeling, is gebleken 
dat MBCT niet alleen effectief is in het voorkomen van terugval, maar ook 
in het verminderen van depressieve klachten bij mensen met een huidige 
depressieve stoornis (van Aalderen et al., 2012). Daarnaast ontstaat er steeds 
meer kennis over hoe MBCT werkt, en wordt duidelijk dat veranderingen in 
mindfulness vaardigheden, rumineren, piekeren, (zelf)compassie en ‘meta-
gewaarzijn’ daarin een belangrijke rol spelen. Het lijkt er bovendien op dat 
deze veranderingen ook in de hersenen terug te vinden zijn. Er zijn namelijk 
verschillen gevonden tussen de hersenen van mensen die aan (mindfulness) 
meditatie doen en mensen die dat nooit hebben gedaan. Dit geldt zowel voor 
de structuur van de hersenen (bijv. de dikte van de hersenschors) als de 
functionaliteit ervan (bijv. hoe actief bepaalde gebieden zijn). Er moet echter 
nog meer onderzoek worden gedaan om te kunnen concluderen dat deze 
verschillen niet alleen samenhangen met, maar ook daadwerkelijk worden 
veroorzaakt door mindfulness beoefening.
Aanleiding voor het MOMENT onderzoek
Samenvattend kunnen we stellen dat het onderzoek naar MBCT tot 
veelbelovende resultaten heeft geleid. Er is echter nog veel werk aan de 
winkel. Er was bijvoorbeeld nog niet onderzocht, of de combinatie van 
MBCT en mADM effectiever is in het voorkomen van terugval in depressie 
dan de behandelingen afzonderlijk. Ook weten we nog maar weinig over 
de invloed van de competentie van mindfulness trainers op de uitkomsten 
van de deelnemers. Een recent overzichtsartikel (Dimidjian & Segal, 2015) 
heeft laten zien dat er relatief veel onderzoek is gedaan naar de ‘basics’ van 
mindfulness-based interventies, dat wil zeggen de onderliggende theorie, 
het testen van het protocol in ‘pilot’ studies in verschillende populaties, 
en de vergelijking met ‘gebruikelijke zorg’ of wachtlijst-controles, veelal 
uitgevoerd in gecontroleerde omstandigheden in een academische setting. Er 
is echter veel minder onderzoek gedaan naar de latere stadia van interventie-
ontwikkeling, dat wil zeggen de effectiviteit van mindfulness training in de 
‘gewone’ klinische praktijk, met meer deelnemers uit verschillende regio’s 
en bij verschillende instellingen. Ook is er een gebrek aan onderzoek naar 
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de disseminatie (het overbrengen van kennis en ervaring) en implementatie 
van mindfulness op grotere schaal. Het opleiden van gekwalificeerde trainers 
om de interventie op competente wijze te kunnen aanbieden is hier een 
belangrijk onderdeel van. Het MOMENT onderzoek heeft zich voornamelijk 
gericht op het onderzoeken van deze laatste twee aspecten (effectiviteit van 
MBCT vergeleken met mADM in de klinische praktijk, en competentie van de 
trainers), met als belangrijkste onderzoeksvragen:
 ▪ Kunnen patiënten met terugkerende depressie na deelname aan 
MBCT hun antidepressieve medicatie afbouwen, zonder een verhoogd risico 
op terugval?
 ▪ Is de combinatie van MBCT en mADM effectiever in het voorkomen 
van terugval dan mADM alleen?
 ▪ Heeft de voorkeur van patiënten voor MBCT of mADM invloed op de 
effectiviteit van MBCT?
 ▪ Heeft de competentie van de trainer invloed op de effectiviteit van 
MBCT?
Samenvatting van de resultaten
Hoofdstuk 2 beschrijft de opzet en het protocol van het MOMENT onderzoek. 
De doelgroep betrof patiënten met 3 of meer eerdere depressieve episodes, 
die op het moment van deelname volledig of gedeeltelijk hersteld waren, 
en sinds minimaal 6 maanden mADM gebruikten. Het onderzoek was 
oorspronkelijk bedacht als een 3-armige ‘randomized controlled trial’ (RCT) 
waarin de effectiviteit van MBCT alleen (met afbouw van mADM), mADM 
alleen, en de combinatie van MBCT en mADM met elkaar zouden worden 
vergeleken. Tijdens de wervingsfase van het onderzoek bleek echter dat 
slechts enkele patiënten bereid waren om willekeurig in één van deze 3 
groepen te worden ingedeeld. Bijna iedereen had ofwel een voorkeur voor 
deelname aan MBCT, ofwel een voorkeur voor het behouden van hun mADM. 
Deze voorkeuren van patiënten leidden ertoe dat we onze opzet aanpasten: 
in plaats van één 3-armige RCT voerden we twee 2-armige RCT’s uit. In 
trial A namen 249 mensen deel die een voorkeur hadden voor MBCT: zij 
werden willekeurig ingedeeld in ofwel MBCT met afbouw van mADM, ofwel 
MBCT met behoud van mADM. Trial B bestond uit 68 deelnemers met een 
voorkeur voor behoud van mADM: zij werden willekeurig ingedeeld in ofwel 
mADM, ofwel mADM plus MBCT. Een nadeel van deze wijziging was dat we 
de 3 interventies niet meer direct met elkaar konden vergelijken. Een groot 
voordeel was echter dat de opzet hierdoor beter aansloot bij de klinische 
praktijk, aangezien een groot deel van de patiënten een therapievoorkeur 
heeft. In beide RCT’s werden de deelnemers gedurende 15 maanden iedere 
3 maanden geïnterviewd om te kijken of er sprake was van een depressieve 
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terugval, onze primaire uitkomstmaat. Daarnaast brachten we de ernst van 
de depressieve (rest)klachten in beeld. Tevens vulden deelnemers voor en 
na MBCT en aan het einde van de follow-up periode vragenlijsten in om 
onder andere kwaliteit van leven, mindfulness vaardigheden, zelfcompassie, 
rumineren en cognitieve reactiviteit te meten. 
 Hoofdstuk 3 beschrijft de belangrijkste bevinding van het MOMENT 
onderzoek: patiënten die hun antidepressieve medicatie afbouwden hadden 
een verhoogde kans op terugval, zelfs na deelname aan MBCT. Als alle 
deelnemers werden meegenomen in de analyse zagen we dat het percentage 
terugval in de afbouwgroep 54% was, tegenover 39% in de combinatiegroep. 
Als we alleen de gegevens meenamen van deelnemers die daadwerkelijk het 
studieprotocol hadden gevolgd, waren deze cijfers zelf nog hoger: 69% in 
de afbouwgroep en 46% in de combinatiegroep. Het afbouwen bleek veel 
moeilijker dan we van tevoren hadden gedacht, en een groot deel van de 
deelnemers (47%) heeft zich dan ook niet aan het afbouwprotocol gehouden, 
dat wil zeggen binnen 6 maanden naar 0 mg. Onze hypothese dat MBCT met 
afbouw van mADM niet zou onderdoen voor de combinatiebehandeling, 
moest worden verworpen. De ernst van de depressieve klachten was over 
het algemeen gedurende de 15 maanden follow-up periode niet verschillend 
tussen de groepen. Alleen direct na de training waren de klachten in 
de afbouwgroep iets hoger dan in de combinatiegroep. Wellicht hing 
dat ook samen met het feit dat zij ten tijde van die meting midden in het 
afbouwproces zaten. Andere secundaire uitkomstmaten zoals de ernst en 
duur van de terugval, het aantal terugvallen en kwaliteit van leven waren 
niet verschillend tussen de groepen.
 In hoofdstuk 4 werden de resultaten van trial B beschreven: het 
toevoegen van MBCT aan mADM leidde niet tot een verdere verlaging van het 
risico op terugval. Met andere woorden: de combinatiegroep en de mADM 
groep hadden een vergelijkbaar terugvalrisico, respectievelijk 36% en 37%. 
Er waren ook geen noemenswaardige verschillen in de ernst van de (rest)
klachten, kenmerken van de terugval (aantal, duur en ernst) en kwaliteit 
van leven. Een mogelijke verklaring voor onze bevinding dat MBCT geen 
aanvullende waarde leek te hebben bovenop mADM is dat er in deze RCT 
alleen mensen deelnamen met een (relatieve) voorkeur voor mADM. Het 
is mogelijk dat de meest gemotiveerde deelnemers vooral in trial A zaten, 
omdat die groep een (relatieve) voorkeur voor MBCT had.
 De invloed van deze voorkeuren werd onderzocht in hoofdstuk 5. Dit 
hoofdstuk beschrijft aanvullende analyses die we hebben gedaan met alle 
deelnemers die waren toegewezen aan de combinatiegroep, zowel uit trial 
A als uit trial B. We vergeleken hun uitkomsten in termen van therapietrouw 
aan beide interventies en de uitkomsten daarvan (risico op terugval, ernst 
van de depressieve klachten, en kwaliteit van leven). We verwachtten dat 
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mensen met een voorkeur voor MBCT meer baat zouden hebben bij MBCT 
als aanvulling, dan mensen met een medicatievoorkeur. Dit bleek echter 
niet het geval: er waren geen verschillen tussen de voorkeursgroepen op 
de therapietrouw en de uitkomsten zoals terugvalrisico of ernst van de 
restklachten. Ook de sterkte van de voorkeur (gemeten met een vragenlijst 
over de verwachtingen die men had over beide interventies) bleek niet 
voorspellend voor de uitkomsten. Wederom waren de resultaten niet in 
overeenstemming met onze hypotheses.
 De invloed van de competentie van de trainer werd onderzocht in 
hoofdstuk 6. Voor dit project gebruikten we videotapes van 15 trainers 
die hadden meegedaan aan het MOMENT onderzoek, en nodigden we 
16 andere trainers uit om een random selectie van deze videotapes te 
evalueren. Van iedere trainer werden 2 á 4 sessies beoordeeld en de 
gemiddelde competentiescore, zoals gemeten met de Mindfulness-Based 
Interventions: Teaching Assessment Criteria (MBI:TAC; Crane et al., 2013), 
werd gebruikt om de uitkomsten van de deelnemers te voorspellen. We 
keken naar het aantal sessies dat deelnemers volgden, de verandering in hun 
scores op mindfulness, zelfcompassie, rumineren, en cognitieve reactiviteit 
als mogelijke werkingsmechanismen, en de verandering in depressieve 
klachten van voor tot na MBCT en de kans op terugval als uitkomsten van 
de training. Ondanks een relatief grote spreiding in de scores van de trainers 
bleek trainerscompetentie op geen van deze variabelen invloed te hebben. 
Tijdens deze studie werd echter ook duidelijk dat het behoorlijk lastig 
was om een betrouwbare schatting te geven van trainerscompetentie: de 
overeenstemming tussen verschillende beoordelaars was doorgaans matig. 
Toch lijken onze bevindingen wel hout te snijden: ook andere mogelijk 
indicatoren van competentie, zoals het aantal jaren werkzaam als clinicus, 
het aantal MBCT trainingen die de trainer had gegeven, en de hoeveelheid 
persoonlijke mindfulness beoefening (inclusief gevolgde retraites) bleken 
geen voorspeller van de patiëntuitkomsten. 
Het voorkomen van terugval bij depressie
In de eerste studie (trial A) vonden we dat mensen met terugkerende 
depressie meer kans hadden op terugval na afbouwen van medicatie, ondanks 
deelname aan de MBCT training, vergeleken met de combinatiebehandeling. 
Hiervoor zijn enkele mogelijke verklaringen. Ten eerste was de medicatie 
mogelijk effectief en leidde het afbouwen daarvan tot terugval. Het zou 
ook kunnen dat angst voor terugval en problemen met het afbouwen (bijv. 
onttrekkingsverschijnselen) ertoe leidden dat mensen een terugval in 
klachten ervoeren. Vergeleken met andere studies naar MBCT gevolgd door 
afbouw van mADM en waarin de percentages tussen de 38% en 47% lagen, 
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is het percentage terugval in deze studie hoger. Dit had mogelijk te maken 
met het includeren van een groep patiënten met relatief ernstige vormen van 
terugkerende depressie, voor wie afbouwen bijzonder lastig lijkt te zijn. Ook 
het feit dat de groepen gemengd waren, waardoor niet iedereen ‘in hetzelfde 
schuitje zat’, kan ertoe hebben geleid dat mensen zich minder ondersteund 
voelden en meer onzeker waren over het afbouwproces. In een toekomstige 
studie willen we voortborduren op dit laatste aspect van ondersteuning 
vanuit de MBCT training zelf. Daarbij willen we gaan onderzoeken of mensen 
die graag willen afbouwen daarin kunnen worden ondersteund door MBCT 
wanneer deze meer specifiek is gericht op het gezamenlijk afbouwen. Maar 
vooralsnog lijkt het dus aan te raden om de antidepressieve medicatie 
te blijven gebruiken na de training, zeker als mensen angst voor terugval 
ervaren.
 Onze bevinding dat patiënten meer baat hadden bij de combinatie-
behandeling in trial A, dus vergeleken met de afbouwgroep, sluit op zichzelf 
goed aan bij eerdere literatuur over het combineren van antidepressiva met 
psychologische behandelingen in het algemeen. Uit meta-analyses blijkt 
namelijk dat een combinatiebehandeling beter werkt in het verminderen 
van depressieve klachten en het voorkomen van terugval. Op basis van 
onze eigen, tweede studie (trial B) moeten we echter concluderen dat 
MBCT weinig aanvullende waarde heeft op het gebruik van antidepressieve 
onderhoudsmedicatie, althans in deze groep mensen die voorafgaand 
aan deelname een voorkeur voor het behoud van antidepressiva hadden 
aangegeven. Dit leek overigens wel een specifieke subgroep te zijn, die 
mogelijk minder hoge verwachtingen had van mindfulness training en 
er daardoor misschien minder baat bij heeft gehad. Aan de andere kant 
zagen we dat bijna een kwart van de mensen die in de mADM groep 
zaten, toch deelnam aan MBCT. Dit heeft mogelijk het verschil tussen 
de groepen verkleind doordat een deel van de mADM groep in feite de 
combinatiebehandeling kreeg. De terugvalpercentages van de deelnemers 
die zich volledig aan het onderzoeksprotocol hadden gehouden lagen 
inderdaad wat verder uit elkaar: MBCT+mADM 39% en mADM alleen 48%. 
Om aan te tonen dat een dergelijk verschil significant is, zou echter een 
onderzoek nodig zijn met ongeveer 500 deelnemers per groep. Tenslotte 
waren de terugvalpercentages in beide groepen eigenlijk relatief laag, als je 
het vergelijkt met andere onderzoeken. Mogelijk was er dus niet veel ruimte 
voor verbetering. Wat betreft terugvalpreventie zouden we dus kunnen 
concluderen uit het MOMENT onderzoek dat de combinatiebehandeling 
beter werkt in vergelijking met MBCT alleen (dat wil zeggen, met afbouw 
van antidepressiva) maar niet in vergelijking met antidepressiva alleen. 
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Patiëntvoorkeur
Zoals in veel eerdere onderzoeken het geval was, had ook binnen het 
MOMENT onderzoek het grootste deel van de patiënten een voorkeur 
voor psychologische behandeling: 79% van alle deelnemers koos voor de 
trial waarin zij in ieder geval MBCT zouden krijgen. Binnen de twee trials 
kan het echter wel zo zijn geweest dat men voornamelijk een voorkeur 
had voor de combinatiebehandeling. Hoewel we dit niet expliciet hebben 
onderzocht, zijn daar wel aanwijzingen voor, bijvoorbeeld dat veel mensen 
in de afbouwgroep toch hun medicatie bleven gebruiken, en dat een kwart 
van de deelnemers uit de ‘alleen mADM’ groep tegen het protocol in toch 
deelnam aan MBCT. Aangezien we de invloed van patiëntvoorkeur hebben 
onderzocht binnen de groep die de combinatiebehandeling kreeg, kan 
dit dus van invloed zijn geweest op onze resultaten: mogelijk waren de 
verschillen in voorkeur minder groot dan we verwachtten en leidde dit ertoe 
dat we ook geen verschil vonden in uitkomsten. Hoewel het interessant zou 
zijn om een dergelijke vergelijking te maken tussen patiënten met sterkere 
voorkeuren, zal het praktisch gezien erg moeilijk zijn, zo niet onmogelijk, om 
deze mensen te motiveren voor vrijwillige deelname aan een studie waarin 
zij hun behandeling door middel van loting krijgen toegewezen. 
Competentie van de trainer
Onze bevinding dat trainerscompetentie niet samenhing met uitkomsten 
van de patiënten was onverwacht. De verwachting dat dit wel het geval zou 
zijn was voornamelijk gebaseerd op eerdere studies in een gecontroleerde 
onderzoekssetting en bij andere vormen van psychologische behandeling 
die veelal individueel plaatsvinden (bijvoorbeeld cognitieve therapie). Een 
meer recente studie naar de invloed van competentie van therapeuten op 
de effecten van cognitieve therapie, die net als het MOMENT onderzoek 
ook meer in een klinische praktijksetting werd uitgevoerd, vond echter 
ook geen duidelijk verband. Wellicht is het in een minder gecontroleerde 
setting moeilijk om een effect van trainerscompetentie te vinden omdat 
de ruis zo groot is, dat wil zeggen dat er veel andere factoren zijn die het 
beloop van depressieve klachten veel sterker bepalen (bijvoorbeeld de 
werksituatie, lichamelijke gezondheid, of problemen binnen de thuissituatie 
van de patiënt). Verder heeft het groepsaspect van MBCT mogelijk ook tot 
gevolg dat de invloed van de trainer kleiner is. Men heeft immers ook de 
ondersteuning van de groep, en de relatie tussen de trainer en de patiënt 
is minder intensief dan bij individuele behandeling. Bovendien wordt er 
binnen de MBCT veel nadruk gelegd op de zelfredzaamheid van deelnemers: 
men wordt aangemoedigd om zelfstandig te oefenen en dit onderdeel te 
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laten worden van hun dagelijkse routine zodat zij ook in de toekomst beter 
in staat zijn om zelf zorg te dragen voor terugvalpreventie. MBCT wordt in 
hoge mate gestandaardiseerd aangeboden, wat zeker het geval was binnen 
de onderzoekssetting van MOMENT, waardoor het programma als het ware 
‘zichzelf draagt’. 
 Samenvattend kan worden geconcludeerd dat we geen aanwijzingen 
hebben gevonden voor een effect van trainerscompetentie, maar dat meer 
onderzoek naar de rol van competentie binnen MBCT absoluut nodig is om 
daar met meer zekerheid iets over te kunnen zeggen, aangezien dit de eerste 
systematische studie betreft.
Methodologische aspecten
Een van de sterkste punten van het MOMENT onderzoek is dat het een 
relatief hoge mate van generaliseerbaarheid heeft doordat patiënten breed 
werden geworven (via zorgverleners binnen de instellingen maar ook via 
huisartsen en zelfverwijzingen naar aanleiding van aandacht in de media of 
via advertenties) en er veel verschillende centra en trainers aan deelnamen. 
Een dergelijke onderzoeksopzet heeft verschillende gevolgen die enerzijds 
als beperking maar anderzijds ook als kracht kunnen worden beschouwd. 
 Het feit dat veel mensen zich niet aan het afbouwprotocol hielden heeft 
bijvoorbeeld wel een negatieve invloed gehad op de interne validiteit van 
de studie, maar daarmee hebben we wel kunnen laten zien hoe moeilijk 
het blijkbaar voor deze doelgroep is om van de antidepressieve medicatie 
af te komen. Als mensen in de klinische praktijk gaan afbouwen na afloop 
van MBCT bieden deze cijfers waarschijnlijk een meer realistisch beeld 
van de te verwachten terugvalkans dan die in meer gecontroleerde studies. 
Een belangrijk verschil tussen deze en eerder studies is dat patiënten in 
de afbouwgroep aan gemengde MBCT groepen deelnamen, dat wil zeggen 
dat er ook mensen uit de combinatiegroep deelnamen en zelfs mensen die 
überhaupt niet meededen met het onderzoek. Zij hebben zich daardoor 
mogelijk minder ondersteund gevoeld dan wanneer het een homogene groep 
zou zijn geweest met alleen ‘mede-afbouwers’. Dit heeft mogelijk geleid tot 
onzekerheid over het afbouwen.
 Een ander gevolg van de onderzoeksopzet waarbij trainers met 
verschillende competentieniveaus meededen is dat het gemiddelde 
competentieniveau lager was dan bij eerdere onderzoeken. Dit heeft 
mogelijk een nadelige invloed gehad op de effectiviteit van de interventie in 
het algemeen (dus over de hele groep bekeken in plaats van per trainer). Het 
voordeel hiervan is echter dat we een beter beeld hebben van de effectiviteit 
van MBCT zoals het in de praktijk wordt aangeboden en het benadrukt 
het belang van zorgvuldige implementatie. Een ander bijkomend voordeel 
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is dat het inzetten van een diverse groep trainers ons als onderzoekers 
in staat stelde om de relatie tussen trainerscompetentie en effectiviteit 
te onderzoeken, waarmee dit de eerste systematische studie is naar dit 
onderwerp bij MBCT voor depressie.
 Verder is een mogelijk probleem binnen deze studie het gebruik van 
vragenlijsten gebaseerd op zelfrapportage, waarvan de validiteit ter 
discussie is gesteld. Bijvoorbeeld de Five Facet Mindfulness Questionnaire 
waarmee mindfulness vaardigheden werd gemeten is door sommige 
auteurs bekritiseerd omdat deelnemers deze na de training mogelijk anders 
interpreteren dan bij aanvang, waardoor een vergelijking tussen voor en na 
niet meer goed mogelijk is. Ook wordt gezegd dat de items slechts enkele 
psychologische aspecten van mindfulness belichten maar dat deze bij 
lange na niet het hele mindfulness ‘spectrum’ (waaronder de filosofische 
en ethische aspecten) vertegenwoordigen. Hoewel deze kritiek gegrond 
is, zijn er vooralsnog  weinig alternatieven voorhanden, en dit was zeker 
het geval ten tijde van de aanvang van dit onderzoek. Het ontwikkelen van 
innovatieve manieren om mindfulness te definiëren en meten staat hoog 
op de onderzoeksagenda, en deze zullen het veld hopelijk een stap verder 
brengen.
Het rapporteren van negatieve bevindingen
De samenvatting van dit proefschrift laat zien dat geen van de 
onderzoekshypotheses uit de hoofdstukken 3, 4, 5 en 6 werden ondersteund 
door de resultaten. Wat dat betreft heeft het MOMENT onderzoek een 
verzameling “negatieve” bevindingen voortgebracht. Deze stimuleren echter 
het wetenschappelijke debat en leiden weer tot nieuwe onderzoeksvragen, 
bijvoorbeeld over het afbouwen van antidepressieve medicatie of de 
rol van trainerscompetentie. Daarmee zijn deze “negatieve” resultaten 
net zo belangrijk als “positieve” resultaten, en dragen ze zelfs bij aan een 
meer gebalanceerd beeld van de effectiviteit van mindfulness, aangezien 
er aanwijzingen zijn dat dit beeld vertekend is (Coronado-Montoya et 
al., 2016). Een mogelijke reden voor deze vertekening (bijvoorbeeld dat 
positieve resultaten eerder worden gepubliceerd dan negatieve) is dat 
auteurs conflicterende belangen hebben. Het zou bijvoorbeeld kunnen 
dat onderzoekers resultaten die ongunstig uitpakken voor de mindfulness 
interventie niet rapporteren omdat ze bang zijn dat dit de mogelijkheden 
voor verdere onderzoekssubsidies verkleint. Vanuit de wetenschappelijke 
gemeenschap wordt hier steeds meer aandacht aan besteed en worden 
onderzoekers aangespoord om hun onderzoeksprotocol van tevoren te 
publiceren om achteraf ‘sjoemelen’ onmogelijk te maken, om de resultaten 
conform de richtlijnen te rapporteren zodat alle onderzoeksaspecten kunnen 
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worden beoordeeld, om hun mogelijke conflicterende belangen duidelijk te 
beschrijven in ieder artikel, en om hun data openbaar te maken. Gelukkig 
worden dergelijke praktijken steeds vanzelfsprekender.
De paradox van mindfulness onderzoek: verandering versus acceptatie
Het is begrijpelijk dat men vanuit het wetenschappelijk of maatschappelijk 
perspectief gericht is op de mogelijke effecten van mindfulness training 
zoals het verminderen van depressieve klachten of de kans op terugval. Deze 
focus op verbetering (oftewel verandering) sluit echter minder goed aan bij 
het theoretisch perspectief waarbij het doel van mindfulness beoefening is 
om de relatie tot de ervaring te veranderen, niet zozeer de ervaring zelf. Het 
streven naar verandering (willen dat de klachten weggaan) wordt juist eerder 
als een belemmerende factor beschouwd in het ontwikkelen van inzicht en 
helder gewaarzijn. Als mensen streven naar verbetering zijn ze eigenlijk in 
de doe-modus, en dit gaat vaak gepaard met denken, evalueren, en soms 
ook rumineren of piekeren. De zijnsmodus wordt juist gekenmerkt door een 
gewaarzijn van moment tot moment, waarin de dingen kunnen zijn zoals 
ze zijn, inclusief mogelijke gevoelens van somberheid, schuld, schaamte, en 
angst. De rationale achter MBCT is om deze ervaringen tegemoet te treden 
met een vriendelijke, niet-veroordelende, accepterende houding, om op die 
manier meer inzicht te krijgen in de automatische denk- en gedragspatronen 
die leiden tot verslechtering van de stemming en uiteindelijk mogelijk een 
depressieve terugval. Dit inzicht brengt een zekere mate van keuzevrijheid 
met zich mee, een daarmee kan een gevoel van bevrijding worden ervaren. 
Hoewel de mentale gezondheid vaak tegelijkertijd verbetert, is dit niet 
het primaire doel van mindfulness training. Daarom is het de vraag of 
uitkomsten die gericht zijn op verbetering wel voldoende sensitief zijn om 
het effect van MBCT te demonstreren. Bijvoorbeeld in een eerder studie 
naar MBCT bij mensen met onverklaarde lichamelijke klachten werd niet 
zozeer een verbetering gevonden op het fysiek functioneren, maar wel op 
het mentaal functioneren, voornamelijk vitaliteit en sociaal functioneren 
(Van Ravesteijn, Lucassen, Bor, Van Weel, & Speckens, 2013). Het leek er 
dus op dat vooral de manier waarop mensen na de training omgingen met 
hun klachten veranderd was. Binnen de huidige doelgroep van mensen met 
recidiverende depressie zouden we als uitkomstmaat bijvoorbeeld kunnen 
kijken naar de mate waarin mensen in staat zijn om toch zoveel mogelijk hun 
werk of sociale contacten te handhaven, ondanks de mogelijke aanwezigheid 
van klachten. 
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Implicaties en aanbevelingen voor de toekomst
De bevindingen uit dit proefschrift leiden tot een aantal implicaties en 
aanbevelingen voor toekomstig onderzoek en voor de klinische praktijk. Ten 
eerste lijkt het voorlopig aan te raden dat patiënten worden geïnformeerd 
over de verhoogde kans op terugval als zij afbouwen, zelfs na het volgen van 
een mindfulness training. Het lijkt echter wel van belang om ervoor te zorgen 
dat we betere informatie en begeleiding ontwikkelen om het afbouwproces 
te ondersteunen gezien de vele patiënten die hier (om diverse redenen) 
interesse in hebben. Meer kennis over de belemmerende en ondersteunende 
factoren is hierin onmisbaar. Mindfulness zou hier een mogelijke rol in kunnen 
spelen, mits aangeboden in een homogene groep patiënten die allemaal 
bewust kiezen voor afbouw van hun medicatie. Zij kunnen bijvoorbeeld 
leren om op een andere manier om te gaan met onttrekkingsverschijnselen 
of angst voor terugval, namelijk met een niet-veroordelende, milde houding, 
die de negatieve spiraal van rumineren en piekeren over deze verschijnselen 
en verdere verslechtering van de stemming in de kiem zou kunnen smoren. 
Andere behulpzame factoren zouden kunnen bestaan uit een weloverwogen, 
gezamenlijke besluitvorming over wel of niet afbouwen, ondersteuning van 
medepatiënten, intensievere begeleiding door artsen en andere hulpverleners 
tijdens de moeilijke momenten in het afbouwproces, en een op maat 
gemaakt afbouwprotocol waar de patiënt zich in kan vinden. Ook kan het 
tijdelijk switchen naar een antidepressivum met een langere halfwaardetijd 
behulpzaam zijn bij kortwerkende middelen. In het Radboud Centrum voor 
Mindfulness en in samenwerking met de afdeling eerstelijnsgeneeskunde en 
Pro Persona zijn we inmiddels gestart met een nieuw onderzoek naar het 
afbouwen van antidepressiva binnen de huisartspraktijk, en de mogelijke 
rol van mindfulness training die daar specifiek op toegespitst is. Er zijn ook 
andere universiteiten die zich in Nederland bezig houden met afbouwen van 
antidepressiva maar dan ondersteund door cognitieve therapie (Bockting et 
al., 2011; Molenaar et al., 2016; Scholten, Batelaan, Van Oppen, Smit, & Van 
Balkom, 2013), dus het lijkt erop dat we de komende jaren meer kennis over 
dit onderwerp zullen opbouwen.
 Ten tweede is het van belang dat we meer te weten komen over de mogelijke 
patiëntkenmerken die voorspellen of MBCT effectief zal zijn of niet. Hoewel 
dit moeilijk te onderzoeken is omdat er talloze factoren zijn die bepalen of 
men er baat bij heeft of niet, staat het wel hoog op de onderzoeksagenda. 
Als we meer inzicht hebben in dergelijke factoren kunnen we de zorg beter 
afstemmen op de individuele patiënt waardoor we ook de zorgkosten in 
gunstige zin zouden kunnen beïnvloeden. Bijvoorbeeld de rol van voorkeur 
voor de verschillende behandelmethoden zou hierin een factor kunnen zijn. 
Hoewel het huidige onderzoek geen aanwijzingen geeft dat dit de effectiviteit 
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beïnvloedt, hebben we daar onvoldoende gedetailleerd naar gekeken en 
zou het interessant zijn om in vervolgonderzoek ook de subcategorieën 
te betrekken: welke mensen willen graag afbouwen, welke mensen willen 
juist de combinatiebehandeling en wie prefereert het continueren van 
antidepressiva zonder MBCT (of psychologische behandeling in het algemeen) 
als aanvulling? Het onderzoeken van de mogelijke werkingsmechanismen 
van MBCT kan bovendien ook een bijdrage leveren aan het optimaliseren 
van de behandeling en het selecteren van (groepen) patiënten die daar het 
meest baat bij zullen hebben. 
 Ten derde zouden we onderzoekers willen aanmoedigen om de 
competentie van de trainers systematisch te onderzoeken, of tenminste 
te rapporteren, in alle RCT’s naar mindfulness interventies, zodat we 
hier meer inzicht in kunnen krijgen. Een interessante vraag zou zijn 
of er een relatie bestaat tussen competentie en uitkomsten van MBCT 
wanneer we een zo breed mogelijk spectrum aan competentieniveaus 
zouden betrekken, dat wil zeggen van beginner tot expert, en waarbij het 
aantal trainers gelijk verdeeld is over de verschillende niveaus. Dit type 
onderzoek is kostbaar en tijdsintensief, maar is wel van fundamenteel 
belang voor de verdere implementatie en disseminatie van MBCT binnen 
de geestelijke gezondheidszorg en daarbuiten. Een andere aanbevelingen in 
dit kader is om gebruik te maken van ‘triangulatie’ bij het bepalen van de 
trainerscompetentie, gebruikmakend van evaluaties van experts, maar ook 
zelf- en patiëntevaluaties. 
 Een algemene aanbeveling voor mindfulness onderzoek zoals beschreven 
in het eerder genoemde overzichtartikel van Dimidjian en Segal (2015) is 
dat er meer onderzoek zou moeten plaatsvinden in de latere stadia van 
interventie-ontwikkeling, dat wil zeggen in de gewone klinische praktijk 
en met aandacht voor implementatie en disseminatie. Zij waarschuwen 
verder voor het welbekende fenomeen dat interventies in de loop van de 
tijd, wanneer zij op grotere schaal worden toegepast, in effectiviteit lijken 
af te nemen door bijvoorbeeld een meer diverse patiëntpopulatie met 
ernstiger klachten en minder uitgebreid geschoolde therapeuten. Naarmate 
de vraag naar MBCT toeneemt, neemt ook de vraag naar gekwalificeerde 
trainers toe. Scholing van therapeuten kost veel tijd en geld, waardoor er een 
spanningsveld bestaat tussen kwaliteit en kwantiteit. Hoewel de resultaten 
van het MOMENT onderzoek niet direct uitnodigend zijn om veel tijd en 
geld te besteden aan het opleiden van trainers, moet worden benadrukt 
dat de kennis hierover in de kinderschoenen staat en dat dit onderwerp 
uitgebreider onderzocht moet worden om er bijvoorbeeld beleidsmatige 
beslissingen op te kunnen baseren.
 Een laatste algemene aanbeveling betreft het transparant rapporteren van 
onderzoeksresultaten. De onderzoeksgemeenschap maar ook de samenleving 
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als geheel zou zich sterk moeten maken voor een wetenschappelijk klimaat 
waarin het rapporteren van “negatieve” resultaten even gemakkelijk is als 
het rapporteren van “positieve”, gegeven dat de methodologie van hetzelfde 
niveau is. Een aantal manieren om de wetenschappelijke integriteit 
te vergroten bestaan, zoals hierboven al beschreven, uit het verplicht 
publiceren van onderzoeksprotocollen, het volgen van de richtlijnen 
omtrent rapportage van RCT’s, het verbeteren en monitoren van procedures 
rondom conflicterende belangen, en het meer openbaar maken van ruwe 
onderzoeksgegevens. Het ‘Center for Open Science’ is een organisatie die 
zich bezighoudt met het faciliteren van dergelijke ontwikkelingen. Het lijkt 
er dus op dat we langzaam maar zeker de goede kant op gaan, waarbij we 
toewerken naar een betrouwbare ‘evidence-base’ die cruciaal is om de best 
mogelijke zorg aan onze patiënten te kunnen leveren.
Conclusie
Dit proefschrift bestaat uit een verzameling van studies waarin we het 
effect van MBCT bij terugkerende depressie hebben onderzocht. Geen van 
de hypotheses die we vooraf hadden opgesteld werd bevestigd door de 
resultaten: afbouw van antidepressiva na afloop van MBCT ging gepaard met 
een verhoogde kans op terugval, het toevoegen van MBCT aan antidepressiva 
had geen aanvullende waarde in het verder reduceren van de terugvalkans of 
depressieve restklachten vergeleken met alleen medicatie, en we vonden geen 
aanwijzingen voor een invloed van patiëntvoorkeur of trainerscompetentie 
op de effectiviteit van MBCT. Deze onverwachte uitkomsten hebben echter 
wel tot nieuwe onderzoeksvragen geleid en zullen het wetenschappelijke 
debat stimuleren omtrent zaken die tot nu toe onvoldoende onder de 
aandacht zijn gekomen (zoals patiëntvoorkeur en trainerscompetentie) 
binnen het onderzoek naar mindfulness. Als gevolg hiervan dragen onze 
bevindingen hopelijk bij aan een meer gebalanceerd en genuanceerd beeld 
van MBCT, waarbij zowel de sterke kanten als verbeterpunten naar voren 
komen waar we in de toekomst op kunnen voortborduren.
166
Chapter  8 - Samenvatting
REFERENTIES
Bockting, C. L., Elgersma, H. J., van Rijsbergen, G. D., de Jonge, P., Ormel, J., Buskens, E., 
. . . Hollon, S. D. (2011). Disrupting the rhythm of depression: design and protocol of a 
randomized controlled trial on preventing relapse using brief cognitive therapy with or 
without antidepressants. BMC Psychiatry, 11, 8.
Coronado-Montoya, S., Levis, A. W., Kwakkenbos, L., Steele, R. J., Turner, E. H., & Thombs, B. 
D. (2016). Reporting of Positive Results in Randomized Controlled Trials of Mindfulness-
Based Mental Health Interventions. PLoS One, 11(4), e0153220.
Crane, R. S., Eames, C., Kuyken, W., Hastings, R. P., Williams, J. M. G., Bartley, T., . . . Surawy, 
C. (2013). Development and Validation of the Mindfulness-Based Interventions–Teaching 
Assessment Criteria (MBI:TAC). Assessment, 20(6), 681-688. 
Dimidjian, S., & Segal, Z. V. (2015). Prospects for a clinical science of mindfulness-based 
intervention. American Psychologist, 70(7), 593-620. 
Kabat-Zinn, J. (1990). Full catastrophe living: Using the wisdom of your body and mind to face 
stress, pain, and illness. New York, NY: Delacorte Press.
Kuyken, W., Warren, F., Taylor, R. S., Whalley, B., Crane, C., Bondolfi, G., . . . Dalgleish, T. (2016). 
Efficacy and moderators of mindfulness-based cognitive therapy (MBCT) in prevention 
of depressive relapse: An individual patient data meta-analysis from randomized trials. 
JAMA Psychiatry, 73(6), 565-574. 
Molenaar, N. M., Brouwer, M. E., Bockting, C. L., Bonsel, G. J., van der Veere, C. N., Torij, H. W., . 
. . Lambregtse-van den Berg, M. P. (2016). Stop or go? Preventive cognitive therapy with 
guided tapering of antidepressants during pregnancy: study protocol of a pragmatic 
multicentre non-inferiority randomized controlled trial. BMC Psychiatry, 16(1), 1. 
Scholten, W. D., Batelaan, N. M., Van Oppen, P., Smit, J. H., & Van Balkom, A. J. (2013). 
Discontinuation of antidepressants in remitted anxiety disorder patients: the need for 
strategies to prevent relapse. Psychotherapy and Psychosomatics, 82(6), 399-400. 
Segal, Z. V., Williams, J. M. G., & Teasdale, J. D. (2002). Mindfulness-based cognitive therapy for 
depression: A new approach to relapse prevention. New York: Guilford Press.
Segal, Z. V., Williams, J. M. G., & Teasdale, J. D. (2012). Mindfulness-Based Cognitive Therapy for 
Depression (2nd ed.). New York: Guilford Press.
van Aalderen, J. R., Donders, A. R., Giommi, F., Spinhoven, P., Barendregt, H. P., & Speckens, 
A. E. (2012). The efficacy of mindfulness-based cognitive therapy in recurrent depressed 
patients with and without a current depressive episode: a randomized controlled trial. 
Psychological Medicine, 42(5), 989-1001. 
Van Ravesteijn, H., Lucassen, P., Bor, H., Van Weel, C., & Speckens, A. (2013). Mindfulness-based 
cognitive therapy for patients with medically unexplained symptoms: a randomized 
controlled trial. Psychotherapy and Psychosomatics, 82(5), 299-310. 
167
Meditation or medication?
Dankwoord
Na vele jaren werk is het nu eindelijk tijd om het dankwoord van mijn 
proefschrift te schrijven. Ik ben de afgelopen maanden al vaker in de 
verleiding gekomen om er een beginnetje mee te maken, maar heb het toch 
tot het allerlaatst weten te bewaren. So here it is. Ik zou het schrijven van 
een proefschrift wel willen vergelijken met een bevalling, in dit geval een 
behoorlijk langdurige en daarmee ook niet al te gemakkelijke (lees: zware) 
bevalling. Het begon met een idee voor een onderzoeksproject dat zich al 
gauw ontwikkelde en groeide, er raakten steeds meer mensen bij betrokken 
en het nam steeds meer concrete vormen aan. Toen er voldoende artikelen 
waren geschreven en gepubliceerd, diende de bevalling zich aan: het laatste 
stukje was het zwaarst. Het resultaat is een proefschrift dat ik gerust als mijn 
derde kindje kan beschouwen! Gelukkig zijn er ook verschillen: anders dan 
met een echte bevalling krijg je het er na afloop niet nóg drukker mee, maar 
kun je welverdiend met een biertje genieten van het werk dat erop zit. Hierbij 
wil ik graag de vele mensen bedanken die me hebben ondersteund tijdens de 
‘zwangerschap’ en bij de bevalling van dit proefschrift, want ik had het nooit 
alleen kunnen doen!
 Als eerste wil ik Anne bedanken voor deze geweldige kans die je mij 
jaren geleden hebt gegeven. Ik was op het juiste moment op de juiste 
plek toen ik informeerde naar mogelijkheden voor promotie-onderzoek 
rondom mindfulness, en tijdens ons kennismakingsgesprek gaf je mij al 
meteen het vertrouwen dat zo onontbeerlijk is geweest tijdens mijn gehele 
promotietraject. Met je analytische en doortastende blik heb je mij vele malen 
de goede richting op weten te sturen waardoor ik mij heb kunnen ontwikkelen, 
als wetenschapper en als mens. Veel dank dat je mij, zeker in de eerste jaren 
van het project, zo intensief hebt kunnen begeleiden ondanks jouw drukke 
agenda. Ik heb met grote bewondering aanschouwd hoe je ons centrum in 
relatief korte tijd zo tot bloei hebt gebracht! 
 Philip, je hebt jouw rol als tweede promotor meer dan dubbel en dwars 
vervuld. Vooral je hulp met de (meer ingewikkelde) statistische analyses is voor 
mij van onschatbare waarde geweest, bovendien was het ook heel erg prettig 
om met je samen te werken. Ik kijk met veel plezier terug op de middagen dat 
we samen achter jouw computer aan het puzzelen waren met MPlus syntax! 
Maar ook jouw terdege kennis van de literatuur in combinatie met een altijd 
enthousiaste en vriendelijke houding heeft mijn proefschrift naar een hoger 
plan getild. Heel veel dank hiervoor!
 Jan, ook jou wil ik als copromotor bedanken voor je ondersteuning tijdens 
het jarenlange onderzoeksproces, waarbij jouw rol tijdens zowel de praktische 
eerste fase als de tweede schrijffase onmisbaar is geweest. In jouw feedback 
betrok je regelmatig een wat breder perspectief, waarna de teksten vaak meer 
168
Dankwoord
op hun plek vielen. Ik ben blij dat we ook in het nieuwe onderzoek weer nauw 
zullen samenwerken.
 Naast mijn promotieteam zijn er heel veel mensen betrokken geweest bij 
het MOMENT-onderzoek, en hoewel ik waarschijnlijk niet iedereen bij naam 
zal kunnen noemen, wil ik allen die een bijdrage hebben geleverd heel hartelijk 
bedanken. Dat geldt in de eerste plaats voor alle deelnemers die zoveel tijd 
en energie hebben gestoken in het beantwoorden van de vele vragen en het 
invullen van de vele vragenlijsten die we hebben gebruikt. Veel dank ook voor 
de bereidheid om jullie kwetsbaarheden met ons te delen, zonder jullie geen 
onderzoek! Moge het jullie goed gaan.
 Mijn grote dank gaat daarnaast uit naar de coördinatoren, trainers, 
psychiaters, onderzoeksassistenten en ondersteunend personeel van de 
verschillende externe locaties: Jan, Joost, Els, Vera, Joke, Florian, Gea, Karin, 
Pieter, Sandra, Elsbeth, en Suleika (Pro Persona); Eric, Ingrid, Sjan, Naomi, 
Mathilda, Geeske (AMC); Anneke, Patricia, Reen, Engel, Len, Sheralynn, Vera, 
Mirjam, Celine, Dionne (GGZ in Geest); Pien, Josje, Jolien, Marit, Emke, Irene, 
Evert, Andreia, Ingrid, Annie, Frans, Martijn (GGZ Leiden en LUMC); Wilfried, 
Iris, Pieter, Marietta (Parnassia); Bert, Doeska, Jos, Annelies (GGZ Duin- en 
Bollenstreek); Marc, Marie-Louise, Krieno, Trudy†, Kees, Patricia, Inge, Bianca 
(PsyQ); Alie, Alex, Melissa (GGZ Centraal); Flip, Frank, Frank, Carla, Sandra, 
Mieke, Anne (GGZ NHN). Jullie hebben onvoorstelbaar veel werk verricht 
in het coördineren, bellen, mailen, meten, begeleiden en trainen van onze 
deelnemers, en ik heb het altijd erg leuk gevonden om ‘op pad’ te gaan door 
het land met mijn tassen vol vragenlijsten en andere materialen, lege heen 
en volle weer mee terug. Ik heb me overal welkom en ondersteund gevoeld. 
Thanks a million!
 Naast de praktische ondersteuning hebben een aantal mensen ook een 
belangrijke bijdrage geleverd aan de artikelen in dit proefschrift. Behalve 
mijn promotieteam zijn dit Eric Ruhé, Anneke van Schaik, Patricia van Oppen, 
Willem Nolen, Hans Ormel, Willem Kuyken, Gert Jan van der Wilt, Marc Blom, 
Aart Schene, Rogier Donders, Rebecca Crane, Lot Heijke en Ingrid van den Hout. 
Hoewel het telkens een hele klus was om bij de RCT-artikelen de feedback van 
maar liefst 13 co-auteurs te verwerken, was het absoluut de moeite waard. 
Gelukkig waren jullie het doorgaans vrij goed met elkaar eens… Veel dank voor 
jullie gedegen feedback! Mijn speciale dank voor Rogier voor de vele malen dat 
je me hebt ondersteund bij de statistische kant van het project, en de tijd die je 
daarvoor wist vrij te maken ondanks je drukke agenda. Another special thanks 
for Willem and Becca who worked with us on the teacher competency project, 
not an easy job… Willem, I remember visiting you in Exeter back in 2010, 
after my first retreat, and feeling so welcome! I much admire your work and 
I always appreciate our encounters. Daarnaast wil ik graag Gert Jan van der 
Wilt, Willem Woertman, Maud Verscheijden en Anne Holtus bedanken voor 
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jullie hulp bij de kosten-effectiviteitsanalyse. Ook wil ik Ton, Rob, Jos, Noud, 
Lot, Joke, Ingrid, Flip, Renée, Engel, Nicole, Anne, Johan, Coen, Franca, Annick, 
en Fabio heel hartelijk danken voor jullie bijdrage aan het teacher competency 
project. Jullie input was erg waardevol en heeft uiteindelijk zelfs geleid tot een 
artikel in mijn proefschrift!
 Dan verder met de (oud-)collega-onderzoekers uit verschillende hoeken 
van de universiteit. Janna was mijn kamergenootje van het eerste uur, en ik heb 
je hulp vele malen zeer gewaardeerd! Je bent een toffe collega. Verder natuurlijk 
Boudewijn, Marten, Denise, Desirée (Oxford was very nice!), Karlijn, Dirk, 
Niels, Niels, Danique, Rose, Janneke, Nikki, Daniël, Andrieke, Jolanda, Kirsten, 
Anoek, Jennifer, Daan, Daphne. Dank voor de maandagmiddagmeetings, 
en natuurlijk de gezellige etentjes en drinkjes, sinterklaasavonden, sociale 
venten. Ook aan de meetings met de Mind-Brain-Mindfulness-groep heb ik 
goede herinneringen. Henk, Stephen, Paul, Yowon, Tracey, het was fijn om met 
jullie te brainstormen over wat er nu eigenlijk écht omgaat in je hoofd als je 
aan het mediteren bent.
 En dan de mensen die letterlijk of bijna letterlijk naast me hebben 
gezeten tijdens het uitvoeren van het MOMENT-onderzoek en het schrijven 
van mijn proefschrift. Allereerst duizendmaal dank aan mijn geweldige 
onderzoeksassistente Iepke, mijn rechterhand gedurende de eerste jaren van 
het project. Wat hebben we samen veel werk verzet en wat ben je belangrijk 
voor mij geweest, niet alleen als ‘assistente’ maar zeker ook als sparring 
partner. Samen de hort op om ‘zieltjes te winnen’ voor het onderzoek, en niet 
zonder resultaat! Ik hoop dat we gauw weer een bakkie koffie gaan drinken als 
ik weer wat meer tijd heb. Mizzi nam het stokje vervolgens over: ik was onder 
de indruk van de energieke manier waarop je je werk deed, prachtig om te 
zien! Tijdens de laatste jaren van het onderzoek kreeg ik gelukkig een nieuwe 
rechterhand, Carolien. Wat ben ik blij dat je mij bent komen ondersteunen bij 
de laatste onderzoeksmetingen, terwijl ik jou kon helpen met je masterscriptie. 
Inmiddels ben je alweer enkele jaren ‘officieel’ mijn collega, sta je altijd voor 
mij klaar, en gaan we nu samen verder met jouw PhD waar ik als co-promotor 
betrokken mag zijn. Super! En wat fijn dat je nu ook als paranimf aan mijn zijde 
wilt staan! Andere mensen die ik wil bedanken voor hun directe bijdrage aan 
het onderzoek zijn Ruth Waumans, Yvonne van der Tuuk, Roos d’Hont, Elzeline 
Bogaards, Esther Simons, Stephan Löcke, Jessica Sluis, en niet te vergeten 
Geert Schattenberg. Wat heb je veel Teleform-formulieren voor mij ontworpen 
en gescand Geert! Heel veel dank daarvoor, en voor je hulp bij het opzetten 
en beheren van de database. Een essentiële taak! Ook alle overige (oud-)
collega’s van de afdeling psychiatrie wil ik bedanken voor de samenwerking 
en ondersteuning, ik heb het zeer gewaardeerd.
 De collega’s binnen het centrum voor mindfulness verdienen natuurlijk 
een speciale paragraaf, want jullie zorgen er iedere dag weer voor dat ik met 
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veel plezier naar mijn werk ga. Ik begin met Ramona, Irma en Kelly, want 
jullie zie ik als eerste als ik ’s ochtends binnen kom lopen. Jullie vormen echt 
een super-secretariaat, ik heb heel veel bewondering voor de zorgvuldige, 
klantgerichte, enthousiaste en vriendelijke manier waarop jullie de boel 
weten te runnen. Want het is een hele klus! Superbedankt daarvoor. Dan de 
collega-onderzoekers. Joël, je bent me precies een jaar geleden voorgegaan en 
ik heb veel bewondering voor hoe je je PhD toch met verve hebt weten af te 
ronden ondanks jouw super-drukke schema met je klinische opleiding en een 
groot gezin. Hiske, jij bent voor mij een voorbeeld in je doen en laten, en ik 
vond het erg leuk dat we samen een kamer deelden en dat ik je vanalles kon 
vragen over psychiatrie als ik mijn intakeverslagen aan het schrijven was. Ook 
vond ik het erg bijzonder dat we elkaar intensiever leerden kennen tijdens 
de opleiding, samen met Inge. Mooi om zo’n traject samen te doorlopen! 
Melanie, mijn mede-Brabander (en mede-JRL-er, we zijn goed afgeleverd): 
wat vond (en vind) ik het gezellig dat je ons team kwam versterken! Prachtig 
om te zien hoe je je hebt ontwikkeld als onderzoeker en als mens gedurende 
de afgelopen jaren. Gij komt ‘r wel! Ik vind het een eer dat je nu als paranimf 
naast mij staat, thanks for being there… Rhoda, ik vind het erg tof dat ik ook bij 
jouw PhD-onderzoek naar compassietraining betrokken mag zijn, ik heb veel 
bewondering voor hoe je dit op zo’n veelzijdige manier weet te organiseren! 
En verder natuurlijk Hanne, Lotte, Mira, Félix, Else, Wendy, Kiki. Jullie zijn stuk 
voor stuk lieve collega’s en het is fijn om met jullie over onderzoek maar ook 
over allerlei andere dingen te praten! Verder gaat mijn grote, grote dank uit 
naar Renée en Hetty voor hun geweldige bijdrage aan het MOMENT-onderzoek 
en voor het zijn van zeer gewaardeerde collega’s. Jullie hebben van mij tig 
vragenlijsten moeten uitdelen en tientallen sessies moeten opnemen. Soms 
met wat frisse tegenzin (Hetty: “moet dat nou nog steeds met die camera?”) 
maar altijd zorgvuldig en daarmee van grote waarde voor mijn onderzoek. 
Renée, ik wil je in het bijzonder bedanken voor de tijd die je nam om mij te 
superviseren in mijn MBCT-stage. Je bent een belangrijk voorbeeld voor me, 
als trainer maar zeker ook gewoon als mens. Ook de andere trainers, Ellen, 
Miep, Rinie, Ineke, Jorke, dank jullie wel voor de fijne samenwerking. Dan wil 
ik, last but not least, ook Nicole en Ton heel hartelijk danken voor de prachtige 
opleiding die jullie mij (en de rest van onze opleidingsgroep) hebben gegeven, 
het was echt geweldig om deel uit te maken van deze groep en samen zoveel te 
ontdekken, delen, inspireren, oefenen, alles onder jullie deskundige vleugels. 
Ook Coen veel dank voor je supervisie. 
 Dan wil ik na deze vele collega’s ook mijn vele lieve vrienden ontzettend 
bedanken voor jullie indirecte (en soms ook directe) ondersteuning tijdens 
mijn promotietraject. Iris, Jeroen, Naomi, Marjolein, Mijntje, Erik, Eveline, 
Joris, Debbie, Erica, Wilma, Dirk, Margot, Bavo, Marielle, Yiannis, Hanneke, Jan, 
Wessel, Geert, Heleen, Maarten, Maaike, Stefan, Marije, Jan-Frans, Mariette, 
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Tom, Anita, Tim, Thijs†, Marina, Jeroen, Jarno, Carlijn, Michiel, Roos, Koos, Sil, 
Jolanda. Speciale dank gaat uit naar Erica en Michiel voor hun hulp bij het 
ontwerp van dit boekje. Ik zou voor jullie allemaal persoonlijk wel een stukje 
willen schrijven maar dan wordt dit dankwoord écht te lang… dus jullie moeten 
het doen met een algemene, maar wel hele dikke vette dank-je-wel voor alle 
fijne avonden, middagen, ochtenden, weekenden, festivals, feestjes, etentjes, 
gesprekken, spelletjes, barbeques, en alle andere dingen die we zo graag met 
jullie delen. Jullie zijn top.
 Dan verder met de ‘kouwe kant’ van de familie zoals we dat in Brabant 
noemen. Gelukkig voelt het alsnog als een warm nest. Lieve Egbert en Mariëlle, 
jullie zijn er door dik en dun voor ons, geven ons alle ruimte. Het is geweldig 
dat jullie iedere week op onze mannetjes komen passen. En jullie gastvrijheid 
is oneindig groot, zelfs nu jullie het afgelopen jaar de boerderij hebben moeten 
verlaten voor de renovatie die hopelijk voorspoedig zal verlopen. Ook in jullie 
tijdelijke, knusse onderkomen wordt alles uit de kast gehaald om telkens weer 
een heerlijk diner op tafel te toveren zodat we met het gezin samen kunnen 
genieten van eten en naar elkaars verhalen kunnen luisteren. Bart, Charlotte, 
Wiebe, ik ben blij dat ik jullie schoonzusje ben en het is fijn om lief en leed met 
elkaar te kunnen delen.
 Lieve pap en mam, zonder jullie was ik er überhaupt niet geweest om dit 
proefschrift te schrijven! Maar sowieso was het nooit gelukt om het af te ronden 
zonder jullie hulp, zeker de laatste jaren met de kids. De ‘schrijfretraites’ in 
jullie kantoortje, inclusief koffie, lunch, oppas etcetera waren ook echt goud 
waard. Jullie zijn een onvoorstelbaar grote steun voor mij, voor ons, in alles. Ik 
ben heel trots op jullie. Lieve Saskia, Eric, Guus en Chiel, lieve Ferry, Annemarie, 
Fleur, Britt, Cas en Tess, dank jullie wel voor de welkome en noodzakelijke 
afleiding van mijn werk, het was fijn om met jullie over heel andere dingen 
te praten dan mindfulness of mijn proefschrift. Dank voor jullie steun en ook 
voor jullie begrip voor de tijd en energie die ik al die jaren in dit kleine boekje 
heb gestopt! Jullie betekenen heel veel voor me.
 Dan als laatste mijn eigen gezinnetje. Lieve, lieve Take, wat hebben we het 
druk maar wat hebben we het goed! In het schrijven van dit proefschrift maar 
ook in alles wat daaraan vooraf is gegaan, en in alles daarbuiten, was en ben 
je voor mij de belangrijkste steun die ik me kan voorstellen. Je betekent de 
wereld voor mij, je bent mijn alles. En tot slot, lieve Sietse en Jelle, hoewel jullie 
strikt genomen niet de grootste bijdrage hebben geleverd aan mijn proefschrift 
maar juist vooral voor enorme vertraging hebben gezorgd, verdienen jullie 
toch deze ereplaats in het dankwoord! Wat hebben jullie mijn leven verrijkt, 
wat ben ik ontzettend gelukkig met jullie. Ik heb er veel zin in om straks na de 
promotie en de verhuizing weer meer tijd te hebben om allerlei leuke dingen 
met jullie te doen. Want hoezeer ik ook geniet van mijn werk, van jullie geniet 
ik toch het allermeest!
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